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High-risk Human Papillomaviruses (HPVs) cause a subset of Oropharyngeal cancer (OPCs), 
with a rising incidence of HPV-OPC in the developed world. This thesis explores the 
epidemiology and epigenetics of oral HPV infection and OPC. 
Methods and Results: 
Systematic Review of 4,365 abstracts and Meta-analysis of 45 studies: Pooled prevalence for 
any oral HPV infection was 4.9% (95% CI: 3.7% - 6.3%) and high-risk HPV 1.8% (95% CI: 
1.2% - 2.6%), with no difference by gender but variability by geography and sample type.  
Prospective Cohort Study in 101 individuals: Oral HPV in oral rinse reduced from 11% 
before tonsillectomy to 2% afterwards. However, 10% had new infections.  
Retrospective Review of 28,846 OPC on HES database: Survival is worse with increasing 
age, poor socio-economic status and multiple co-morbidities (p<0.05).  
Genomics and Epigenetics Study on 40 FFPE samples from HPV-OPC: 40% had viral E2 
gene disruption detected by PCR, with no differences in methylation at E2-binding sites 
(E2BS).  
Conclusions:  
Oral HPV prevalence is low and tonsillectomy may affect its natural history. 60% HPV-OPC 
have an intact E2 gene with no differences in E2BS methylation. Survival from OPC depends 
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1.1 Background and Epidemiology: 
1.1.1 Increasing Incidence of Oropharyngeal cancer: 
There is an increasing incidence of Oropharyngeal cancer (OPC) in the UK (Shaw et al., 
2011), with similar trends reported across much of the developed world and America 
(Chaturvedi et al., 2013). The National Cancer Intelligence Network in the UK reported the 
direct standardised incidence rates of OPC in the UK which has doubled from 1.2 per 100,000 
population in 1996 to 2.3 per 100,000 in 2006 (NCIN 2010). This increasing incidence of 
oropharyngeal cancer as demonstrated in Figure 1.1, is contrary to the declining incidence of 
some head and neck squamous cell carcinomas (HNSCC) such as laryngeal cancers that have 
the traditional associated risk factors of cigarette smoking and alcohol consumption.  
 
Figure 1.1: Trends in oropharyngeal cancer (OPC) incidence in England (NCIN 2010) 




This decline in laryngeal cancers and smoking-related cancers such as lung cancer, coincides 
with the steady decline in smoking rates across England in the last 30 years (ONS 2016). 
There is therefore an aetiologic driving factor separate to cigarette smoking accounting for the 
rise in OPC rates. 
1.1.2 Human Papillomavirus-associated Oropharyngeal cancer: 
The increasing incidence of oropharyngeal cancer across America, Europe, Scandinavia and 
the developed world has been described as an epidemic (Sturgis and Ang 2011). Oncogenic 
human papillomavirus (HPV) causes cervical cancer as well as a subset of anal, penile, 
vaginal and vulvar cancers (zur Hausen 2009, Graham 2010). These are non-enveloped DNA 
viruses with over 100 HPV strains described however the high-risk HPV genotypes 16 and 18 
are responsible for the vast majority of these cancers in humans (Graham 2010). Recent 
strong epidemiologic and laboratory evidence has shown oncogenic HPV (in particular HPV 
16) as an aetiological agent in the causation of a sub-set of Oropharyngeal cancer (OPC) 
(D’Souza et al., 2007b; Wiest et al., 2002) and is responsible for over 90% of HPV-associated 
oropharyngeal cancer (Gillison et al., 2000; Schache et al., 2011). A meta-analysis on head 
and neck cancers indicates strongly that HPV is aetiology in the oropharynx, less so in the 
oral cavity and no significant causal correlation in the larynx (Hobbs et al., 2006). There is a 
disparity in the strength of association observed between HPV in oral cavity cancers and in 
oropharyngeal cancer (Javadi et al., 2017).  
Infection with high-risk genotypes of oral human papillomavirus (in particular HPV 16 and 
18) therefore partly explains the rising incidence trend in oropharyngeal cancer. A recent 




2000 – 2009, with a significantly more rapid increase observed in Europe compared with 
North America (Mehanna et al., 2013). 
Compared with HPV negative OPC, HPV-associated OPC tends to affect a younger 
demographic who may not have been exposed to cigarette smoking or alcohol consumption. 
HPV-OPC also appears to respond better to current treatments including chemo-radiotherapy 
and surgery with better survival outcomes (Fakhry et al., 2008, Shah et al., 2009, Reimers et 
al., 2007, Weinberger et al., 2006, Rischin et al., 2010, Mellin et al., 2002, Lindel et al., 2001, 
Licitra et al., 2006). Epidemiologic studies have confirmed risk factors for oral HPV infection 
to include oral sex and multiple lifetime sexual partners (D'Souza et al., 2009). 
HPV status alongside nodal stage and smoking status is now employed as a prognostic 
classifier in patients with OPC in work done by (Ang et al., 2010), stratifying them into low, 
intermediate or high risk. HPV-OPC has a 3 year survival benefit following treatment 
compared with age and sex matched negative OPC (Ang et al., 2010). There are currently 
large multicentre UK trials on-going with a focus on HPV in OPC, disease progression and 
modifications to treatment modalities based on HPV status.  
1.1.3 Survival from Oropharyngeal cancer: 
Disease-free survival following a diagnosis of oropharyngeal cancer is dependent on a 
number of factors including patient factors, degree of exposure to risk factors, socio-economic 
factors, tumour factors and presence or absence of transcriptionally active human 
papillomavirus in the tumour. Survival worsens with increasing age and increasing levels of 
deprivation. Tobacco smoking and heavy alcohol intake are associated with worse survival 
outcomes with on-going exposure to these risk factors predisposing patients to higher cancer 




underestimated especially in these patients with sub-optimal cardiorespiratory reserves. The 
presence of significant co-morbidities and the complications of surgical treatments and 
prolonged rehabilitation also take their toll on both the quality of life experienced as well as 
survival.  
This alarming upward trend in OPC incidence in the UK has continued over the last decade 
and is now projected to be 30 times the current burden by the year 2025 (Louie et al., 2015). 
This represents a significant public health concern with huge implications for early diagnosis, 
treatment, resource allocation and long-term rehabilitation efforts which will come at a huge 
cost (Chesson et al., 2012; Schache et al., 2016).   
The key concepts and current literature underlying this thesis will now be discussed including 
oral cavity / oropharynx anatomy, HPV biology, oral HPV infection and risk factors, oral 
HPV prevalence and persistence, oropharyngeal cancer, HPV 16 genome and epigenetic 
regulation. 
1.2 Anatomy of the Oropharynx: 
The Oropharynx is the anatomic area at the back of the throat and is visible on mouth 
opening. It consists of the palatine tonsils, lingual tonsils (or base of tongue), soft palate, 
uvula, posterior and lateral pharyngeal walls (Figures 1.2 and 1.3). Embryologic development 
of the tonsils occurs during the third month in-utero. Formation is from the lining of the 
endoderm, mesoderm of the second pharyngeal membrane, second pharyngeal pouch and first 
two pharyngeal arches. The second pharyngeal pouch epithelium form endodermal buds that 
develop outwards into the mesoderm. When the core cells in the buds regress, they convert 
into the tonsillar crypts that become impregnated with lymphoid tissue. Anatomically, the 




posteriorly. Superiorly tonsils are related to the lateral aspect of the soft palate whilst 
inferiorly they merge with the lingual tonsils (tongue base). Blood supply is mainly from the 
tonsillar artery which is a branch of the facial artery and enters the tonsils from their inferior 
poles. Other arterial supply is from the dorsal lingual artery, ascending palatine artery, 
ascending pharyngeal artery, and the lesser palatine artery. Venous drainage is from the 
peritonsillar venous plexus into the lingual and pharyngeal veins which empty into the 
internal jugular veins. Nerve supply is from the lesser palatine nerves (branches of the 
maxillary division of the trigeminal nerves) and tonsillar branches of the glossopharyngeal 
nerves bilaterally. The oropharynx extends from the hard palate superiorly to the hyoid bone 
inferiorly, and is divided into anterior wall (tongue base posterior to foramen cecum, 
vallecular, lingual surface of epiglottis; bounded by the pharyngoepiglottic folds), a lateral 
wall (palatoglossus, palatopharyngeus, and pharyngeal palatine tonsil), a roof (oral surface of 
the soft palate), a posterior wall (superior and middle constrictors and buccopharyngeal 
fascia), and the tongue base (genioglossus muscle) (Homer and Rees 2012). 
 
The palatine tonsils and lingual tonsils (tongue base) are lymphoid tissue in the oropharynx 
that form the Waldeyer’s ring alongside adenoidal tissue in the nasopharynx. These play a 
more prominent role in humoral immunity in childhood but tend to regress both in their 
relative size and immune function as individuals become adults. Tonsils play a role in 
providing defence systems against oral pathogens, including bacterial and viral. The tonsils 
consist of troughs and crests with non-keratinizing stratified squamous epithelium overlying 
the superficial layer or crests (McClory et al., 2012) and a specialized reticulated epithelium 





Figure 1.2: Anatomy of the oropharynx (Rayur.com 2012 / image thanks to uc.edu)            
The oropharynx is demonstrated with subsites soft palate, uvula, palatine tonsils and 
posterior pharyngeal wall shown. 
 
Tonsils are infiltrated with lymphocytes and have germinal centres which produce immune 
cells called memory B cells and an antibody called Immunoglobulin A. T-lymphocyctes or T-
cells which are largely produced in the thymus gland and are essential components for 
immune functioning, have also recently been shown to be produced in the tonsils (McClory et 
al., 2012). In addition, cytokine-producing cells have also been identified in tonsillar tissue 
including T-helper 1 and T-helper 2 cytokines and cytokine messenger RNA. The specialized 
surface of tonsils contains M cells that capture antigens and subsequently trigger a stimulatory 






Figure 1.3: Anatomic relations of Oropharynx (sagittal view) Blausen.com staff (2014) 
Sagittal section of the face showing the oropharynx along with its boundaries. 
1.3 Human papillomavirus biology: 
HPV is a common cause of sexually transmitted infections, many of which are transient. The 
vast majority of the population are exposed to and acquire infection with HPV at some stage 
in their lives (Baseman and Koutsky, 2005). Over 120 HPV genotypes have been described 
with mucosal HPV accounting for 40% of the genera (Fernandes et al., 2013) and cause a 
spectrum of diseases ranging from benign lesions to malignancy. HPV can be stratified 
depending on their transformative potential for malignancy.  Low-risk such as HPV 6 or 11 
are responsible for anogenital warts which are benign lesions while high risk such as HPV 16 




HPV is a non-enveloped, double-stranded DNA virus protected by a capsid. The major capsid 
protein is L1 is present in 72 copies in each virus while L2 protein occurs in variable copies 
(Longworth and Laimins, 2004; zur Hausen, 2009). Each HPV contains structural proteins L1 
and L2 as well as E1, E2, E4 – E8. The structural proteins help viral particle assembly while 
viral DNA replication and control of transcription is undertaken by E1, E2, E4, E5 and E8 
genes. E6 and E7 are involved in maintaining the competence of replication (Bodily and 
Laimins, 2011). The E4 protein has been shown to be an important regulator of the HPV 
lifecycle with diverse actions that involve cell organisation, host cellular DNA suppression 
and cell cycle dysregulation (Roberts et al., 2008). The HPV genome is passed to daughter 
cells during mitosis and it is able to do this by hijacking the natural cellular mechanisms to 
maintain stability. In particular, the HPV E2 protein targets several cellular proteins during 
mitosis to facilitate transfer of genomes to chromosomes ensuring persistence (Feeney and 
Parish, 2009). 
In the cervix, HPV infects the basal undifferentiated cells following trauma. The virus then 
replicates in tandem with the basal cells. Most high risk HPV infections are cleared by the 
immune system within 12 – 18 months but sometimes persistent infection occurs (Kero et al., 
2012). In 2008, Harald zur Hausen was awarded the Nobel Prize in Physiology or Medicine 
for his discovery of the causative role of HPV in cervical cancer. Incredibly, the Nobel Prize 
that year was shared with Françoise Barré-Sinoussi and Luc Montagnier who discovered the 
human immunodeficiency virus. Today we now know that HPV infection, persistence and 
carcinogenesis in the cervix, anogenital region or oropharynx are all increased in the presence 





1.4 Oral HPV Lifecycle: 
Oral mucosa consists of epithelium and connective tissue separated by basement membrane. 
Epithelium can be keratinised or non-keratinised. The keratinised type has basal, spinous, 
granular and squamous layers. The non-keratinized epithelium can be divided into a 
superficial layer, an intermediate layer and a basal layer. In the cervical epithelium, micro-
abrasions or trauma allows human papillomavirus access to the basal layer of cells supported 
by the basement membrane (Woodman et al., 2007; Doorbar et al., 2006). HPV begins to 
replicate its viral genome in the basal layer and progresses with exponential multiplication 
towards the superficial squamous layer where eventual viral release occurs. Once HPV 
infection has been established, early viral genes are produced (E1, E2, E4, E5, E6 and E7) 
until late viral genes (L1 and L2) are expressed in the superficial layers with capsid formation 
(Woodman et al., 2007).  
 
Figure 1.4: HPV Lifecyle in skin (Roberts 2015 – used with permission)                                   
HPV lifecycle in host cells depicted with viral DNA replication commencing in the basal cells 
with exponential replication and amplification to >105copies/cell, virus assembly and then 




The HPV replication machinery is a complex system that is dependent on the replication of 
the host cell. Viral DNA replication progresses from 10 – 50 copies per basal layer cell, 
through a proliferative phase and subsequent amplification to >105 copies / cell in the 
intermediate layer (Figure 1.4; from Roberts 2015). Virus assembly is completed in the 
superficial layer with expression of capsids. This phase is modulated by the late viral genes 
L1 (major capsid protein) and L2 (minor capsid protein). Ultimately release of HPV occurs 
until the infection clears. The described HPV lifecycle has largely been derived from 
observations in the cervix. In the tonsils however, HPV has been shown to localise in the 
specialized epithelium of the tonsillar crypts (Begum et al., 2005). Oral sex has been shown to 
be an independent risk factor in the acquisition of both oral HPV infection and in case control 
studies on HPV associated oropharyngeal cancer (Gillison et al., 2012). It is unclear if the 
theory of micro-abrasions preceding HPV localisation in the basal cell layer holds true in the 
tonsils. The cells in the oral cavity and oropharynx are rapidly dividing cells and often 
exposed to various shades of trauma daily from such activities as tooth brushing, eating, and 
deep kissing, which could precipitate micro-abrasions. The lymphoid nature of the tonsils also 
means that micro-organisms such as viruses and bacteria get trapped and elicit inflammatory 
reactions in such established conditions as tonsillitis and glandular fever. Digital transmission 








1.5 HPV Genotypes detected in normal oral mucosa: 
HPV can be classified as either high risk (HR) or low risk (LR) depending on their ability to 
cause cancer. HPV can also be classified as cutaneous or mucosal depending on the cellular 
surfaces infected and specific tissue tropism (Suzich et al., 1995). 
High risk HPV can be divided into the most prevalent strains of either species 7 (HPV 18, 39, 
45, 59, 68, 70 and 85) or those of species 9 (HPV 16, 31, 33, 35, 52, 58, and 67) (D'Souza et 
al., 2007a). 
Studies have identified the following high risk strains in normal oral mucosa: HPV16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58 and 59, in addition to LR-HPV strains. (Kreimer et al., 2010). 
Oral HPV 16 is the most frequently identified HPV genotype (Kreimer et al., 2010; Kreimer 
et al., 2011) in the healthy population.  
1.6 Oral HPV detection techniques: 
Detection of HPV in oral samples is very important for accurate diagnosis and risk 
stratification. A number of detection techniques currently exist but standardised protocols for 
HPV testing are required to facilitate clinical usefulness (Suwalska et al., 2014). The 
following HPV detection methods have been used: p16 immunohistochemistry, in-situ 
hybridisation (ISH), polymerase chain reaction (PCR), reverse transcriptase PCR, and 
serology (Schiffman et al. 1991; Blitzer et al., 2014; Singhi and Westra 2010). 
Detection of cyclin-dependent kinase-inhibitor 2A (CDKN2A or p16) by 
immunohistochemistry is widely used in the initial evaluation of HPV status. It is relatively 
cheap and quick to perform but p16 positivity is not necessarily indicative of HPV infection 




Southern blots are useful for identifying specific HPV subtypes (Schiffman et al., 1991). The 
role of southern blot technique in routine clinical practice is limited as it requires large 
amounts of DNA and takes up time to perform. In-situ hybridisation is another HPV detection 
technique which has a lower specificity compared to Southern blots (Singhi and Westra, 
2010) but it has increased utility as it can be used on fixed or paraffin embedded samples. ISH 
utilises oligonucleotide probes that can detect high-risk HPV. Highly sensitive detection 
techniques include polymerase chain reaction (PCR) and reverse transcriptase PCR. PCR 
detects viral DNA while reverse transcriptase PCR detects RNA. The presence of viral DNA 
alone is not predictive of cancer development while the overexpression of E6 and E7 predicts 
carcinogenesis (Blitzer et al., 2014). The Roche Linear Array was used by (Kreimer et al., 
2011) for HPV identification while PCR and type-specific hybridisation was employed by 
(Gillison et al., 2012). Hybrid capture 2 assay has also been proposed as a reliable detection 
technique for HPV in head and neck squamous cell carcinomas (Smith et al., 2014). This 
however lacks genotype-specificity.  
1.7 Oral HPV prevalence in healthy populations: 
The currently available data on the prevalence of HPV infection in the mouth in the general 
population and the age and gender distribution of this infection is limited to small studies.  
These are usually retrospective and most of the study cohorts are over ten years old – 
therefore most of the prevalence data available is at least ten years old.  Furthermore, the 
studies used a variety of sample types and different HPV detection techniques which are 
polymerase chain reaction (PCR), p16 immunohistochemistry, in-situ hybridisation (ISH).  
Therefore the results vary widely with reported HPV prevalence rates in tonsil specimens 
using Polymerase Chain Reaction (PCR) to identify viral DNA reported between 0% and 16% 




al., 2006, Mammas et al., 2006) and in oropharyngeal exfoliated specimens between 0% and 
31.6% (D'Souza et al., 2007a, Smith et al., 2004, Summersgill et al., 2001, Rintala et al., 
2006, Jenison et al., 1990, Puranen et al., 1996). These data were compared with the findings 
from the meta-analysis in this study in Table 2.3.  
In children, oral HPV transmission is documented as this can be vertically transmitted during 
delivery from mother to child (Syrjanen and Puranen, 2000; Pakarian et al., 1994; Chatterjee 
et al., 1998; Rombaldi et al., 2009; Syrjanen et al., 2010; Pinheiro et al. 2011; Koskimaa et al., 
2012). A recent study by Martinelli et al (2012) has identified HPV in the oropharyngeal 
mucosa in 25 out of 177 (14.1%) newborns in Italy which indicates further studies are 
required to fully understand the methods of HPV acquisition. The mode of delivery (either via 
caesarean section or normal delivery) has not been shown to impact on the oral HPV 
prevalence in 190 children assessed using PCR (Mammas et al., 2012).  
Reported prevalence rates of oral HPV infection in adults varies considerably as described 
below. This is partly due to the lack of standardised HPV testing regimes and the variability 
in the interpretation of what constitutes a positive result.  
In the most recent systematic review on oral HPV infection, Kreimer et al (2010) documented 
pooled prevalence estimates from 4,070 healthy individuals and found 4.5% (95% CI: 3.9-
5.1) for any oral HPV, 3.5% (95% CI: 3.0-4.1) for HR-HPV and 1.3% (95% CI: 1.0-1.7%) for 
HPV 16. The pooled prevalence obtained from the meta-analysis in this thesis will be 
compared directly to those published by Kreimer et al. (2010).  
In a large cross-sectional study of 5579 adults in America, (Gillison et al., 2012) described a 
6.9% (95% C.I: 5.7% - 8.3%) prevalence of oral HPV infection and 1.0% (95% CI 0.7% – 




also shows a double peak for oral HPV infection in the age groups 30 – 34years and 60 – 
64years. In men, 10.1% (95% CI: 8.3 – 12.3%) prevalence was found in this population 
compared with a prevalence of 3.6% (95% CI: 2.6% - 5.0%) in women. Men had a 
significantly higher prevalence than women, with oral HPV infection more common among 
those with a history of any type of sexual contact, multiple sexual partners and cigarette 
smoking (Gillison et al., 2012).  
Similarly, Kreimer et al. (2011), sampled 1680 healthy men in the US population for oral 
HPV infection and found a prevalence of 4.0% (95% C.I: 3.1% - 5.0%).  Prevalence of oral 
HPV infection in the US population was reported by (Sanders et al., 2012)  as 7.3% (95% CI: 
6.0 – 8.9) from oral rinse with HR-HPV accounting for 3.1% (95%CI: 2.4, 3.9).  
The literature on the natural history of oral HPV infection in adults comes largely from the 
Finnish family study where 324 pregnant women and their partners were tested for oral HPV 
infection at intervals over a 7year period prospectively (Kero et al., 2012). In this prospective 
study, point prevalence of oral HPV in oropharyngeal scrapings obtained from 131 males in 
Finland was determined with the Multimetrix® test (Progen, Heidelberg, Germany). 
Detection of oropharyngeal HPV DNA in men was found to be common, with HPV16 being 
the most prevalent genotype. Point prevalence of oropharyngeal HPV infection fluctuated 
from 15.1% to 31.1% over the study period (Kero et al., 2012). It was suggested that the 
oropharyngeal mucosa may play a significant role in HPV transmission. 
A recent Swedish study found oropharyngeal HPV prevalence of 9.3% in 483 patients in a 
youth clinic (Du et al., 2012). Detection of oral HPV was found to be significantly higher 
among females with cervical HPV infection compared to those without cervical HPV 




genotypes in women with cervical HPV infection (Du et al., 2012). This suggests some 
population groups may be at-risk of having higher proportions of oral HPV infection. In 
Pakistan, oropharyngeal cavity HPV was found in 47 of 200 normal subjects (23.5%) using 
real-time PCR and a correlation with smoking was documented (Gichki et al., 2012). This 
high rate of oral HPV infection could be indicative of underlying cultural differences in 
Pakistan or a reflection of detection technique sensitivity. In contrast, in a sample of healthy 
Australian University students, a prevalence of 2.3% was found for oral HPV infection with a 
male preponderance. This study was conducted on 307 students. (Antonsson et al., 2014). 
This lower oral HPV prevalence rate (when compared with the studies in America), and the 
high oral HPV prevalence in the Gichki et al. (2012) study in Pakistan, could suggest 
geographic variation in oral HPV epidemiology. This thesis will explore any such geographic 
variation in pooled prevalence of worldwide studies.  
Prevalence rates of 2.3 – 25% have been reported from saliva testing using lavage for sample 
collection (Herrero et al., 2003; Goncalves et al., 2006; Seaman et al., 2010; Zhao et al., 2005; 
D'Souza et al., 2007a; Tachezy et al., 2009; Fakhry et al., 2006; Turner et al. 2011). In 
contrast to oral rinse, biopsy specimens taken from healthy adults have reported prevalence 
rates between 0 – 15% (Ostwald et al., 1994; Mao, 1995; Bouda et al., 2000; do Sacramento 
et al., 2006). This thesis investigate any differences in sample type used for the detection of 
oral HPV as compared with these literature (Table 2.3).  
Data on oropharyngeal HPV prevalence is essential for the assessment of the need for and 
cost effectiveness of HPV related public health measures, such as including boys in the HPV 
vaccination programmes. It is also important for the determination of the age of viral 
acquisition in the general population and hence the age of start of vaccination programmes 




potential feasibility cost-effectiveness of screening programmes, and preventative educational 
programmes (Smith et al., 2007).  
1.8 Risk factors and transmission routes for oral HPV infection: 
Current smoking, male gender, and number of sexual partners have all been associated with 
oral HPV infection (Gillison et al., 2012). In particular, current tobacco use seemed to 
increase the odds of oral HPV infection 2.4 times (Kreimer et al., 2011). Oral HPV infection 
has been shown to have a high male preponderance (Antonsson et al., 2014). It is unclear why 
males are more predisposed but it could be linked to at-risk sexual behaviours. 
Maternal transmission has been suggested as a plausible route of oral HPV transmission 
(Syrjanen and Puranen, 2000; Pakarian et al., 1994; Rombaldi et al., 2009). Up to 80% of 
children born to mothers who are positive for genital HPV will have acquired HPV infection 
in their nasopharynx or oral cavity (Martinez and Troconis, 2014). HR-HPV infections in 
children may persist for a considerable length of time (Syrjanen et al., 2010; Pakarian et al., 
1994; Kravchenko 2011). Rombaldi et al., (2009) reported a 24.5% perinatal transmission rate 
of HPV DNA. A recent meta-analysis has also shown that vertical transmission could occur in 
up to 20% of cases (Syrjanen, 2010). 
Oral HPV infection appears to be sexually transmitted in adults, with strong associations with 
multiple sexual partners, an early age of sexual debut, oral sex and French kissing 
(Satterwhite et al., 2013; Pickard et al., 2012; Gillison et al., 2012; D'Souza et al., 2009; 
Sanders et al., 2012). People with Human Immunodeficiency Virus (HIV) infection are at an 
increased risk for simultaneous oral HPV infection too (Beachler et al., 2012). There appear to 
have been changing trends in sexual behaviours that has coincided with the increasing trend 




Some authorities have suggested sexual behaviours such as fellatio and cunnilingus may be 
high risk behaviour in the acquisition of oral HPV and that past sexual behaviours have an 
impact on the risk of OPC (Schnelle et al., 2017) but there is a lack of conclusive evidence to 
support this view (Rosenquist 2012). There has definitely been a shift in recent times in 
sexual attitudes and practices observed between the younger generation and the older cohort 
of participants in the NATSAL studies in the UK (Mercer et al., 2013). The younger 
participants had higher proportions participating in orogenital and anal sex.  
D’Souza et al. (2014a) similarly documented recently in a study on a US population the 
differential rates of oral HPV infection by increasing age based on the sexual behaviour 
reports provided in the National Health and Nutrition Examination Survey (NHANES). The 
older generation appeared to have lower oral HPV incidence rates compared to the younger 
cohort which was associated with less high risk sexual behaviours. This landmark study was 
on 2,116 men and 2,140 women and showed that although high proportions of both men and 
women (85.4% vs 83.2%) had ever performed oral sex, men were more likely to have higher 
numbers of lifetime oral and vaginal sexual partners with higher oral HPV 16 rates. There 
were statistically significant decreasing proportions of participants that had ever performed 
oral sex with advancing age as follows in these age groups: 30 – 44 years (90.3%), 45 – 59 
years (84.8%) and 60 – 69 years (72.7%), p<0.001 (D'Souza et al., 2009).  For oral HPV 16 in 
particular, multivariate analysis showed oral sexual behaviour as the primary predictor. There 
appeared to be no statistically significant difference reported in the prevalence of oral HPV in 
gay / bisexual men compared with heterosexual men (13.3% vs 11.0% p=0.65) or between 
lesbian / bisexual women compared with heterosexual women (6.1% vs 3.2%, p=0.45). 
(D'Souza et al., 2014a). It is unclear if digital-oral transmission is plausible. Further studies 




Recent work investigating if partners of individuals with HPV positive oropharyngeal cancer 
were at any increased risk, also showed no difference in oral HPV prevalence rates in these 
partners compared to the rest of the normal population (D'Souza et al., 2014b). 
1.9 Oral HPV persistence: 
Persistence of high risk HPV especially HPV 16 has been shown to be a critical step in ano-
genital carcinogenesis and associated with progression of disease in dysplastic cervical lesions 
(Remmink et al., 1995) and the development of cervical neoplasia (Cuschieri et al., 2005; 
Schettino et al., 2014). Syrjanen et al., (2012) suggested that a similar natural history in the 
oral cavity could mean that persistent infection with HPV 16 especially over 18 months leads 
to early oropharyngeal cancer. The mechanisms that help oncogenic HPV escape detection 
and clearance in the oropharynx remain unclear. The majority of oral HPV infections will be 
cleared by the immune system within 12 – 18 months (Kero et al., 2012) but sometimes oral 
HPV infections persist (Brendle 2014). New infections can occur in the natural history of oral 
HPV infection with previously HPV negative individuals becoming positive in consecutive 
interval testing. Multiple infections can also occur either with several high-risk HPV or a 
combination of both high- and low-risk strains (Brendle 2014). 
Work done in the prospective Finnish HPV family study on 324 pregnant women who had 
repeated oral HPV testing with nested PCR and Multimetrix® test (Progen, Heidelberg, 
Germany) over 6 years, showed HPV 16 and 6 were the genotypes that tended to persist most 
often (Rautava et al., 2012). The definition of persistence used in this study was having at 
least two positive oral samples with the same HPV strain. 74 of the 324 women (22.8%) had 
persistent HPV infection in the oropharynx although point prevalence varied between 15 – 




1.10 Oral HPV carcinogenesis: 
High risk HPVs are the oncogenic genotypes that have been shown to be associated with 
cancers and include genotypes 16, 18, 31, 33, 35, 51, 56, 66 (Munoz et al., 2006). HPV DNA 
has been found in cervical cancer (96%), anal cancer (90%), vaginal / vulval cancers (40%), 
oral cancers (26%) (Suwalska et al., 2014). 
Exposure to tobacco has been shown to be associated with oral premalignant lesions. HPV 16 
in particular has also been found to have high expression in oral leukoplakia (Sikka and Sikka 
2014). Benign oral lesions associated with HPV infection include condyloma acuminatum, 
squamous cell papilloma, verruca vulgaris and focal epithelial hyperplasia (Syrjanen et al., 
2003; Gonzalez et al, 2007)).  
High-risk HPV has been associated with oral epithelial dysplasia (McCord et al., 2013) and 
oral intraepithelial neoplasia (Woo et al., 2013). A recent meta-analysis by (Syrjanen et al., 
2011) has shown conclusively that HPV is associated with premalignant lesions of oral 
cancer. This is a confirmatory work since the group first documented the association between 
HPV and oral squamous cell carcinomas in 1983. This systematic review looked at 1885 
cases of oral squamous cell carcinoma and 2248 controls as well as 956 cases of oral 
potentially malignant disorders with 675 controls. HPV DNA was found to have significant 
associations with oral squamous cell carcinoma (OR=3.98; 95% CI: 2.62 – 6.02) and oral 
potentially malignant disorders (OR=3.87; 95% CI: 2.16 – 6.86) (Syrjanen et al., 2011). 
Oncogenic HPV especially HPV 16 has been implicated in the vast majority of HPV-
associated head and neck squamous cell carcinoma (HNSCC). HPV 16 is the most prevalent 
genotype in HPV-associated cancers of the oropharynx, particularly in tonsils and tongue base 




head and neck cancers with this proportion rising in oropharyngeal cancer to 50 – 80% (Ang 
et al., 2010; Chaturvedi et al., 2008). A systematic review by Hobbs et al (2016) showed the 
oropharyngeal cancer (tonsil and tongue base) had the strongest association with HPV. In a 
historic paper on risk factors for HPV-OPC, D’Souza et al (2007b) showed oro-genital 
transmission was important in the pathogenesis of HPV-OPC as well as multiple sexual 
partners, multiple lifetime sexual partners >6, and cigarette smoking.  
The anatomic origin of HPV-OPC is unknown. Some studies have suggested the tonsillar 
crypts as the site where carcinogenesis commences (Begum et al. 2005). Kim et al (2007) also 
published work that showed HPV integration begins in the tonsillar crypts and leads to the 
alteration of p16, EGFR and c-myc during tumourigenesis. Most tonsil cancers associated 
with HPV arose from the tonsillar crypts, and tended to be inverted and poorly differentiated. 
P16 expression localizes to HPV-positive cancers, and has been found to be intrinsic to the 
specialized epithelium of the tonsillar crypts (Begum et al., 2005). HPV has been isolated in 
the saliva of patients presenting with oral squamous cell carcinoma (Sahebjamee et al., 2009) 
A landmark research (Ang et al., 2010) in the RTOG 0129 randomised controlled trial has 
indicated OPC can be further stratified into high, intermediate and low-risk based on the HPV 
status, the primary and nodal stage of the disease. This prognostic classifier has been 
validated in an Italian population (Granata et al., 2012). This has implications for survival as 
demonstrated by (Fakhry et al., 2008) with a 95% 2 year overall survival in the HPV-OPC 
group compared with 62% in the HPV negative controls. The low risk group consist of 
patients who are HPV positive and do not smoke cigarettes; the intermediate group are HPV 
positive and smoke whilst the high risk group have HPV negative disease and smoke 
cigarettes. The best survival estimates have been demonstrated in the HPV positive, non-




70.8% and 46.2% respectively. It is clear HPV status has a strong prognostic effect coupled 
with these risk factor and disease stage parameters. HPV 16 positive cervical lymph node 
metastases strongly predict the primary tumour site as oropharyngeal in cancers of unknown 
primary (Weiss et al., 2011). 
1.11 Oropharyngeal cancer risk factors and clinical staging:  
Cancers affecting the oropharynx can involve any or a combination of the anatomic sub-sites 
that include the tonsils, base of tongue, soft palate, uvula and pharyngeal walls. The tonsils 
are the most commonly involved oropharyngeal sub-site in cancers of the oropharynx 
followed by the base of tongue (Syrjanen et al., 2003). The vast majority of oropharyngeal 
cancer are squamous cell carcinomas with lymphomas less frequently presenting as 
asymmetrical tonsil enlargement. Risk factors for oropharyngeal cancer include tobacco 
smoking, excessive alcohol consumption (working synergistically) and infection with high-
risk human papillomavirus in a subset of cases. Chewing of betel quid or areca nut is also a 
recognised risk factor in oropharyngeal cancer development especially in individuals from the 
Asian sub-continent where this practice is rife. There is also a male predisposition as is 
similarly observed for head and neck cancers generally.  
Patients present with a sore throat, swallowing difficulty, and a neck lump (which may be the 
only presenting symptom). There can be weight loss, tonsillar hypertrophy or ulceration, 
trismus and on occasion, voice change and breathing problems. The tumour can metastasize to 
distant organs especially the lungs and bone.                               




Staging of oropharyngeal cancer is undertaken using the TNM Classification based on the 
Tumour size, Nodal disease and Metastasis. The most recent AJCC TNM 8th edition (Amin et 
al., 2017) includes p16 positive (HPV) oropharyngeal cancer for clinical classification:  
T0: No primary identified 
T1: Tumour measures ≤ 2cm in greatest dimension 
T2: Tumour measures >2cm but ≤ 4cm in diameter 
T3: Tumour measures >4cm in diameter or extension to lingual surface of epiglottis 
T4: Moderately advanced local disease. Tumour extension involving muscles of 
tongue base, hard palate, constrictor muscles, medial and lateral pterygoid plates, pre-
vertebral fascia, or carotid encasement 
Nx: Regional lymph nodes cannot be assessed 
N0: Absence of nodal involvement in neck 
N1: One or more ipsilateral lymph nodes measuring ≤ 6cm in diameter 
N2: Contralateral or bilateral metastasis in lymph nodes, all ≤ 6cm in dimension 
N3: Nodal involvement >6cm in diameter 
Mx: Distant metastasis not assessed 
M0: Absence of metastasis to distant organs 
M1: Presence of metastasis to distant organs 
Depending on the stage of disease, current treatments for oropharyngeal cancer include 
chemo-radiation and surgical ablation using trans-oral approaches and selective neck 
dissections. Patients who have had chemo-radiotherapy for oropharyngeal cancer can now be 
monitored for recurrent disease in the primary site or neck using PET CT scans done 3 
months post-treatment (Mehanna et al., 2016). This paradigm shift has ensured patients avoid 
neck dissections (with the attendant complications) if their PET CT scans do not indicate avid 
uptake of 5 Fluoro-deoxy-glucose after primary treatment.                                                                                                 




The significant burden of cervical cancer propelled the development of the HPV vaccine. It is 
hoped that the vaccination of pre-pubertal girls will reduce the incidence of cervical cancer 
and the attendant mortality. There are currently two HPV vaccines available called Gardasil 
(Merck and Co. Whitehouse Station, NJ) and Cervarix (GlaxoSmithKline, Philadelphia PA). 
They both cover the high-risk genotypes HPV 16 and 18 while Gardasil in addition covers for 
the low-risk HPV 6 and 11. Neither is constituted with HPV DNA but contains virus-like 
particles made up of the L1 capsid protein of the targeted genotypes. Vaccination stimulates 
the recipient’s immune system to subsequently recognise the L1 capsid protein which 
constitutes 90% of the outer layer of HPV. Vaccination prevents development of HPV-
associated lesions (Suzich et al., 1995).  
Population coverage varies from country to country but at present HPV vaccination across 
Europe is primarily given to girls. There is now a ground-swell of opinion amongst experts in 
epidemiology, virology, public health and ENT surgery in favour of gender-neutral HPV 
vaccination, given the increasing incidence of HPV-associated oropharyngeal cancer and its 
predilection towards young males (Syrjanen et al., 2012). In the UK, HPV vaccination 
commenced in 2008 and has been delivered to girls aged 12 – 13 years, which is thought to be 
the age-group that precedes the age of sexual acquisition. The United States policy on HPV 
vaccination has been modified recently and the programme now includes the vaccination of 
males. The impact of vaccination both boys and girls will be evaluated in the coming years. 
There are however protagonists on either side of the discourse around the cost effectiveness of 
instituting gender-neutral vaccination in the UK. It must be borne in mind the cost of treating 
these young males who are in the prime of their productive years and the resultant dependence 




Since the background on this thesis was written, there has been a significant development 
with both boys and girls now included on the HPV vaccination programme commencing 
2018. This will be further reviewed in the discussion to follow on current trends.  
Certainly vaccinating boys will also provide protection for penile cancers, anal cancers, 
anogenital intraepithelial neoplasia, condylomata acuminate (genital warts) and recurrent 
respiratory papillomatosis which affect the general population and in addition may be 
commoner in the immunocompromised (Palefsky, 2010). This systematic review and meta-
analysis will provide required data on the baseline prevalence of oral HPV infection amongst 
healthy individuals stratified by their geographic locations and will help to inform vaccination 
strategies. 
1.13 HPV 16 genome 
HPV 16 is a double-stranded DNA virus composed of approximately 8,000 base pairs. The 
viral life-cycle is linked to the host cell’s differentiation and control mechanisms (Graham 
2013) as described in section 1.4.  
The HPV genome encodes for early and late genes (Figure 1.5). The early genes include E1, 
E2, E4, E5, E6, and E7. The late genes are L1 (major capsid protein) and L2 (minor capsid 
protein) and are required for viral assembly and release (Schiffman et al., 2007). The HPV E1 
gene is involved in viral replication, the E2 gene in replication and transcription, the E4 gene 
in viral release, the E5 gene in immune evasion mechanisms, E6 oncogene binds p53, and the 
E7 oncogene binds the tumour suppressor gene retinoblastoma, RB (McLaughlin-Drubin et 
al., 2012; Ghittoni et al., 2010). This ultimately leads to a loss of cell-cycle regulation. HPV-




a loss of regulation for and over-expression of viral oncogenes E6 and E7 (Doorbar et al., 
2006).  
The expression of E6 and E7 genes critical in carcinogenesis as described, is controlled by the 
upstream regulatory region (URR) of the HPV 16 genome. The HPV 16 URR consists of p97 
promoter, enhancer elements which contain E2 binding sites and the viral origin of replication 
(ORI) (Figure 1.5). The role of E2 binding in E6 / E7 transcription regulation has been well 
described. In addition to E2 binding sites, the HPV 16 URR contains TAT and E2 binding site 
2. Regulation of HPV gene expression also occurs at the level of RNA splicing and 
polyadenylation with dysregulation leading to persistent infection and ultimately cancer 
(Johansson and Schwartz 2013). The early (AE) and late (AL) polyadenylation sites in the 






Figure 1.5: Human Papillomavirus 16 genome (Stanley et al., 2012)                                               
HPV 16 genome encodes for early genes E1, E2, E4, E5, E6 and E7 as well as late genes L1 
and L2.  The viral upstream regulatory region (URR) is also shown containing the origin of 
replication (ORI), promoter and enhancer elements.  
 
1.14 HPV 16 E2 gene: 
The HPV 16 E2 gene encodes for a transcription factor that plays an important role in viral 
regulation at multiple levels and via different mechanisms. These include initiation of viral 
DNA replication, maintenance and segregation of viral genomic DNA (Graham 2013). It is 
also required for replication stability long-term with regulation of the expression of viral 
helicase E1. Importantly, the E2 protein binds to E2 binding sites located in the Upstream 
Regulatory Regions (URR) of the HPV genome in order to modulate the p97 promoter in 
HPV 16 and subsequently the expression of E6 and E7 (zur Hausen 2009; Bernard 2002). 
Loss of E2 regulation, as a consequence of viral integration and disruption of the E2 open 
reading frame (described in detail in 1.18) is considered a key step in carcinogenesis 
especially in anogenital cancers (Kalantari et al 1998, Arias-Pulido et al 2006).  
1.15 HPV 16 E2 binding sites: 
The HPV 16 E2 recognizes and binds to palindromic DNA sequences (51-ACCG-(N)4-CGGT-
31) (Phelps and Howley 1987; Romanczuk et al 1990). There are four recognized E2 binding 
sites in the HPV 16 URR, with three of them being transcriptionally relevant: the high-affinity 
E2 binding site 1 (E2BS1) which involves CpG positions 7452 and 7458 and the low-affinity 
E2 binding sites 3 (E2BS3) located at CpG positions 37, 43 and the E2 binding site 4 (E2BS4) 
located at CpG position 52, 58. The fourth E2 binding site – E2BS2 located at CpG position 




1.16 HPV E6 and E7 mechanisms of action in carcinogenesis: 
Early oncoproteins produced by HPV include E6 and E7, with their expression retained in all 
HPV-induced cancers. These two oncoproteins lead to deregulation of tumour suppressor 
genes and ultimately genomic instability (Roberts 2015). Several cellular pathways 
responsible for cell cycle control are targeted by both E6 and E7, in addition to regulation of 
apoptosis and cell polarity (Vjekoslav et al., 2016). The dysregulation of cell cycle pathways 
and apoptosis caused by oncoproteins E6 and E7 allows HPV proliferation to be maintained 
in suprabasal epithelium and eventual viral genomic amplification in the HPV lifecycle (Ganti 
et al., 2015; Doorbar et al., 2012).  
When viral integration occurs into host genome during carcinogenesis, most of the early 
proteins are lost but E6 and E7 expression remains uncontrollable leading to cellular 
immortalization and transformation (Smotkin and Wettstein 1986). The actions of E6 and E7 
have been shown to be complementary with E6 promoting survival pathways in the cell while 
E7 promotes cellular proliferation (Barbosa et al., 1989; Hawley-Nelson et al., 1989; 
Mantovani and Banks 2001). Overexpression of E6 and E7 leads to dysregulation of p53 and 
RB proteins respectively (Villavicencio-Torres et al., 2013) (Figure 1.6). However, in head 
and neck squamous cell cancers, oncoprotein E7 appears to play a more dominant role in 
tandem with E6 which acts in later cancer stages (Strati and Lambert 2007).  
The E7 oncogene is involved in DNA synthesis initiation and also stimulates continuous cell 
growth. The retinoblastoma gene pRB, is an important negative regulator of the cell cycle S 
phase entry. When RB is unphosphorylated (in the early G1 phase), it interacts with E2F 
transcriptional factors and functions as a transcriptional repressor of promoters that contain 




associated with cell cycle progression (Slansky and Farnham 1996). G1 cyclin-dependent 
kinases mediate phosphorylation of p RB which causes E2F release accompanied by cell 
cycle progression to the S phase (Figure 1.6). In HPV 16 infected cells, E7 targets and 
degrades unphophorylated RB through the ubiquitin-proteasome pathway (Boyer et al., 1996) 
(Figure 1.6). This interaction can cause a disruption of the p RB – E2F complexes and induce 
premature entry of cells into the S phase of the cell cycle (zur Hausen 2000, 2002; Boyer et 
al., 1996; Jones et al., 1997; Berezutskaya et al., 1997; Nguyen et al., 2002). Specifically in 
HPV 16, the association of E7 with the cullin 2 ubiquitin ligase complex is also contributory 
(Huh et al., 2007). The HPV 16 oncoprotein E6 is involved in a number of interactions in 
HPV infected cells. Broadly, these important interactions include a proteasome-mediated 
degradation of p53 tumour suppressor gene, degradation of PDZ and expression of hTERT 









Figure 1.6: HPV E6 and E7 critical interactions in cell cycle deregulation and 
carcinogenesis. High-risk human papilloma virus E6 and E7 oncoproteins react with the 
tumor suppressor gene products p53 and pRb in host cell proteins, respectively. E7 inhibits 
the retinoblastoma family and constitutive activation of E2F responsive genes. E6 inhibits 
p53-dependent growth arrest and apoptosis. Degradation of p53 bypasses the normal growth 
arrest of the cell cycle from G1 to S phases (Senba and Mori 2012).  
 
Following DNA damage in untransformed cells, the tumour suppressor gene p53 is involved 
in apoptosis. p53 is also involved in the regulation of cell cycle phases G1/S and G2/M 
(Thomas et al., 1999). HPV infected cells cause a loss of inhibition of apoptosis via E6 
inactivation of p53.  The HPV E6 oncoprotein labels the p53 tumour suppressor gene for 
degradation by transporting ubiquitin peptides from the E6 associated protein (E6AP) to p53 
(Figure 1.6). This results in activation of human telomerase reverse transcriptase (hTERT) 




tumour cells not being subject to cellular aging (Senba and Mori 2012). E6 also causes a 
dysfunction of some proteins that induce apoptosis namely, BAK, FADD and procaspase 8 
(Thomas et al., 1999; Garnett et al., 2006). BAK proteins are responsible for apoptosis in 
differentiated epithelium. High-risk HPV E6 oncoprotein binds to BAK proteins with high 
affinity, resulting in suppression of cellular apoptosis and immortalization (Modrow et al., 
2013; Haedicke and Iftner 2013).  
 
The complex viral and host cell interactions initiated by HPV oncoproteins E6 and E7 are 
aptly summarised by Chung and Gillison (2009) in Figure 1.7. It shows ubiquitination by E7 
and the cullin 2 ubiquitin ligase complex leads to degradation of p RB (Dyson et al., 1989; 
Huh et al., 2007; Harbour et al., 1999; Rubin et al., 2005) (Figure 1.9A). Inhibition of cell 
cycle arrest occurs when E7 interacts with p27Kip1 (Zerfass-Thome et al., 1996) and p21Cip1 
(Jones et al., 1997b) respectively (Figure 1.9B and C). Ubiquitination by E6 and ubiquitin 
ligase E6AP leads to p53 degradation (Scheffner et al., 1990 and 1993; Huibregtse et al., 
1991) (Figure 1.9 D) with apoptosis resistance and genomic instability. This complex 
degradation of p53 also leads to deregulation of DNA damage repair and cellular senescence. 
There is increased expression of p16INK4A as a consequence of feedback loops resulting 
from pRB dysfunction (Khleif et al., 1996) (Figure 1.9 E). The transcriptional repressor of 
hTERT called NFX-1 is also degraded by the E6-E6AP complex with resultant cellular 
immortalization (Katzenellenbogen et al., 2009) (Figure 1.9F). The combination of these cell 
cycle dysregulations by HPV oncoproteins E6 and E7 lead to genomic instability and 







Figure 1.7: Malignant transformation in keratinocytes mediated by HPV E6 and E7 
oncoproteins (Chung and Gillison 2009; Used with permission – RightsLink licence 
number 4447620877537) 
Clockwise from A, ubiquitination by E7 and the cullin 2 ubiquitin ligase complex leading to 
pRb degradation; B, interaction between E7 and p27Kip1 resulting in inhibition of cell cycle 
arrest contributing to carcinogenesis; C, interaction between E7 and p21Cip1 resulting in 
inhibition of cell cycle arrest contributing to carcinogenesis; D, ubiquitination by E6 and 
ubiquitin ligase E6AP leading to p53 degradation; E, increased expression of p16INK4A by a 
consequent of feedback loops from the absence of pRb function; and F, degradation of NFX1, 
a transcriptional repressor of hTERT, by association with E6/E6AP resulting in hTERT 






1.17 HPV 16 viral auto-regulation 
Auto-regulation of the HPV 16 viral genome ensures low levels of E6 and E7 transcripts 
when the E2 gene is intact (Reuschenbach et al., 2015). This auto-regulation is shown in the 
upper panel of Figure 1.8 (A). The E2 protein will preferentially bind to the high-affinity 
E2BS1 resulting in activation of the p97 promoter which leads to increased expression of E6 
and E7 but also E2 itself. The increased levels of E2 would in turn result in enhanced binding 
to the low-affinity E2BS3 and E2BS4 sites, responsible for promoter inhibition. Therefore, 
binding of E2 protein to these 2 binding sites results in a counteracting inhibitory effect to the 
promoter stimulatory effect produced by E2 binding to E2BS1. Loss of E2 protein and hence 
this auto-regulation results in over-expression of oncogenes E6 and E7 which inhibit the 
actions of tumour suppressor proteins p53 and RB respectively as shown in the lower panel, 
Figure 1.8 (B). There are two proposed mechanisms as to the loss of viral autoregulation: 






Figure 1.8: Auto-regulation of E6/E7 oncogene expression by E2 protein binding 
in the HPV 16 URR and the methylation-mediated over-expression of E6/E7. 
(Adapted from Reuschenbach et al 2015). When the E2 gene is intact as shown in 
upper panel, the E2 protein binds avidly to the high-affinity E2BS1(resulting in 
activation of p97 promoter) as well as the low affinity E2BS3 and 4(with promoter 
inhibition). The balance achieved results in low levels of E6/E7 expression. With E2 
gene disruption as shown in lower panel, the low concentrations of E2 protein 
preferentially bind to the high-affinity E2BS1 resulting in promoter hyperactivation. 
The reduced binding to E2BS3 and E2BS4 leads to a loss of promoter inhibition. The 
combined effect is evidenced by high expression levels of E6 and E7. E2BS1 location 
overlaps with CpG sites 7453, 7459; E2BS3 with CpG sites 37, 43; and E2BS4 with 







1.18 HPV 16 integration in oropharyngeal cancer and E2 gene disruption 
HPV integration results in disruption of the viral regulatory E2 gene. This step in 
carcinogenesis has been shown to be an associated but not necessary step for all 
cervical cancers (Graham 2013, Raybould et al., 2014). The disruption of the E2 gene 
occurs in approximately 70% of cervical cancer cases in published literature. 
However, in tonsillar cancers, the viral genome integration has been reported at much 
lower frequency with approximately 16 – 43% E2 gene disruption assessed by PCR, 
reported in the available literature as shown in Table 1.1. This range of integration in 
tonsil cancer is pooled only from studies using PCR-based methods and that include 
tumour samples for ten or more patients (Table 1.1).  
When the E2 gene is disrupted in a mixed (intact and episomal) infection, there is less 
E2 protein concentration available to bind to the E2 binding sites in the HPV 16 URR. 
In this scenario, the available E2 protein binds preferentially to the high-affinity 
E2BS1 with unopposed activation of the p97 promoter (Figure 1.8, lower panel). In 
addition to disruption of E2 sequence itself, it has become clear from recent studies 
using next-generation sequencing techniques, that HPV integration might occur at 
multiple sites outside of E2 gene, including E1, L1, and L5 (Wilson et al., 2013). The 
HPV 16 genome transcription mechanisms are poly-cistronic and a dysfunction along 
the chain upstream of the E2 gene could affect its function even if the E2 gene remains 
undisrupted and intact when assessed by PCR. Therefore, the conclusion that HPV 
integration is absent based on E2 disruption solely should be drawn with caution. This 
is a crucial point that exposes the limitation in the technique used in determining the 
physical status of the viral E2 gene in this study i.e. PCR with overlapping primers to 




explain the differences in HPV integration observed across published studies as shown 
in Table 1.1. For example, in-situ hybridisation identified 100% HPV integration 
when used in combination with p16 immunohistochemistry on 8 OPC samples 
(Begum 2005) but on its own, in-situ hybridisation demonstrated HPV integration in 
67% of 12 OPC samples (Hafkamp et al., 2003) and 42% integration in the largest 
OPC cohort of 77 samples (Mooren et al., 2013) (see Table 1.1). APOT-PCR on the 
other hand, as shown in Table 1.1, showed HPV integration in 37% - 67% of the 
OPCs analysed in various studies (Reuschenbach et al., 2015; Olthof et al., 2015; Lace 
et al., 2011; Wiest et al., 2002). 
In addition, integration and/or E2 disruption is rarely accompanied by a loss of E2 
expression in OPC due to the presence of both intact (episomal) and disrupted viral 
genomes (Reuschenbach et al., 2015). Therefore, additional mechanisms of E2 












Table 1.1: Literature on HPV 16 integration and E2 disruption in OPC. This table lists 
the studies reporting HPV integration in OPC and the different techniques used including 
detection of integrated papillomavirus sequences by ligation-mediated polymerase chain 
reaction (DIPS-PCR), amplification of papillomavirus oncogene transcripts (APOT)-PCR, 
fluorescence in-situ hybridisation (FISH), p16 immunohistochemistry (IHC), real-time q PCR, 
genome-wide next generation sequencing, restriction enzyme cleavage, ligation and PCR 
(rliPCR), E2 mRNA level mapping, E2: E6 ratio <0.5, and bioinformatics analysis of RNA 
Seq data.  
First Author Year OPC sample 
size 
HPV integration technique Percentage HPV 
integration 
Olthof 2015 75 DIPS and APOT-PCR 39 
Reuschenbach 2015 49 APOT and DIPS-PCR 37 
Khoury 2013 36 Bioinformatics analysis of RNA Seq 
data 
67 
Vojtechova 2016 14 Mapping  E2 mRNA level, APOT and 
Southern blot 
43 
Gao 2014 13 Genome-wide mate pair next 
generation sequencing 
15 
Hafkamp 2003 12 FISH 67 
Mellin 2002 12 Restriction enzyme cleavage, 
ligation and PCR (rliPCR) 
0 
Wiest 2002 9 APOT-PCR 67 
Begum 2005 8 HPV 16 in situ hybridization and P16 
IHC 
100 
Lace 2011 4 APOT-PCR 50 
Wilson 2013 3 HPV whole genome sequencing  
Mooren 2013 77 FISH 42 
Barbieri 2014 51 real-time q PCR, E2: E6 ratio <0.5 16 
Park 2011 20 real-time q PCR, E2: E6 ratio <0.5 35 
Koskinen 2003 23 real-time q PCR, E2: E6 ratio <0.5 48 




1.19 HPV epigenetics and the role of DNA methylation: 
DNA methylation is an addition of a methyl group to cytosine to form 5-methylcytosine 
(Figure 1.9). Enzymes that add a methyl group are called DNA methyltransferases. Cytosines 
are methylated within CpG dinucleotides. The CpG sites or CG sites are dinucleotides where 
a cytosine nucleotide occurs next to a guanine nucleotide in the linear sequence of bases along 
its length. High densities of CpGs are often present at gene promoters and transcriptional start 
sites and such regions are referred to as CpG islands. In mammals, CpG island methylation 
can silence the gene.  
 
Figure 1.9: Conversion of cytosine to 5-Methylcytosine (Fakhr et al., 2013) 
In mammals, DNA methylation is essential for normal development and is associated with a 
number of key processes including genomic imprinting, inactivation of the X-chromosome, 
suppression of repetitive elements, and carcinogenesis. In HPV 16 genome, methylation has 
been involved in regulation of the HPV E2 protein binding affinity to the URR, leading to 






1.20 HPV 16 E2 binding sites methylation and epigenetic controls 
In cervical cancer research, it has been shown that increasing levels of HPV methylation 
correlate with increasing severity of cervical cancer grade i.e. progressing from intraepithelial 
neoplasia to frank cervical cancer (Chaiwongkot et al., 2013). In oropharyngeal cancer, work 
done by Doeberitz and Vinokurova (2009) and subsequently by Reuschenbach et al., (2015), 
revealed the impact of methylation on the auto-regulation of the HPV 16. They hypothesized 
that hypermethylation of the high-affinity E2 binding site 1 (E2BS1) located in the long 
control region (LCR) of the HPV 16 Upstream Regulatory Region (URR) at the 5’ end results 
in further promoter activation (Figure 1.10). In contrast, methylation of the low-affinity 
inhibitory E2 binding sites (E2BS3 and E2BS4) located in the promoter region of the HPV 16 
URR results in loss of promoter inhibition. Similar conclusions have been drawn from the in 
vitro studies (Thain et al., 1996). The combination of these two methylation events at the E2 









Figure 1.10: Impact of E2 binding sites methylation on E6 and E7 expression. The upper 
panel shows preferential binding of the E2 protein to E2BS1 and reduced binding to 
inhibitory E2BS3 and E2BS4 in the presence of E2 gene disruption (in mixed infection), with 
over-expression of E6 and E7 oncoproteins. The lower panel depicts the potential impact of 
methylation on the E2BSs with methylation at E2BS1 resulting in promoter activation while 
methylation at E2BS3 and E2BS4 results in loss of promoter inhibition. The combination of 
these effects leads to over-expression of E6 and E7 (Reuschenbach et al., 2015) 
 
So far, studies on methylation in oropharyngeal cancer indicate that the LCR region of HPV 
16, location of the E2BS1, is mostly unmethylated (see Table 1.2). However, Barbieri et al. 
(2014) investigated the methylation profiles at the HPV 16 URR in a cohort of 60 tumours 
and found that the promoter activating E2BS1 had higher methylation frequency when 
compared with the promoter inhibiting E2BS3 and E2BS4. This was similar to the 
observations made in cervical cancer (Jacquin et al., 2013). In another study on HPV OPC, 
Reuschenbach et al. (2015) found E2 gene disruption by PCR in 37% of their cohort. In this 
study, there was no significant difference in methylation at the high-affinity E2BS1 regardless 
of the E2 status (intact or disrupted) while these Oropharyngeal cancer could be stratified into 




Significantly, cases of oropharyngeal cancer with hypermethylation at the inhibitory E2 
binding sites had a worse 5 year survival when compared to those cases with intermediate 
methylation (Reuschenbach et al., 2015).  
Table 1.2: HPV methylation in oropharyngeal cancer 
Author Year OPC 
sample 
size 
Viral methylation findings 
Reuschenbach 2015 57 3 subgroups with differential methylation at E2BS 3 and 4; 
high methylation associated with worse overall 5yr survival 
Barbieri 2014 60 E2BS1 has higher methylation frequency compared to  
E2BS 3 and 4 
 
Park 2011 22 HPV 16 epigenome is hypomethylated in advanced HPV 
HNC with the LCR preferentially hypomethylated 
Wilson 2013 3 453 differentially methylated regions in the HPV host 
methylome. HPV 16 integrates at multiple sites and 
predominantly involves E2 viral genome. LCR unmethylated 
 
Some of the reported techniques for determination of viral methylation patterns in head and 
neck squamous cell carcinomas are listed in Table 1.3 and discussed by van Kempen et al. 
(2014) in a systematic review that also covers changes in DNA methylation in the host. These 
include methylation-specific PCR (MSP), combined bisulfite restriction analysis, 







Table 1.3: Methylation techniques in head and neck cancers 
Methylation determination technique Literature 
Methylation specific PCR (MSP) Ren 2018 
Combined bisulfite restriction analysis (COBRA) Bennett 2010 
Furniss 2008 
Pyrosequencing analysis (PMA) Poage 2011 
Richards 2009 
Bead Array Method (BAM) Colacino 2013 
Lechner 2013 
Sartor 2011 
Quantitative MSP (q-MSP) Kostareli 2013 
Gubanova 2012 
 
Pyrosequencing has been used to quantify HPV 16 DNA methylation in transcriptionally-
active HPV OPC (Barbieri et al., 2014). The E2 binding site 1 (E2BS1) had higher mean 
methylation frequency compared with E2BS3/4. In this study, mean methylation frequency 
>10% in the promoter region of the HPV genome, was associated with a worse clinical 
prognosis (Barbieri et al., 2014).  
Hypomethylation of the long control region (the regulatory region of the viral genome) was 
also observed in advanced stage III/IV HPV-associated oropharyngeal cancer which 
correlated with expression levels of the E6 and E7 oncogenes (Park et al., 2011). There 
appears to be variability in the viral load in head and neck cancers as well as the existence of 
both episomal and integrated HPV in oropharyngeal cancer (Park et al., 2011). The authors 




cancer was detectable in saliva and serum using methylation-specific PCR. This could be a 
significant biomarker for HPV DNA integration if confirmed in a study with a larger sample 
size. 
1.21 PhD project rationale: 
The epidemiology and natural history of oral HPV infection in OPC remains incompletely 
described. This information is crucial to our understanding of how high-risk human 
papillomavirus (HR-HPV) infection in the oral cavity progresses through persistence, latency, 
immune system evasion or modification and ultimately cancer causation. The systematic 
review and meta-analysis in Chapter 2 of this thesis aims to provide a comprehensive 
overview of oral HPV epidemiology and natural history in healthy populations with respect to 
prevalence, persistence, associated risk factors, and any variations in geographic location, 
detection technique or oral sample type.  This has implications for the development of any 
screening strategies, the identification of any at-risk population groups and the evaluation of 
the need for and efficacy of HPV vaccination programs.  
HPV oropharyngeal cancer is significantly different to HPV negative oropharyngeal cancer in 
every sphere – epidemiologically, biologically, in disease progression and in response to 
current treatments. In the main, patients with HPV positive oropharyngeal cancer tend to be 
males, are younger than patients with HPV negative OPC and do not necessarily have a 
history of tobacco smoking or excessive alcohol consumption.  
There is an on-going discourse around the potential impact of tonsillectomy as an intervention 
that abrogates the natural history of oral HPV infection and therefore protects against the 
development of HPV-associated oropharyngeal cancer long-term. A recent Danish study 




rates in a cohort of people who had a history of tonsillectomy when compared with 
individuals who did not have tonsillectomy (Fakhry et al., 2015). The study also showed this 
protective effect was greatest when tonsillectomy was performed over a year prior to a 
diagnosis of oropharyngeal cancer. This finding needs validation in other populations as it 
could mean that tonsillectomy is a cost-effective preventative secondary measure alongside 
primary prevention with HPV vaccinations. Chapter 3 of this thesis presents for the first time 
in the UK, data on the potential impact of tonsillectomy on the prevalence of oral HPV 
infection in a prospective cohort of healthy individuals who had tonsillectomy for non-cancer 
reasons.  
Oropharyngeal cancer is linked to various demographic and risk factor behaviours which also 
have a significant impact on recurrence-free and overall survival. Chapter 4 of this thesis 
describes a retrospective review of 28,846 oropharyngeal cancer cases registered in the UK 
Hospital Episodes Statistics (HES) database and identifies the impact of age, gender, 
socioeconomic status or deprivation scores on survival and cancer recurrence. This chapter 
also investigates any regional variations in the UK in the incidence of oropharyngeal cancer. 
This is important for targeted cancer-risk assessments and resource allocation with a view to 
better understand the underlying reasons for any regional predispositions and the institution of 
appropriate preventative and diagnostic pathways.  
There is very little published on the HPV genome and epigenome in HPV-OPC despite its 
distinct molecular profile when compared with HPV negative OPC. The physical status of the 
virus and methylation has been studied in some centres with conflicting accounts on relevance 
to clinical outcomes. This thesis explores genomic or epigenetic modifications such as HPV 
E2 gene disruption and aberrant methylation at the E2 bindings sites in the viral upstream 




survival in a cohort of HPV positive OPC described in Chapter 5. The possible impact of risk 
factors such as smoking and demographic variables such as gender and age, on the HPV 
genome and epigenome itself, are also investigated in this thesis.  
The findings from this thesis will corroborate current literature on the epidemiology of oral 
HPV infection in healthy individuals in a global meta-analysis and also reiterate determinants 
of survival in a cohort of UK patients with oropharyngeal cancer. There will be new 
information on the potential impact of tonsillectomy on oral HPV burden as well as new 
observations on viral genomic and epigenetic mechanisms in a cohort of HPV-associated 




















PhD CHAPTER 2 
PREVALENCE AND PERSISTENCE OF OROPHARYNGEAL HUMAN 
PAPILLOMAVIRUS INFECTION IN HEALTHY ADULT POPULATIONS BY 
SAMPLE TYPE, DETECTION TECHNIQUE AND GEOGRAPHY: 














There remain significant gaps in our knowledge of HPV-OPC and HPV infection of the 
mouth at this time including its prevalence, natural history, risk factors, transmission, viral 
persistence, the presence of premalignant lesions, and the effect of vaccination, effective 
treatment modalities and the projected disease burden. This systematic review of the current 
literature focused on the natural history of oral HPV infection in particular viral prevalence 
and persistence, with a view to facilitating our understanding of this disease. This information 
is important for the assessment of the need for and cost effectiveness of HPV related public 
health measures, such as including boys in the HPV vaccination programmes. It is also 
important for the determination of the age of viral acquisition in the general population and 
hence the age to start vaccination programmes (Kim et al., 2008; Smith et al., 2007). These 
data are also essential for the evaluation of the potential feasibility cost-effectiveness of 
screening programmes, and preventative educational programmes (Smith et al., 2007). There 
is currently no UK data available on the subject of persistence of oropharyngeal HPV 
infection which this study aimed to provide with an elucidation of the possible risk factors 
that ultimately lead to cancer development. It is also unclear if geographic location plays any 
role in the prevalence of oral HPV infection and this review interrogated this further.  
2.2 Review questions: 
1. To describe the prevalence of oral and oropharyngeal HPV infection in healthy 
adult populations by age, gender, viral type, sample type, HPV detection 
technique, and geography. 
2. To identify the high risk HPV genotype(s) that persists in the oral cavity / oropharynx 





2.3 Review protocol:  
The protocol for this systematic review and meta-analysis was published online in 
accordance with international guidelines for the conduct of systematic reviews on 
PROSPERO (International Prospective Register of Systematic Reviews) in 2014:  
Oladejo Olaleye, Esmond Carr, Jayne Wilson, Hisham Mehanna. Prevalence and 
Persistence of oral and oropharyngeal human papilloma virus infection in the healthy 
population by sample type, detection technique and geography: a systematic review and 
meta-analysis. PROSPERO 2014 CRD42014009205 Available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42014009205 
2.4 Population, exposure and outcomes: 
Population: Normal population. 
Exposure: Oral or Oropharyngeal human papilloma virus infection. 
Outcomes: Prevalence and persistence of oral HPV infection 
 Stratified by sample type, detection technique and 
geography. 
2.5 Inclusion criteria for participants: 
1. Patients or healthy volunteers aged 12 years and above, from any geographic 
location in the world and regardless of whether they were sexually active or not.  
2. Participants with or without any documented risk factors such as cigarette 
smoking, alcohol consumption, oral sex, French kissing or multiple sexual 
partners. 
3. Any human studies with oral HPV status documented as well as duration of 
persistent infection in any age group and with any HPV detection technique done 




2.6 Primary outcomes: 
1. Prevalence of oral HPV infection expressed as pooled prevalence with 95% 
confidence intervals 
2. Prevalence of oral HPV infection by detection technique, tissue type, gender, age, 
and geography 
3. Persistence of oral and oropharyngeal human papilloma virus infection and the 
duration of persistence. 
4. The analyses were expressed as weighted proportions, with accompanying 95% 
confidence intervals.  
2.7 Secondary outcomes: 
1. Investigated time-trends of oral HPV prevalence reported in all included studies.  
2. Identified by age-distribution analyses, any particular age-group susceptible to higher 
oral HPV prevalence 
3. Documented any variations in oral HPV persistence by gender, sample type (tonsil, 
oral rinse, tongue base / pharyngeal swabs), detection technique (p16 
immunohistochemistry, HPV DNA by polymerase chain reaction, ELISA) and 
geography. 
4. The analyses were expressed as weighed proportions, with accompanying 95% 







2.8 Types of studies included: 
1. Randomised controlled clinical trials (RCTs) were considered eligible for inclusion if:  
 Oral HPV status was included as part of the demographics for healthy adults 
 Oral HPV detection techniques were specified 
 Healthy adults were in the non-intervention arm of the RCT e.g. receiving no HPV 
vaccination  
2. Cross-sectional studies on healthy adult populations that tested for oral HPV infection 
3. Prospective or retrospective Cohort studies of healthy adults for oral HPV testing 
4.  Population screening studies for oral HPV infection. 
5. Studies that documented oral HPV prevalence by any detection technique in any 
geographic location 
6. Studies that assessed the diagnostic efficacy of oral HPV screening tests including use 
of PCR, ELISA, p16 immunohistochemistry, E4 or E6 proteins 
7. Studies that assessed differences in HPV detection in various samples such as oral 
rinse, oral / throat swabs, pharyngeal swabs / brushes, tongue base brushes, tonsil 
specimens 
8. Studies that documented repeated sample testing for persistence of oral HPV infection 
regardless of duration from index testing 
2.9 Exclusions:  
1. Case-control studies with oral HPV infection status including both cancer and non-
cancer case-control studies 
2. Studies in populations that could not be classed as healthy adults or could be at-risk 




immunocompromised (HIV), sexually transmitted diseases clinic attendees, women 
with HPV positive cervical tests, genetic abnormalities, Fanconi’s anaemia patients, 
and participants with any clinically detectable oral lesions. 
3. All oral HPV studies on children or anyone less than 12 years old were excluded as 
viral acquisition and transmission routes differ in this group.  
4. All studies with sample size less than 50 healthy adults.  
5. Exclusions also included letters, opinion papers, editorials, case reports 
6. All animal studies 
7. All in-vitro studies 
2.10 Searches: 
A comprehensive search of the published literature was performed as detailed in the published 
protocol on PROSPERO in 2014 cited in section 2.3. Studies were identified from reviews, 
database searches, clinical trials, specialized databases and grey literature.  
2.10.1 Reviews included Cochrane database of systematic reviews, Database of Abstracts 
of Reviews on Effects (DARE), International Prospective Register of Systematic 
Reviews (PROSPERO) and Health Technology Assessment (HTA).  
2.10.2 Databases searched included MEDLINE, EMBASE, NICE and the Cochrane 
Central Register of Controlled Trials 
2.10.3 Clinical trials included trials on the current controlled metagister: 
http://www.controlled-trials.com/mrct/ ClinicalTrials.gov http://clinicaltrials.gov/, 
the UK International Clinical Research Network Portfolio (NIHR CRN) 




International Clinical Trials Registry Platform (ICTRP) 
http://www.who.int/ictrp/en/ 
2.10.4 Specialised databases were searched on the websites for the International Agency 
for Health Technology Assessment (INAHTA), the International Agency for 
Research into Cancer (IARC), and the University of York National Health Service 
(NHS) Centre for Reviews and Dissemination (CRD)  
2.10.5 Grey literature search and other literature searches were conducted by reviewing 
relevant paper from Conference papers index, Zetoc database of conference 
abstracts https://zetoc.mimas.ac.uk/ , internet searching (e.g. Google scholar), 
hand-searching of Journals such as Head Neck, Clinical Otolaryngology, European 
Archives of Otolaryngology, Head and Neck Surgery, Virology, Oral Oncology. 
Content experts were also contacted for additional studies, and for further 
information regarding on-going trials or studies. No language restrictions were 
used. The reference lists of all potentially relevant papers including reviews, meta-
analyses, editorials, consensus statements, letters, recent text books and conference 
proceedings were reviewed for studies that could be included. In order to update 
the literature, alerts were established in PubMED/MEDLINE, EMBASE, ZETOC 
and current additions to the literature were added throughout the conduct of the 
systematic review. 
2.11 Data selection and coding 
The initial literature search results were examined independently by two reviewers (Oladejo 
Olaleye and Esmond Carr). Pre-specified inclusion and exclusion criteria were applied and 




or citations were selected if their title, abstract or key words suggested inclusion of relevant 
information on prevalence and persistence of oral HPV infection. 
The two reviewers then independently reviewed each retrieved article to formally appraise it 
against the pre-specified inclusion and exclusion criteria. All articles selected and excluded by 
each reviewer were then compared. Any disagreements regarding article inclusion were 
resolved by consensus or if required, with the assistance of a third reviewer (Jayne Wilson or 
Hisham Mehanna). 
At every screening or selection stage, the reason(s) for exclusion of any study were 
documented. Reference lists of excluded manuscripts were however searched for any relevant 
trials or studies. 
2.12 Data extraction and management: 
For each included study or review, data was collected including year of data collection, year 
of publication, study design, geographic location of study, patient / participant demographics 
(mean age, median age, gender, number of males and females in total, number of males and 
females with oral HPV infection), risk factor exposure such as cigarette smoking, alcohol 
consumption, oral sex, french kissing, multiple sexual partners. Oral HPV positive data was 
sub-divided into overall, high-risk HPV, HPV 16, and HPV 18 total numbers and proportions. 
Data on oral HPV persistence were extracted from all studies that retested participants after a 
period of time from the index test using any HPV detection techniques. Oral HPV detection 
techniques used in each study reporting prevalence were collected as well as the sample type 
e.g. oral rinse, oral swab / brush, pharyngeal swab / brush, tonsil specimens, exfoliated 




each included study. Differences were resolved by consensus or with the help of an 
independent third expert (Jayne Wilson or Hisham Mehanna). Whenever it was required, 
further information was sought from the authors of studies.  
2.13 Risk of bias (quality) assessment 
All included studies were assessed critically for methodological quality, internal and external 
validity by two independent reviewers. For included systematic reviews, the checklist used 
was AMSTAR (A Measurement Tool to Assess Systematic Reviews) www.amstar.ca. 
Observational studies were also assessed for quality. 
To explore the quality, internal/external validity and overall strength of the evidence included, 
the following were considered: 
 Quality of randomised controlled trials including the study designs. Strength of the 
evidence where non-RCTs were included 
 Potential sources of bias including publication bias, publication status (i.e. published 
reports vs grey literature), language bias and sources of funding. 
2.14 Strategy for data synthesis 
2.14.1 Statistical analysis: 
Depending on the quantity, quality and statistical/clinical homogeneity of the included 
studies, pooled estimates of oral HPV prevalence and persistence in healthy populations, by 
gender, detection technique or samples were computed in order to produce a quantitative 
meta-analysis for each domain. The choice of a fixed or random effects model was based on 




review was conducted when the obtained results for any of the domains could not be 
appropriately combined. 
STATA was used to analyze the dichotomous (binary) data obtained from this review. The 
analyses was expressed as pooled prevalence and persistence, with accompanying 95% 
confidence intervals. Separate analysis of oral HPV prevalence by detection technique was 
performed including for HPV DNA by PCR, ELISA, p16 immunohistochemistry. Separate 
analysis of oral HPV persistence by tissue type was also undertaken for samples grouped as 
oral rinse, oral swab/brush, pharyngeal brush/swab, or tonsil specimens. 
2.14.2 Heterogeneity: 
Heterogeneity was tested using a Chi-squared test with (N - 1) degrees of freedom, where N 
equals the number of trials from which data was included (Petitti et al., 2001). Standard forest 
plots were also be used to explore the observed heterogeneity graphically. 
2.14.3 Publication bias: 
Publication bias was explored with the use of the inverted funnel plot technique. Specific tests 
of publication bias were utilised as appropriate (Egger et al., 1997). 
2.14.4 Reporting of results:  
The systematic review was conducted and reported based on the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. 
2.14.5 Analysis of subgroups or subsets: 




appropriate, to investigate the differential prevalence and persistence in age-groups and the 
associations with risk factors such as cigarette smoking, alcohol consumption, and sexual 
practices. Subgroup analysis of the various screening tests currently available for oral HPV 
testing were performed where appropriate. 
2.14.6 Dissemination plans: 
We aim to publish our findings in a leading peer-reviewed journal with a focus on Ear, Nose 
and Throat Surgeons, Epidemiologists, Virologists, General Practitioners, Public Health 
physicians and Pharmaceuticals. We have also disseminated our findings through oral and 
poster presentations at both national and international conferences including ENT UK and the 














2.15 Meta-analysis results: 
 
The flow chart of this systematic review and meta-analysis is shown in Figure 2.1.  
4,389 abstracts were initially identified and after removal of duplicates, screening against 
inclusion criteria and exclusions, 159 studies were included in the qualitative analysis and 45 




Records identified through database 
searching  
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Figure 2.1: Systematic review flow chart. The flow chart shows the number of abstracts included, 




45 studies were included in this systematic review and meta-analysis on oral HPV prevalence 
in healthy individuals. This analysis included cross-sectional studies (n=33), cohort studies 
(n=10), randomised controlled trial (n=1) and cluster randomised study (n=1). There were 42 
prospective studies and 3 retrospective studies. A total of 29,050 healthy individuals (cancer-
free) were included from a population with age range of 12years – 89years, with a worldwide 
distribution. Population sizes varied from 50 subjects (the least) to 5501 subjects (the 
maximum size). Of the 45 included studies, 36 studies reported on at least 100 or more 
healthy individuals, with 11 of these studies reporting on over 500 participants and 
remarkably, 7 studies with 1000 or more healthy subjects. Two studies (Gillison et al., 2012; 
Hang et al., 2014) accounted for over 5,000 participants in each study. Table 2.1 shows the 
included 45 studies, the year of study, total sample size, geographic location, study types and 
% positivity for any HPV, high-risk HPV and HPV 16. Figure 2.2 shows the distribution of 
included studies and their respective population sizes.   
The meta-analysis of HPV proportions in each study was conducted using a random effects 
model. For interpretation, each meta-analysis transcript has the included studies, the effect 
size (ES) and the 95% confidence intervals. There is also the % weighting assigned to each 
study dependent on the sample size and the statistical corrections inherent in the model. The 

















Figure 2.2: Studies reporting oral HPV prevalence in healthy populations. Studies with at 
least 50 healthy participants included with the highest number of participants in 2 studies 





There were 1,442 healthy individuals positive for any HPV type (high-risk or low-risk) out of 
the 29,050 healthy individuals included. This is a pooled prevalence of any HPV type of 4.9% 
(95% CI: 3.7% - 6.3%) in healthy subjects (Figure 2.3). This pooled prevalence is further 
stratified by gender, geography, and oral sample type and detection technique in our 
subsequent analyses.  
2.15.1 Oral HPV detection techniques: 
43 out of the 45 studies included in this review used PCR based detection methods for HPV 
detection. This was used either alone or in combination with other techniques such as p 16 
immunohistochemistry, in-situ hybridisation and type-specific PCR. Hybrid capture was used 
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Figure 2.3: Pooled overall oral HPV prevalence. The pooled overall prevalence for any 
oral HPV infection was calculated using STATA and presented as a proportion with effect 
size (ES) and 95% confidence intervals depending on the weighting assigned based on sample 
size. The x-axis measures the effect size (oral HPV prevalence) in proportions from 0 – 1.  
 




There were 536 healthy individuals with oral high-risk HPV from a total sample size of 
28,516 individuals available from all studies. High-risk HPV included genotypes 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58 and 66. The pooled prevalence of high-risk oral HPV 
(carcinogenic HPV) was therefore 1.8% (95% CI: 1.2% - 2.6%) as shown in Figure 2.4. 
(Rautava et al., 2012) reported the highest prevalence of 14.5% (95% CI: 11.1% - 18.8%) in 
Finland. This study was a prospective cohort study on 324 pregnant women on the Finnish 
Family Study who were followed up for 6 years. 47 of these pregnant women tested positive 
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High Risk Oral HPV
 
Figure 2.4: High risk oral HPV prevalence in healthy populations. The pooled prevalence 
for high-risk oral HPV infection was calculated using STATA and presented as a proportion 
with 95% confidence intervals depending on the weighting assigned based on sample and 
effect size. The pooled prevalence of high-risk oral HPV was 1.8% (95% CI: 1.2% - 2.6%). 
 




Oral HPV 16 accounts for over 90% of HPV positive head and neck squamous cell 
carcinomas. It is therefore important to establish its prevalence in healthy individuals. In this 
meta-analysis, Oral HPV 16 pooled prevalence in healthy individuals was 0.7% (95% CI: 
0.4% - 1.0%) (Figure 2.5). Studies that reported oral HPV 16 prevalence were included and 
showed 221 individuals positive out of a total sample size of 28,439 individuals. Rautava et 
al., (2012) similarly reported the highest oral HPV 16 baseline prevalence in their Finnish 
cohort of 10.5% (95% CI: 7.6% - 14.3%). The majority of studies however reported oral HPV 
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Figure 2.5: Pooled oral HPV 16 prevalence in healthy populations. The pooled prevalence 
for oral HPV 16 infection was calculated using STATA and presented as a proportion with 
95% confidence intervals depending on the weighting assigned based on sample and effect 
size. The pooled prevalence of oral HPV 16 was 0.7% (95% CI: 0.4% - 1.0%). 




Further estimates of oral HPV 18 were extracted from studies that provided the information. 
There were 66 out of 28,439 healthy individuals positive for oral HPV 18. The pooled 
prevalence of oral HPV 18 was thus 0.1% (95% CI: 0.0% - 0.3%) (Figure 2.6). The majority 
of the included studies reported very low oral HPV 18 prevalence of <1.0%, with the highest 
prevalence of 5.7% (95% CI: 3.2% - 10.0%) reported in Pakistan (Gichki et al., 2012). The 
second highest prevalence for oral HPV 18 was 4.4% (95% CI: 1.9% - 9.9%) reported by 
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Figure 2.6: Pooled oral HPV 18 prevalence in healthy populations. The pooled prevalence 
for oral HPV 18 infection was calculated using STATA and presented as a proportion with 
95% confidence intervals depending on the weighting assigned based on sample and effect 
size. The pooled prevalence of oral HPV 18 was 0.1% (95% CI: 0.0% - 0.3%).  




2.16 Regional variation in oral HPV prevalence by geographic location 
The impact of geographic location on oral HPV prevalence (high-risk or low-risk) was 
investigated by grouping studies from the same WHO geographic region together and 
calculating regional pooled prevalence. Any variability in pooled prevalence between 
geographic regions was further assessed. The 45 included studies were divided into the 
following world regions as shown in Figure 2.7: North America (n=13), South America (n=8), 
Central America (n=3); Europe / Scandinavia (n=6), Western Europe (n=3), Eastern Europe 
(n=1); Asia (n=2), Far East (n=3), Middle East (n=2); Africa (n=2); Australasia (n=2).  
 
 
Figure 2.7: Pooled prevalence for any oral HPV infection in healthy populations by 
geographic region. The pooled prevalence by geographic region for any oral HPV infection 
was calculated by amalgamating all the studies from each region and presented as 
proportions. The studies from the American continent coloured in blue, included 13 studies 
from North America, 8 from South America, and 3 from Central America. In Europe, studies 
are coloured in red with 6 from Scandinavia, 3 from Western Europe and 1 from Eastern 
Europe. Studies from Asia are coloured green with 2 studies from Asia, 3 from the Far East 
and 2 from the Middle East. There were 2 studies from Africa coloured purple and 2 studies 





In North America (n=13 studies), the pooled prevalence of any oral HPV is 3.3% (95% CI: 
2.0% - 4.9%) (Figure 2.7 and Table 2.2). The included studies (in time order) were by 
(Summersgill et al., 2001), (Smith et al., 2007), (D'Souza et al., 2009), (Ernster et al., 2009), 
(Kreimer et al., 2011), (Turner et al., 2011), (Bekker et al., 2012), (Edelstein et al., 2012), 
(Flake et al., 2012), (Gillison et al., 2012), (Pickard et al., 2012), (Schlecht et al., 2013), 
(Cook et al., 2014), and (Fu et al., 2015). The largest study in North America was the Gillison 
et al (2012) cross-sectional study of 5,501 healthy American men and women aged 14years – 
69 years, who had oral rinse / gargle testing for any oral HPV by multiplex PCR and type-
specific hybridisation, with 385 participants positive. They reported a prevalence of 6.9% for 
any oral HPV in a population representative for the background American population using 
the National Health and Nutrition Exercise Survey (NHANES). Heterogeneity in the North 
American series was I2=91.98%, p=0.000. 
 
In South America, 8 studies were available with 6 prospective cross-sectional studies from 
Brazil (do Sacramento et al., 2006; Esquenazi et al., 2010; Tristao et al., 2012; Cavenaghi et 
al., 2013; Araujo et al., 2014; Machado et al., 2014), one large prospective cross-sectional 
study with 980 individuals from Peru (Rosen et al., 2016) and one prospective cross-sectional 
study of 85 people from Venezuela (Ruiz et al., 2009) (Figure 2.7 and Table 2.2).  
In the South American studies, the pooled prevalence for any oral HPV was 7.8% (95% CI: 
2.9% - 14.6%). Two studies that accounted for the largest effect sizes were (Araujo et al., 
2014) that reported a prevalence of 24.1% (95% CI: 18.2% - 31.1%) and (Tristao et al., 2012) 
that reported a prevalence for any oral HPV of 23.2% (95% CI: 16.7% - 31.3%). Both studies 
(Tristao et al., 2012; Araujo et al., 2014) were conducted in Brazil and were partly responsible 




studies conducted in Brazil with oral HPV prevalence lower than the 4.9% pooled prevalence 
in the meta-analysis (Esquenazi et al., 2010; Cavenaghi et al., 2013; Machado et al., 2014). 
Esquenazi et al., (2010) analysed oral scrapings from 100 healthy individuals (40 males, 60 
females) by PCR and found 0% prevalence (95% CI: 0% - 0.4%). Machado (2014) undertook 
a cross-sectional study of 514 asymptomatic men and found 7 oral brushings positive on PCR 
with a prevalence of 1.4% (95% CI: 0.7% - 2.8%).  Cavenaghi et al. (2013) also reported oral 
HPV prevalence of 2.4% (95% CI: 0.8% - 6.9%) in a sample size of 124 individuals in Sau 
Paulo. Overall heterogeneity for the South American cohort was I2=95.01%, p=0.000. 
 
The pooled prevalence of oral HPV in Central America was 4.8% (95% C.I: 0.0 – 16.3%). 
(Figure 2.7 and Table 2.2). The three studies included were Gonzalez-Losa Mdel et al. (2008), 
Kuhs et al. (2013) and Gonzalez-Losa et al. (2015). Gonzalez-Losa Mdel et al. (2008) used 
hybrid capture 2 technique to identify oral HPV in oral brushings of 77 participants in Mexico 
and found a prevalence of 1.3% (95% C.I: 0.2 – 7.0%). There was no type-specific prevalence 
possible with this hybrid capture 2 technique. Gonzalez-Losa et al. (2015) study however used 
nested PCR with MY09/11, GP5+/6+ primers and sequencing to characterise oral HPV in a 
cross-sectional prospective study of 383 women from Yucatan, Mexico and found a 
prevalence of 14.9% (95% C.I: 11.7 – 18.8%). Kuhs et al. (2013) was a randomized 
controlled trial on 2,926 women in Costa Rica allocated to the control arm of a HPV vaccine 
trial. 55 women aged 18 – 25years old, were found to have oral HPV at the end of the trial on 
oral rinse / gargle using HPV SPF10 PCR-DEIA (DNA enzyme immunoassay)-LiPA25. This 
indicated an oral HPV prevalence of 1.9% (95% C.I: 1.4 – 2.4%). The results published in 
this RCT (Kuhs et al., 2013), are similar to the data published by Herrero et al. (2013) and 




on HPV vaccine efficacy rather than prevalence and were excluded to avoid duplication. 
Overall heterogeneity in this Central America cohort was I2=97.81%, p=0.000.             
 
In Europe / Scandinavia, the pooled prevalence for any oral HPV infection was 5.2% (95% 
C.I: 0.9 – 12.5%) (Figure 2.7 and Table 2.2). The studies included were Eike et al. (1995), 
Kero et al. (2012a), Pedersen and Hariri (2012), Rautava et al. (2012), Forslund et al. (2013), 
and Nordfors et al. (2013). There were two studies that accounted for a higher oral HPV 
prevalence in this Europe / Scandinavia group and both were published from the same group 
working on the Finnish Family Study (Kero et al., 2012b; Rautava et al., 2012). Kero et al. 
(2012a)  reported oral HPV prevalence of 18.3% (95% C.I: 12.6 – 25.8%) in 131 male 
partners of pregnant women on a prospective cohort study over a 7 year period. Oral HPV 
prevalence fluctuated between 15.1% and 31.1% in oral scrapings with cytobrush using 
nested PCR with MY09/11, GP5+/6+ primers and Multimetrix kit (Progen Biotechnik, 
Heidelberg, Germany). Similarly Rautava et al. (2012) reported oral HPV prevalence of 
17.0% (95% C.I: 13.3 – 21.4%) in the same prospective cohort but only on the 324 pregnant 
women in the Finnish family Study over a 6 year period. Data from these two studies are 
therefore correlated and accounted for higher oral HPV prevalence rates from both the 
pregnant women and their male partners when compared to the other studies in the region. 
The other studies from Scandinavia in this series were Eike et al. (1995) from Denmark 
reporting any oral HPV prevalence 0% in 61individuals; Pedersen and Hariri (2012) from 
Denmark reporting 0.7% prevalence in 442 individuals; Forslund et al. (2013) from Sweden 
reporting 5.7% prevalence in 311 individuals; and Nordfors et al. (2013) from Sweden 
reporting oral HPV prevalence of 1.8% in 335 high school students. Overall heterogeneity for 




In Western Europe, pooled oral HPV prevalence in healthy individuals was 1.8% (95 C.I: 0.4 
– 4.0%). The three studies included were Klingenburg et al. (2010) from the Netherlands, 
Migaldi et al. (2012) from Italy, and Knight et al. (2016) from the United Kingdom. 
Klingenberg et al. (2010) reported a prevalence of 1.0% (95% C.I: 0.3 – 3.7%) in 195 tonsils 
using PCR, p16 immunohistochemistry, and in-situ hybridization techniques. Migaldi et al. 
(2012) reported oral HPV prevalence in oral smears of 81 participants from a Northern Italian 
population of 1.2% (95% C.I: 0.2 – 6.7%). In the United Kingdom, Knight et al. (2016) in a 
prospective cross-sectional study of 124 young adults, found a prevalence of 4.0% (95% C.I: 
1.7 – 9.1%). Overall heterogeneity in this Western Europe cohort was I2=33.98%, p=0.220.             
 
In Eastern Europe, the only study included was (Durzynska et al., 2011) which was a 
prospective cross-sectional study of 2,837 adolescents in Poland using PCR to identify HPV 
in oral rinse. The reported prevalence for any HPV was 1.3% (95% C.I: 0.9 – 1.8%) (Figure 
2.7 and Table 2.2) 
 
In the Far East, the pooled prevalence of oral HPV was 2.9% (95% C.I: 0.0 – 9.3%) (Figure 
2.7 and Table 2.2). The 3 studies included were Shindoh et al. (1994), Kurose et al. (2004) 
and Hang et al. (2014). Shindoh et al. (1994) was a cross-sectional prospective study done in 
Japan on oral scrapes from 56 individuals using nested PCR and found oral HPV prevalence 
of 3.6% (95% C.I: 1.0 – 12.1%). Kurose et al. (2004) was a prospective cohort of 662 
residents of Miyako Island, Japan. Buccal mucosa scrapes were analysed for oral HPV using 
consensus PCR with MY09/11 primers and found a low prevalence of 0.6% (95% C.I: 0.2 – 
1.5%). Hang et al. (2014) is a recent cross-sectional prospective study done on a large cohort 




swabs and exfoliated cells using general primer-mediated (SPF1/G6+) PCR and sequencing, 
resulting in a prevalence of 6.2% (95% C.I: 5.6 – 6.9%). Overall heterogeneity in this Far 
East cohort was I2=97.06%, p=0.000.             
 
In Asia, the two studies included were Gichki et al. (2012) and Wimardhani  et al. (2015) with 
a pooled prevalence of 13.8% (95% C.I: 10.5 – 17.4%) (Figure 2.7 and Table 2.2). This 
prevalence was the highest when compared with the other world regions. A closer review of 
the studies indicates that (Gichki et al., 2012) reported the highest prevalence of all included 
studies in this review at 24.5% (95% C.I: 18.9 – 31.0%). This was a cross-sectional 
prospective study on 192 adults from Pakistan using real-time PCR. High-risk HPV was 7.8% 
while HPV 16 was 2.1% in this cohort. Wimardhani et al. (2015) conducted a cross-sectional 
prospective study on 200 female Indonesian and Thai Dental students, using PCR to analyse 
saliva samples for presence of HPV. The oral HPV prevalence was 6.0% (95% C.I: 3.5% - 
10.2%). Overall heterogeneity in this Asia cohort was I2=66.99%, p=0.082.  The high oral 
HPV prevalence observed in the Asia cohort must be interpreted cautiously as the driver for 
the high rate comes from a particular study in Pakistan on 192 adults using real-time PCR 
(Gichki et al., 2012). This technique can be considered highly sensitive for HPV detection.           
 
In the Middle East, the pooled prevalence for oral HPV was 2.1% (95% C.I: 0.5 – 4.7%). 
(Figure 2.7 and Table 2.2). The two studies in this group were (Seifi et al., 2013) and (Arbabi-
Kalati et al., 2014). (Seifi et al., 2013) reported a prevalence of 6.1% (95% C.I: 3.0 – 12.1%) 





In Africa, pooled oral HPV prevalence was 4.7% (95% C.I: 2.5% - 7.3%) from 2 included 
studies – (Marais et al., 2006) and (Davidson et al., 2014). In Australasia, the pooled oral 
HPV prevalence was 7.0% (95% C.I: 4.5 – 9.9%) accrued from 2 studies – Lawton et al., 
1992) and (Antonsson et al., 2014) (Figure 2.7 and Table 2.2).  
Table 2.2: Oral HPV prevalence worldwide by geographic location. Pooled prevalence 
for any oral HPV infection by geographic location is presented as % with 95% confidence 
intervals. The pooled prevalence was calculated from studies published in each world region.  
 




South America 7.8 2.9 – 14.6 
Central America 4.8 0.0 – 16.3 
North America 3.3 2.0 – 4.9 
   
Scandinavia 5.2 0.9 – 12.5 
Western Europe 1.8 0.4 – 4.0 
Eastern Europe 1.3 0.9 – 1.8 
   
Asia 13.8 10.5 – 17.4 
Far East 2.9 0.0 – 9.3 
Middle East 2.1 0.5 – 4.7 
   
Africa 4.7 2.5 – 7.3 
   




2.17 Oral HPV prevalence by sample type: 
The data included from the 45 studies included in this review was further stratified into the 
sample type in which HPV was detected. Sample type was broadly divided into the following: 
a) Oral rinse / gargle / saliva 
b) Scrapings / brushings / swabs 
c) FFPE (Formalin Fixed Paraffin Embedded) tonsil tissue 
d) Fresh frozen tonsils 
Pooled prevalence for any oral HPV in the studies that collected oral rinse / gargle / saliva 
from participants was 3.5% (95% C.I: 2.4 – 4.9%) (Table 2.3). In the studies that collected 
scrapings / brushings / swabs from the oral cavity / oropharynx, the pooled prevalence was 
found to be higher at 5.9% (95% C.I: 3.4 – 8.9%) (Table 2.3). Ernster et al. (2009) undertook 
a retrospective analysis of 226 FFPE from tonsils using type-specific PCR to HPV 16 and 18. 
There was no single positive FFPE sample to oral HPV with a prevalence of 0.0% (95% C.I: 
0.0 – 1.7%) (Table 2.3). There were two studies that reported HPV prevalence in tonsils 
(Klingenberg et al., 2010; Bekker et al., 2012). Klingenberg et al., (2010) performed a 
retrospective cross-sectional study in the Netherlands of 195 tonsils using PCR, p16 
immunohistochemistry and in-situ hybridisation. They found only 2 tonsils positive for HPV 
with a prevalence of 1.0% (95% C.I: 0.3 – 3.7%). Similarly, Bekker et al. (2012) in America, 
undertook a retrospective analysis of 200 clinically benign tonsils using p16 
immunohistochemistry, PCR and in-situ hybridisation techniques. They reported 2 tonsils 
positive for HPV with a prevalence of 1.0% (95% C.I: 0.3 – 3.6%) (Table 2.3). 
Oral HPV positivity was highest in those studies that used scrapings / brushings / swabs at 




3.5%; and low oral HPV positivity in actual tonsils at 1.0% or FFPE at 0.0% (Table 2.3). 
Overall heterogeneity between these groups was 95.33%, p = 0.000.  
 
Table 2.3: Pooled prevalence for any oral HPV infection by sample type. The sample 
types in all studies were grouped as (oral rinse/ gargles/ saliva), (scrapings/ brushings/ 
swabs), Fresh frozen tonsils, and FFPE (Formalin Fixed Paraffin Embedded). The pooled 
prevalence for each sample type is presented as % with the corresponding 95% confidence 
intervals. The comparative literature for each sample type cited in section 1.7 is also shown 
but with a wide variation in sensitivity of different techniques.  
 
Sample Type Pooled 
prevalence for 







any oral HPV 
(%) 
Oral rinse / 
gargles / saliva 
3.5 2.4 – 4.9  2.8 – 25 




5.9 3.4 – 8.9  0 – 32 
    
Fresh frozen 
tonsils 
1.0 0.2 – 2.3  0 – 16 









2.18 Oral HPV 16 prevalence: 
Pooled prevalence of oral HPV 16 by geographic location of the included studies showed 
some variation in prevalence across different world regions. The overall pooled prevalence of 
oral HPV 16 worldwide was low at 0.7% (95% C.I: 0.4 – 1.0%). In North America, the 
pooled prevalence of oral HPV 16 from the 13 included studies was 0.6% (95% C.I: 0.3 – 
1.1%). In the Far East, this pooled prevalence from 3 studies (Shindoh et al., 1994; Kurose et 
al., 2004; Hang et al., 2014), was lower at 0.2% (95% C.I: 0.0 – 0.5%). Similarly, 2 studies 
from Central America (Kuhs et al., 2013, Gonzalez-Losa et al., 2015) indicated a pooled 
prevalence for oral HPV 16 of 0.4% (95% C.I: 0.2 – 0.7%). There was only one study from 
Eastern Europe (Durzynska et al., 2011) that reported a prevalence of oral HPV 16 of 0% 
(95% C.I: 0.0 – 0.1%) in oral rinse in a cross-sectional study of 2,837 teenagers aged 16 – 18 
year old using PCR. There were 6 studies from South America (do Sacramento et al., 2006; 
Esquenazi et al., 2010; Cavenaghi et al., 2013; Araujo et al., 2014; Machado et al., 2014;  
Rosen et al., 2016) from which oral HPV 16 pooled prevalence of 0.2% (95% C.I: 0.0 – 
1.1%) was calculated. The prevalence of oral HPV 16 was generally low in the South 
American series with only 2 studies reported prevalence above the global average of 0.7%. 
(do Sacramento et al., 2006) reported the highest oral HPV prevalence of 4.0% (95% C.I: 1.1 
– 13.5%) while Rosen et al. (2016) reported oral HPV 16 prevalence of 1.2% (95% C.I: 0.7 – 
2.1%).  
In Europe / Scandinavia, the pooled prevalence of oral HPV 16 from the included 6 studies 
(Eike et al., 1995; Kero et al., 2012a; Pedersen and Hariri, 2012; Rautava et al., 2012; 
Nordfors et al., 2013; Forslund et al., 2013) was 2.1% (95% C.I: 0.1 – 5.8%). This prevalence 
was higher than the average reported in other world regions. The two studies that accounted 




C.I: 3.1 – 11.6%) and Rautava et al. (2012) reporting 10.5% prevalence (95% C.I: 7.6 – 
14.3%). It has been previously noted that these two studies are correlated as they represent 
data from the Finnish Family Study. Rautava et al. (2012) reported prevalence in 324 
pregnant women over a six-year period whilst Kero et al. (2012a) reported prevalence in 131 
of their male partners over a 7 year period during which point prevalence for any oral HPV 
fluctuated between 15.1 – 31.1%. Both studies utilised nested PCR with MY09/11, GP5+/6+ 
primers and Multimetrix kit (Progen Biotechnik).  
Antonsson et al. (2014) in Australasia reported an oral HPV 16 prevalence of 0.3% (95% C.I: 
0.1 – 1.8%). In Western Europe, 2 studies reported oral HPV 16 prevalence in healthy 
individuals (Klingenberg et al., 2010; Migaldi et al., 2012) with a pooled prevalence of 0.5% 
(95% C.I: 0.0 – 2.0%).  
In Asia, the pooled prevalence for oral HPV 16 was 3.0% (95% C.I: 1.5 – 5.0%) obtained 
from two studies (Gichki et al., 2012; Wimardhani et al., 2015). In Africa, there were only 2 
studies (Marais et al., 2006; Davidson et al., 2014), with a pooled prevalence of 0.6% (95% 
C.I: 0.0 – 1.9%). There was no reported detection of oral HPV 16 in the 2 studies in the 
Middle East (Seifi et al., 2013; Arbabi-Kalati et al., 2014), giving a pooled prevalence of 0% 











2.19 Oral HPV prevalence in males: 
A meta-analysis of the data in this systematic review showed an overall oral HPV prevalence 
in males for any HPV genotype was 4.1% (95% C.I: 2.4 – 6.1%) (Figure 2.8). The vast 
majority of the studies that included a gender distribution in their publication reported oral 
HPV prevalence in males close to this pooled prevalence of 4.1%. There were outlier studies 
that reported higher oral HPV prevalence though, as shown in Figure 2.8 including Flake et 
al. (2012), Gichki et al. (2012), Kero et al. (2012a), and Tristao et al. (2012). These studies 
may have inherent flaws in their design, variations in the HPV detection technique utilised, or 
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Overall Oral HPV Prevalence for Males
 
Figure 2.8: Pooled prevalence for any oral HPV infection in healthy males. The pooled 
prevalence for any oral HPV infection in males was calculated using STATA and presented as 
a proportion with 95% confidence intervals depending on the weighting assigned based on 
sample and effect size. The pooled prevalence for any oral HPV in males was 4.1% (95% C.I: 
2.4 – 6.1%). 




2.20 Oral HPV prevalence in females: 
In females, the pooled oral HPV prevalence for any HPV genotype worldwide in those studies 
reporting a gender distribution was 4.5% (95% C.I: 3.1 – 6.1%) (Figure 2.9). Some studies 
had higher prevalence reported (Gichki et al., 2012; Rautava et al., 2012; Ruiz et al., 2009; 
Tristao et al., 2012; Schlecht et al., 2013; Gonzalez-Losa et al., 2015). This is comparable to 
the pooled prevalence of 4.1% shown in males. There was no statistically significant 
difference in the pooled prevalence of any oral HPV between males and females in this meta-
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Overall Oral HPV Prevalence for Females
 
Figure 2.9: Pooled prevalence for any oral HPV infection in healthy females. The pooled 
prevalence for any oral HPV infection in females was calculated using STATA and presented 
as a proportion with 95% confidence intervals depending on the weighting assigned based on 
sample and effect size. The pooled prevalence for any oral HPV in females was 4.5% (95% 
C.I: 3.1 – 6.1%).  
 
 





Our meta-analysis using 45 studies in current literature has provided the following pooled 
prevalence for oral HPV in healthy individuals:  
– Any HPV:  4.9% (95% CI: 3.7% - 6.3%) 
– High-risk HPV: 1.8% (95% CI: 1.2% - 2.6%) 
– HPV 16:  0.7% (95% CI: 0.4% - 1.0%) 
– HPV 18:  0.1% (95% CI: 0.0% - 0.3%) 
Oral HPV prevalence by gender: 
– Males:   4.1%  (95% CI: 2.4% - 6.1%) 
– Females:  4.5%  (95% CI: 3.1% - 6.1%) 

















2.21 Sub-populations at higher risk of oral HPV infection: 
The meta-analysis presented so far has focused on oral HPV prevalence amongst healthy 
individuals from 45 published studies that meet the inclusion criteria. It is important to try and 
identify any sub-sets of populations that may be at increased risk of acquiring oral HPV 
infection. The systematic review conducted in achieving the final 45 studies included in the 
prevalence in healthy individuals, also provided concurrent literature on sub-populations 
potentially at-risk of higher oral HPV prevalence rates. The studies excluded from the healthy 
cohort were reviewed and stratified into populations with higher oral HPV prevalence. There 
were 4,365 papers identified on initial search of the relevant databases. After duplicates were 
removed, there were 2, 231 papers on oral HPV prevalence from which the final 45 studies on 
healthy populations were extracted. The remaining studies not selected for the ‘healthy 
population’ meta-analysis contained the required data to assess high-risk groups.  
In 4,628 individuals worldwide with positivity to Human Immunodeficiency Virus (HIV) in 
this meta-analysis, 31.0% had oral HPV positivity for high-risk HPV and 11.5% prevalence 
for high-risk HPV (Table 2.4). In comparison to the healthy population, this indicates a 
relative risk of 11.5 for HIV positive individuals in terms of acquisition of oral high-risk HPV 
(Table 2.4).  
Oral high-risk HPV prevalence was found to be 28.9% in 373 sex workers (relative risk – 
10.7), 14% in 920 women with simultaneous HPV positivity in the cervix (relative risk – 5.2). 
T-test for each group compared with the healthy meta-analysis cohort was significant 





Table 2.4: Populations at-risk for higher oral HPV prevalence. This table summarises the 
pooled prevalence for oral high-risk HPV infection obtained in sub-populations considered to 
be at higher risk compared to healthy populations. Papers reporting oral high-risk HPV 
prevalence in women with cervical HPV positivity, sex workers and individuals with HIV 
were pooled using STATA and the relative risk calculated in relation to the prevalence 
identified in healthy individuals from this study.  
Population Type Population 
Aggregate 
Total (N) 






Healthy 28,516 1.8 1.0 
HPV positivity in 
Cervix 
920 14.0 5.2 
Sex Workers 373 28.9 10.7 














2.22 Oral HPV persistence in healthy individuals (N – 11 studies): 
Persistence of oral HPV infection in healthy individuals was investigated in this systematic 
review. ‘Persistence’ was defined as the detection of any oral HPV genotype in oral cavity 
samples in the included studies on healthy individuals using any HPV detection techniques on 
two consecutive HPV testing time points. Genotype-specific persistence indicates the same 
oral HPV genotype was detected on two consecutive tests. General persistence is when 
different genotypes of HPV are identified at index testing and the follow up testing. The 
limitation with these definitions is that ‘true oral HPV persistence’ cannot be determined as it 
is impossible to show that the oral HPV genotype identified on follow up testing is the exact 
same virus detected initially at the index testing. The concept of oral HPV clearance is also 
based on the premise that tested individuals are shown to be negative for oral HPV infection 
on two consecutive tests after initially testing positive for any HPV genotype.  
2.22.1 Systematic review papers on oral HPV persistence: 
There were 11 studies identified from the 45 included studies on oral HPV prevalence in 
healthy individuals that had tested for the presence of oral HPV infection at least on two 
occasions (Table 2.5). Repeat detection of oral HPV genotypes in healthy individuals in this 
review ranged between 0% - 14.0%. The time lapse on follow up testing after the initial test 
for oral HPV infection varied between the included studies from 3 months (Pickard et al., 
2012) to 7 years (Kero et al., 2014). Some observational studies employed multiple repeat 
tests over a long study period while some studies only reported two testing time points. The 






Table 2.5: Studies on oral HPV persistence in healthy individuals. Oral HPV persistence 
in healthy individuals was extracted from the prevalence studies in the systematic review. Any 
studies that carried out repeat testing after a period of time were included. The sample size, 































7 years PCR 24/131 18.30% 18/129 
(14.0%) 




3 Kurose 2004 Japan 662 2.5 years PCR 4/662 0.60% 2/662 
(0.3%) 
4 Garolla 2014 Italy 98 
(49 
couples) 











5 Edelstein  2012 USA 212 adults 1 year PCR 16/212 7.5% 5/212 
(2.4%) 






7 Pickard 2012 USA 1000 3 
months 
PCR 24/1000 2.4%  9/1000 
(0.9%) 





PCR  10/63 15.9% 6/63 
(9.5%) 







19/1010  1.9 0/1010 
(0.0%) 
10 Herrero 2013 Costa 
Rica 
7466 4 years  PCR 
SPF/DEIA 
127 / 7466 1.7% 15/2924 
(0.5%) 












Data on the oral HPV genotypes identified on repeat testing was also extracted in this 
systematic review. HPV 11 (which causes warts) had the longest mean detection time in 
repeat sampling of 55.2 months, followed by HPV 66 (33.4 months), HPV 51 (30.7 months), 
HPV 12 (28 months), HPV 78 (28 months), and HPV 16 (20.15 months) (Figure 2.10). 
Significantly, the main oral HPV genotypes associated with head and neck cancer – namely 
HPV 16 and HPV 18 – had duration of persistence in healthy individuals of 20.15 months and 

















2.22.2 Oral HPV genotypes and persistence: 
High-risk HPV genotypes found on repeat oral HPV testing in these included studies (from 
the lowest to highest persistence in mean months) were HPV 18, 39, 33, 58, 16, 51, and 66 
(Figure 2.10). Similarly, low risk oral HPV identified and their relative persistence in mean 
months from least to longest included: HPV 6, 78, 12 and 11 (Figure 2.10).  
Oral infections with multiple HPV genotypes had a mean duration for persistence on repeat 
testing of 11.65 months. Overall persistence for any oral HPV genotype ranged between 6 

















Figure 2.10: Duration of persistence of oral HPV genotypes (mean months). Persistence 
of oral HPV infection in included studies showed a range of 6 – 55 mean months. Among low-
risk HPV, genotype 11 had the longest duration of persistence while in the high-risk group, 









2.23.1 Oral HPV prevalence in healthy individuals: 
Our current understanding of HPV-mediated carcinogenesis comes from robust studies and 
clinical trials conducted into how persistent infection with high-risk HPV leads to carcinoma 
in-situ in the cervix (CIN) and ultimately cervical cancer (Cuschieri et al., 2005; Remmink et 
al., 1995; McCredie et al., 2008). High-risk HPV genotypes 16 and 18 cause the vast majority 
of cervical cancer worldwide. In addition, high-risk HPV genotypes cause a significant 
proportion of other genital cancers including vulval cancers, vaginal cancers, rectal cancers, 
penile cancers, and anal cancers. In recent times, high-risk HPV infection has been confirmed 
as causal for a subset of Oropharyngeal cancer (cancers of the tonsils, tongue base, soft palate 
and pharyngeal walls). Causality was established by strong epidemiologic and laboratory 
studies worldwide, with ratification at the International Agency for Research into Cancer 
(IARC) Conference in Lyon, France in 2007 (WHO 2007).  
There is limited data available on the natural history of oral human papillomavirus infection, 
its associated risk factors, the population groups at increased risk and any variations in oral 
HPV prevalence by gender, tissue type, and world geographic location. This meta-analysis 
addresses these fundamental questions and provides further insight into the acquisition and 
natural history of oral HPV infection. This is important information as it adds to the on-going 
discourse on the progression of oral HPV infection to the development of HPV-associated 
oropharyngeal cancer. 
The prevalence of oral HPV infection in healthy individuals was described in the most recent 
systematic review by Kreimer et al. (2011). In 4,070 participants, pooled prevalence for any 




found in 3.5% (95% C.I: 3.0% - 4.1%); while in 3,977 participants, oral HPV 16 was found in 
1.3% (95% C.I: 1.0% - 1.7%) (Kreimer et al., 2011). Direct comparison with this systematic 
review and meta-analysis shows a significantly higher proportion of healthy individuals 
(28,516) from the 45 studies included. This demonstrates the increasing number of 
publications in this field in the last 6 years. The pooled prevalence for any oral HPV, oral 
high-risk HPV and oral HPV 16 reported in this meta-analysis is comparable to the figures 
published by (Kreimer et al., 2011) and therefore corroborates their findings. This meta-
analysis reports pooled prevalence in healthy individuals worldwide for any oral HPV of 
4.9% (95% CI: 3.7% - 6.3%); oral high-risk HPV of 1.8%  (95% CI: 1.2% - 2.6%); oral 
HPV 16 of 0.7% (95% CI: 0.4% - 1.0%); and oral HPV 18 of 0.1% (95% CI: 0.0% - 0.3%). 
This meta-analysis reports a comparatively lower pooled prevalence for oral high-risk HPV of 
1.8% (95% CI: 1.2% - 2.6%) with distinct 95% confidence intervals when compared with the 
pooled prevalence for oral high-risk HPV of 3.5% (95% C.I: 3.0% - 4.1%) reported in the 
systematic review by Kreimer et al. (2011). The difference in reported rates in oral high-risk 
HPV between the two systematic reviews is likely due to the inclusion of some studies with 
participants that have been classified as ‘at-risk’ for their systematic review. In particular, 
there were studies with sex workers, and participants recruited from sexually transmitted 
infections clinics in the Kreimer et al. (2011) review that have been excluded from our meta-
analysis. The lower rate of high-risk HPV thus found in this review could reflect less 
heterogeneity in the inclusion criteria for ‘healthy individuals’ and as such, a better 
representation of the true prevalence.  
2.23.2 Oral HPV prevalence and gender: 
This systematic review did not show a statistically significant difference in pooled prevalence 




HPV infection was 4.1% (95% CI: 2.4% - 6.1%) while the corresponding prevalence in 
females was 4.5% (95% CI: 3.1% - 6.1%). This finding is consistent with the (Kreimer et al., 
2011) systematic review that also did not show a difference in oral HPV prevalence by gender 
with reported rates of 4.6% in males and 4.4% in females. Significantly, HPV-associated 
Oropharyngeal cancer disproportionately affects males more than females (Javadi et al., 2017; 
D'Souza et al., 2007a; Mehanna et al., 2013). It is therefore of interest that gender does not 
appear to have an effect on acquisition of oral HPV infection in younger healthy individuals 
but becomes a major factor with male preponderance when Oropharyngeal cancer occurs in 
the cohort aged over 50years. It is unclear whether hormonal factors play a protective role in 
females with regards to HPV carcinogenesis in the Oropharynx, but what is clear is the fact 
that males (as is the case with head and neck cancers generally) represent the vast majority of 
HPV-associated Oropharyngeal cancer. The impact of sexual habits and engagement in high-
risk sexual behaviours may also be a factor to consider in the observed gender disparity in 
HPV-OPC. Oral sex has been shown to be an independent risk factor in the development of 
HPV-associated Oropharyngeal cancer (D'Souza et al., 2009). The concept that the female 
genital tract acts as a reservoir for HPV infection in sexually active women positive with HPV 
in the cervix, with the attendant risk of transmission to males during oro-genital contact, has 
been explored as a possible explanation for the higher oropharyngeal HPV load in males that 
could facilitate oropharyngeal cancer development in males.  
2.23.3 Oral HPV prevalence and risk factors: 
Risk factors identified to be associated with an increased prevalence of oral HPV infection in 
healthy populations include male gender, unmarried women, cigarette smoking, number of 
lifetime sex partners, ever having had sex, number of lifetime oral sex partners (Gillison et al., 




Oral sexual behaviours have been shown to elevate both the odds for oral HPV infection as 
well as the odds for developing HPV-associated Oropharyngeal cancer (D'Souza et al., 2009). 
There exists the possibility that sexual behaviours in Western populations have changed in 
recent times, with more people engaging in high-risk sexual activity. The current literature in 
the UK that supports this narrative comes from the three National Survey of Sexual Attitudes 
and Lifestyles ‘NATSAL’ studies. Johnson et al. (2001) reported on the changing patterns of 
sexual behaviour in Britain in the NATSAL 2000 survey as compared to NATSAL 1990. The 
survey concluded there was an increase in risky sexual behaviours over the decade mirroring 
the observed changes in cohabitation trends and the underlying increase in sexually 
transmitted diseases. Mercer et al. (2013) went further in NATSAL 3 to confirm that there 
have been significant changes in sexual behaviours and attitudes in the United Kingdom in the 
last 60years. In particular, women had experienced more fluctuations in sexual behaviours 
and in general there had been a distinct rise in oral sex and anal sex over time. The increase in 
the uptake of these high-risk behaviours has coincided with the rise of HPV-associated 
Oropharyngeal cancer. There is some evidence to indicate deep kissing as a transmission 
route for oral HPV infection. Kissing is well documented to be a transmission route for other 
viruses such as Epstein Barr Virus (EBV) which causes glandular fever or ‘infectious 
mononucleosis’. EBV also affects the tonsils (as does HPV) and significantly, is causative for 
nasopharyngeal cancer. EBV has been found to co-exist in some forms of nasopharyngeal 
carcinoma with HPV (WHO Type III classification). The viral milieu in the oral cavity and 
oropharynx is therefore transmissible by sexual activity that involves contact with a sexual 
partner’s secretions – be it orogenital contact or oro-oral contact. The number of lifetime 
sexual partners with whom patients with HPV-OPC engaged in sexual intercourse, kissing or 




compared with other head and neck cancer patients (Schnelle et al., 2017). Patients with HPV-
OPC had significantly elevated odds of having participated in oral sex with four or more 
partners when compared with patients with other head and neck cancers that were not HPV 
positive (Schnelle et al., 2017).  
This systematic review and meta-analysis on oral HPV infection in healthy people did not 
extract data on sexual behaviours in participants included in the 45 studies as this data was 
often absent or not uniformly collected. However oral sex has been shown to increase the risk 
of acquiring HPV infection in the oral cavity even in healthy populations (D'Souza et al., 
2009).  
2.23.4 Oral HPV prevalence and geography: 
This meta-analysis sought to identify any variations in the pooled prevalence of oral HPV 
infection based on the geographic location of the background population in each of the 
included 45 studies. The heterogeneity in the populations worldwide as well as variations in 
the HPV detection techniques utilised by each study means the meta-analysis results should 
be interpreted with caution. The pooled oral HPV prevalence for any HPV genotype across all 
world regions was between the range 1.3% (95% C.I: 0.9 – 1.8%) in Eastern Europe and 
13.8% (95% C.I: 10.5 – 17.4%) in Asia. The highest prevalence was reported in Asia however 
this figure was driven by a single study in Pakistan that utilised a highly sensitive HPV 
detection technique called real-time PCR (Gichki et al., 2012). This may therefore be an over-
representation of the true prevalence of oral HPV infection in that country and comparisons 
with other world regions that used mainly PCR-based methods is sub-optimal. True 




universally standardised and type-specific techniques compared against each other rather than 
using any HPV detection technique from all studies.  
2.23.5 Oral HPV prevalence and sample type: 
This meta-analysis investigated any differences in HPV prevalence depending on the oral 
samples collected in the studies. Using all techniques, HPV detection was highest at 5.9% in 
oral scrapings / brushings / swabs. Studies that collected oral rinse / gargle / saliva had a 
lower HPV detection rate of 3.5%. Surprisingly, studies that identified HPV in tonsils 
reported the lowest rates at 1.0% and FFPE from tonsils at 0.0%. A large UK study 
corroborates these findings with 0% oral HPV in 3,377 FFPE specimens and 0% oral HPV in 
511 non-malignant tonsils (Palmer et al., 2014). Given that HPV has been demonstrated to 
localise in tonsillar crypts (Begum 2005), a higher prevalence inside tonsil specimens was 
expected. This fact is corroborated by a recent study investigating oral HPV infection in 
healthy individuals undergoing tonsillectomy for non-cancer reasons in the UK 
(OROMOUTH). HPV detection from 937 tonsil specimens using p16 IHC and PCR, yielded 
only 1.4% prevalence (Mehanna 2017 – unpublished work). The HPV lifecycle could explain 
the increase in detection in oral cavity specimens and fluids in comparison with the actual 
tonsil reservoir itself. There is more shedding of viral particles at the epithelial layer when 
virus assembly is complete with millions of genomic HPV released, in contrast to the 
significantly smaller viral load present in the basal layer or reticulated epithelium of the 
tonsillar crypts. This has implications in terms of the development of screening techniques 
and approaches for the oral cavity and oropharynx. It will be useful for screening programmes 
to incorporate into their repertoire for oral HPV detection, tissue sampling that will likely 




2.23.6 Oral HPV prevalence and HPV detection technique: 
There are wide variations in HPV detection techniques with a lack of consensus worldwide on 
which technique or combination of techniques constitute true HPV positivity. In the UK, 
consensus PCR and positivity on p16 Immunohistochemistry has become the benchmark for 
defining HPV positivity in recent clinical trials. In clinical practice however, the majority of 
hospitals and treating centres utilise positivity only on p16 IHC to stratify patient groups into 
HPV positive or negative. This approach is supported in part by current evidence that shows 
HPV positivity on p16 IHC is a reliable surrogate marker of HPV positivity for clinical 
applications. In-situ hybridization (ISH) and real-time PCR are also sensitive HPV detection 
technique used in some of the included studies. There is however the risk of over-estimating 
oral HPV prevalence using these techniques. 43 of the 45 studies in this review used PCR 
alone or in combination with other detection techniques such as ISH and p16 IHC. Other less 
frequently used HPV detection techniques include hybrid capture which was used in 2 of the 
included studies in this systematic review. Hybrid capture has been used in the identification 
of HPV in cervical specimens however, the main limitation with this technique is its inability 
to identify the exact HPV genotype present in the sample. It simply provides a binary 
outcome: HPV present or absent. This is therefore less useful in stratifying results into those 
associated with high-risk or low-risk HPV or even type-specific HPV.  
2.23.7 Oral HPV infection and sub-populations at-risk: 
An investigation into which groups in the population are at increased risk of acquiring oral 
HPV infection (with a higher prevalence than the healthy population), is necessary to better 
understand its aetiopathogenesis and for facilitating resource allocation when considering the 




higher pooled prevalence of oral HPV infection when compared to the pooled prevalence in 
healthy individuals of 4.9% (95% CI: 3.7% - 6.3%) for any HPV, 1.8% (95% CI: 1.2% - 
2.6%) for high-risk HPV, and 0.7% (95% CI: 0.4% - 1.0%) for oral HPV 16. The sub-
populations at increased risk of oral HPV infection thus include a) individuals with positivity 
to Human Immunodeficiency Virus (HIV), b) sex workers, c) women with positivity to HPV 
in the cervix, d) patients with Fanconi’s anaemia.  
The highest pooled prevalence for oral HPV was identified in individuals positive for HIV. In 
4,628 HIV positive individuals, high-risk HPV was found in 31%. This represents a relative 
risk of 11.5 when compared with healthy populations. The immune system plays a role in 
ensuring the necessary balance between exposure and infection with the ubiquitous HPV, and 
ultimately persistent oral HPV infection and progression to disease states. Strong 
epidemiologic evidence has shown that oral HPV infection is cleared in immune-competent 
individuals between 18 – 24 months from viral acquisition (Kero et al., 2014, D’Souza et al., 
2014a). This may not be the case in individuals with compromise of their immune system 
such as occurs with HIV infection, renal transplant patients, patients on chemotherapy, or 
other immune-deficiency states. There are on-going studies investigating the role of the 
immune system in the natural history of oral HPV infection and progression to oropharyngeal 
cancer. 
Expectedly, among 373 individuals who identified as sex workers in some of the included 
studies, 28.9% were found to have oral high-risk HPV. This was a relative risk of 10.7 when 
compared to healthy populations with high-risk HPV of 1.8% as indicated previously. 




In 920 women positive for HPV in the cervix and simultaneously tested for oral HPV, 14% 
were found to have high-risk HPV in oral samples – a relative risk of 5.2.  
2.23.8 Oral HPV persistence: 
This systematic review identified papers that investigated the natural history of oral HPV 
infection in terms of persistent infection. Persistence was defined as the detection of oral HPV 
on two consecutive tests done at two separate time points. There was wide variability in the 
reported rates of oral HPV persistence with a range between 0.0% - 14.0% in the 11 included 
studies. There were 2 prospective longitudinal studies from the FINNISH family study that 
took serial oral samples from 325 pregnant women and their partners over a 7year period that 
have provided the clearest observation of how oral HPV infection progresses in healthy 
populations. In immune-competent individuals, oral HPV infection was cleared within 18 – 
24 months on repeat testing (D'Souza et al., 2014a). Risk factors identified to be associated 
with persistent oral HPV infection include current smoking and use of oral contraceptives 
(Kero et al., 2014). There are a few caveats to bear in mind when interpreting results reporting 
oral HPV ‘persistence’. True persistence is difficult to ascertain because studies usually do 
not test whether the exact HPV detected in the first oral sample is the same virus detected 
again in the second sample after a time interval (it is however possible to know by 
genotyping).  It is obvious that the oral cavity hosts a dynamic and changing viral community 
and therefore, HPV infection can be acquired, cleared and re-acquired over a period of time. It 
follows therefore, that the HPV infection detected on the second test could as well be a new 
HPV infection rather than the same HPV infection identified ab initio. It is pertinent however 
to note that persistent HPV infection in the cervix is a recognised precursor to the initiation of 
cervical intraepithelial neoplasia and ultimately cervical carcinoma. This model of 




persistent oral HPV infection leads to Oropharyngeal cancer, is credible and worthy of 
scientific consideration. Gillison et al. (2012) described a bi-modal peak for oral HPV 
infection with the first peak in teenagers and adults in their twenties and the second peak 
observed in adults aged over 50 years. Our understanding of how oral HPV infection 
translates into oropharyngeal cancer through the lens of this described bi-modal peak, 
indicates either that these two peaks are related and as such persistent oral HPV infection 
leads to OPC development, or that these two peaks are unrelated and represent two separate 
‘new oral HPV infections’. If the latter hypothesis is true, then the first peak represents the 
age of initiation of sexual activity while the second peak may be indicative of changing sexual 
patterns that may occur in middle age such as divorce and sexual activity with new partners.  
2.23.9 Oral HPV infection and vaccination: 
HPV vaccination is available either as a bi-valent vaccine (Cervarix), a quadrivalent vaccine 
(Gardasil), and even a vaccine covering 9 HPV genotypes. Pre-pubertal girls aged 12 – 13 
years in the UK, USA, Canada, Australia and some countries in Europe receive HPV 
vaccination on national programmes. The HPV vaccine was primarily aimed at prevention of 
HPV associated diseases ranging from benign conditions like anogenital warts (HPV 6, 11) to 
cervical and anogenital cancers (HPV 16, 18 and other high-risk HPV). There are increasing 
calls for gender-neutral vaccination that protects boys as well as girls. There is an expectation 
that vaccination will offer a protective effect against anogenital cancers and benign HPV 
conditions in boys too. Countries such as the United States of America, Canada, Australia and 
some others across Europe, have in recent times begun vaccinating boys as well as girls 
against HPV-related diseases. In summer 2018, the UK followed in approving vaccination for 




oropharyngeal cancer prevalence is yet to be fully determined however Herrero et al. (2013) 
showed a reduction in oral HPV prevalence from 1.7% to 0% 4 years after HPV vaccination.  
2.23.10 Oral HPV infection and screening: 
HPV screening currently exists for cervical intraepithelial neoplasia and cervical cancer based 
on the observed changes on cervical cytology from scrapings from the transitional epithelium 
at the squamo-columnar junction of the cervix. Recently, cervical cancer screening 
programmes have begun the transition from a cytology-based process to a HPV-based 
screening focused on identifying high-risk HPV. Screening in the cervix for HPV-driven 
disease and cancer is possible in part due to the presence of a pre-malignant state (CIN) 
identifiable in the transitional zone of epithelium and changes that can be observed from pre-
malignancy to cervical cancer. In contrast, these conditions are not replicated for HPV-
Oropharyngeal cancer. In the first instance, there is a lack of a known pre-malignant state in 
HPV-OPC. Dysplasia is rarely identified in the oropharynx in healthy individuals while HPV 
positive dysplasia is even rarer. HPV has been shown to localise in the reticulated epithelium 
of the tonsillar crypts and therefore it is challenging to develop screening tools that can 
effectively access these sites like a ‘pap-smear’ equivalent of the cervical cytology screening. 
Further research is required to establish which oral sampling techniques will be most 
productive in the development of any screening programme for oropharyngeal HPV infection 
or cancer. It is also important to thoroughly investigate which oral samples – oral rinse, oral 
scrapings, swabs, biopsies or tonsil tissue – will be adopted into any screening programme on 
oral HPV infection. There will also need to be universal consensus on the HPV detection 
techniques and what parameters constitute oral HPV positivity e.g. p16 positivity and the 













PhD CHAPTER 3 
THE IMPACT OF TONSILLECTOMY ON THE NATURAL HISTORY OF ORAL 
HUMAN PAPILLOMA VIRUS INFECTION IN HEALTHY INDIVIDUALS:  










3.1 Introduction:  
High-risk human papillomaviruses (HR-HPV), are causal for a subset of oropharyngeal 
cancer (OPC) (Gillison et al., 2000; Chaturvedi et al., 2013; D'Souza et al., 2007a). In 
particular, HPV 16 is associated with over 90% of HPV oropharyngeal cancer. There is 
currently limited data on the natural history of oral HPV infection itself. Available studies 
indicate oral HPV acquisition coincides with the onset of sexual activity and in immune-
competent individuals, is cleared within 18 – 24 months (Chung et al., 2014; Kreimer et al., 
2013; Kero et al., 2012a; Edelstein et al., 2012; D'Souza et al., 2007b). Persistence of high-
risk HPV demonstrably increases the risk of progression to high grade squamous 
intraepithelial cervical neoplasia (Cuschieri et al., 2005; Vega-Pena et al., 2013; Remmink et 
al., 1995; Schettino et al., 2014). In contrast, persistence of oral high-risk HPV infection has 
yet to be shown in any longitudinal studies to be a direct prelude to OPC development. The 
obvious limitation of such a study design (amongst others), is the length of follow up required 
due to a latency of over 20 years between oral infection and overt oropharyngeal cancer. It is 
known that p16 expression localises to the specialised epithelium of tonsillar crypts (Begum 
et al., 2005) but it remains undetermined if tonsillectomy affects the natural history of oral 
HPV infection. This is the first study to investigate the natural history of oral HPV infection 
after tonsillectomy.  
3.2 Patients and methods:  
The OROMOUTH study was a multicentre cross-sectional study on oral HPV prevalence in 
healthy individuals in the UK undergoing tonsillectomy for non-cancer reasons 
http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=1234. The OROMOUTH study 




UK with recruitment of patients undergoing tonsillectomy. Patients signed consent forms and 
had oral rinse and urine samples taken before their surgery as well as swabs of the posterior 
pharyngeal wall and tongue base in theatre. All samples including the tonsils were collected 
and sent for HPV DNA analysis at DDL Belgium. Patients aged 16years and above on 
OROMOUTH also completed sexual behaviour questionnaire with the data anonymised, 
returned in a sealed envelope and analysed by the research team in a blinded fashion. The 
results of the larger OROMOUTH study is currently being analysed and will be published in a 
peer-reviewed journal soon.  
The oral HPV persistence study presented in this thesis was a longitudinal study (N – 126) on 
a subset of the OROMOUTH cohort in which the student collected oral rinse samples from 
patients following tonsillectomy. The patients were identified from a random sample of 
patients who had tonsillectomy on the OROMOUTH study and were willing to provide 
second oral rinse samples post-operatively. They were approached at the time of surgery and 
consented to second sample collection. They were reminded by telephone by the student when 
their appointments were due following surgery. The oral rinse samples were collected by the 
student in clinic at the hospital.  
3.2.1 Setting: Hospital-based, multi-centre study in the West Midlands United Kingdom.   
3.2.2 Participants: All participants on the OROMOUTH study who were positive for the 
presence of HPV DNA (all ages) and a control group of patients negative for HPV DNA 
(stratified into participants >14 years old and children ≤ 14 years old) with pre- and post-
tonsillectomy oral rinse samples available for analysis.  
3.2.3 Samples: Oral rinse (gargles with normal saline for 30seconds) was taken on the day of 




pre- and post-operative oral rinse samples tested for HPV DNA by PCR. 2nd visit samples 
were collected in the Ear, Nose and Throat clinic by the student and pipetted into 
preservative-containing bottles, stored in – 800C ready for laboratory analysis by a diagnostic 
laboratory in Belgium.  
3.2.4 Laboratory tests: These tests were not performed by the student but undertaken by 
scientists at the diagnostic laboratory in Belgium. HPV DNA amplification was performed 
using a broad-spectrum short-PCR-fragment assay [SPF10] PCR-DNA Enzyme Immunoassay 
(DEIA) followed by a primer SPF10-based line probe assay (SPF10LiPA) and MPTS 123 (a 
novel E6-based multiplex type-specific system that uses the Luminex xMAP technology). For 
this analysis, DEIA positivity was regarded as HPV positivity and the HPV genotype was any 
strain identified from either the LiPA or MPTS 123 assays.  
3.2.5 Statistical analysis: All demographic and laboratory test results were anonymised, 
sequentially entered on to a central database and extracted on to Excel spreadsheets by the 
student. The required variables were analysed by the student and correlated with oral HPV 
positivity using a statistical package (STATA SE).  
3.2.6 Ethical approval: Approval was secured for this study with OROMOUTH MREC No.: 
11/WM/0283, UKCRN ID: 12344. 
The role of the student included arranging second visits for a subset of the OROMOUTH 
cohort following tonsillectomy, collection of oral rinse samples post-tonsillectomy, statistical 






3.3 Results:  
All participants included in this analysis (children and adults) have all had pre- and post-
tonsillectomy oral rinse samples taken for HPV DNA identification. 126 participants (in total) 
were included in this analysis. 25 participants were aged < 14 years old, while 101 
participants were aged ≥ 14 years old. Both groups are analysed separately, as oral HPV 
acquisition and transmission routes are likely to be different between children and adults. 
3.4 Tonsillectomy cohort of participants aged 14 years or more: 
Demographic variables: 
Overall, the age range of participants aged ≥ 14 years old was 14.8 – 55.2 years, with median 
age 22.1 years (IQR: 18.8 – 30.5years) and mean age 25.3years. There were 19 males (18.8%) 
and 82 females (81.2%) in this cohort. The age range for males was 15 – 23 years; median age 
28.4years (IQR: 20.8 – 31.5 years) and mean age 28.2 years. The age range for females was 
14.8 – 55.2 years; median 22 years (IQR: 18.7 – 29.8 years) and mean age 24.7 years. These 
demographic data are shown in Table 3.1. The difference in mean age by gender was not 










Table 3.1: Tonsillectomy population aged 14 years and over. This table presents the 
sample size of participants aged 14 years and above in a tonsillectomy population, their age 
range, median and mean stratified by gender.  
 Overall Males Females Statistical 
testing 
Sample size              
(N) (%) 







14.8 – 55.2 15.0 – 23.0 14.8 – 55.2  
Median age    
(IQR) 
22.1 
(18.8 – 30.5) 
28.4 
(20.8 – 31.5) 
22.0 

















3.5 Paired oral rinse samples: 
In this study, there were 101 participants aged ≥ 14 years with paired oral rinse samples (i.e. 
before and after tonsillectomy) available for analysis. In the pre-operative oral rinse samples, 
there were 11/101 (10.89%) positive for oral HPV on testing (Table 3.2). Of the 11 oral HPV 
positive individuals, there was 1 male and 19 females. The gender distribution of oral HPV 
positivity pre-operatively was therefore 1/19 males (5.26%) and 10/82 females (12.20%).  
Following tonsillectomy, oral rinse samples were collected from all 101 participants (aged ≥ 
14 years) and tested using the same HPV testing protocol as performed pre-operatively. Of 
note, only 2 participants remained HPV positive following tonsillectomy among the 11 
participants who were positive pre-operatively. There were however 9 participants with new 
oral HPV infections detected in oral rinse samples following tonsillectomy from the 90 
patients previously HPV negative pre-operatively. This indicates a 9/90 (10%) proportion of 
the cohort developed new oral HPV infections after tonsillectomy.  
Oral HPV positivity for any oral HPV genotype remained the same at 11/101 (10.89%) pre-
and post-tonsillectomy. However, following tonsillectomy, 82% of those with existing 
infections cleared their infection. Four of the six cases with high-risk HPV oral infection 
cleared their infections after tonsillectomy. The only person with HPV 16 oral infection 
cleared their infection. There was no patient with oral HPV 18 pre-operatively. Tonsillectomy 
was associated with a reduction in the burden of any oral HPV infection by 80.1% and high-
risk oral HPV by 63.5% but these reductions were not statistically significant given there 






Table 3.2: Pre-operative oral HPV infection status in the tonsillectomy cohort aged 
14years and over. This table shows the demographic distribution of the tonsillectomy 
population pre-operatively stratified by oral HPV status 















14.8 – 55.2 14.9 – 43.8  14.8 – 55.2  
Median age    
(IQR) 
22.1 
(18.8 – 30.5) 
21.9 
(18.6 – 23.8) 
22.15 








3.6 Oral HPV genotypes: 
The oral HPV genotypes identified before tonsillectomy was performed in the 11 participants 
using LiPA and MPTS, are as follows: oral HPV 11, 16, 39, 51, 52, 59, 66 and 68. There were 
5 oral rinse samples in which the oral HPV present was not typeable. Most oral HPV 
infections were multiple infections with more than one HPV genotypes as there were 8/11 
multiple infections noted pre-operatively. Oral HPV infection in these healthy participants 




3.7 Oral HPV positivity stratified by oropharyngeal sites: 
HPV was detected in oral rinse in 11/101 (10.89%) of participants before tonsillectomy. The 
tongue base brushes yielded only one positive sample for which the HPV genotype was not 
typeable. In both the posterior pharyngeal wall brushes and the tonsils specimens, there was 
no oral HPV identified.  
In terms of correlation with other oral samples, only one patient who was found to be positive 
for oral HPV in oral rinse pre-operatively who was also HPV positive in any other oral 
sample (tongue base brush) at the same time. This was with a concordant ‘not typeable’ 
genotype in both oral rinse and tongue base brush.  
3.8 All pre-operative oral samples and HPV detection: 
The different oral samples yielded varying degrees of oral HPV positivity. HPV positivity 
was found in oral rinse in 11/101 (10.89%), in tonsils in 4/101 (3.96%), in tongue base 
brushes in 3/101 (2.97%) and in pharyngeal wall brushes 0/101 (0%). Oral rinse therefore 
provided the highest yield of oral HPV pre-operatively. The HPV genotypes found in the 3 
positive tongue base brushes were HPV 53, and 2 samples with ‘non-typeable HPV’ 
(regarded as low-risk HPV). Only 1 tongue base positive sample also showed positivity in the 
corresponding oral rinse sample. In the 4 positive tonsils, the oral HPV genotypes identified 
included HPV 16 (in 2 tonsils), HPV 66 and ‘non-typeable HPV’. Remarkably, none of the 4 
individuals with HPV detected in their tonsils had simultaneous detection of HPV in their oral 
rinse. There were no patients with oral HPV positivity on pharyngeal wall brushes so 
sensitivity on oral rinse testing was not possible. The true sensitivity and specificity of the use 
of oral rinse and the other sampling techniques (tongue base brush, pharyngeal wall brush, 




3.9 Impact of tonsillectomy on the natural history of oral HPV infection: 
Before tonsillectomy, there were 11 subjects positive for oral HPV and 90 subjects negative 
for oral HPV. After tonsillectomy, only 2/11 HPV positive patients remained positive on oral 
rinse testing (Table). Importantly, 9/90 (10%) subjects who were HPV negative before 
tonsillectomy, were subsequently found to have HPV positivity on oral rinse after their 
tonsillectomy. These were regarded as new oral HPV infections.  
Although tonsillectomy reduced the prevalence of oral HPV infection in the infected people 
with a reduction from 11/101 (10.89%) pre-operatively to 2/92 (2.17%) post-operatively, this 
was not statistically significant on McNemar’s test due to the 9 new infections observed in the 
cohort. McNemar chi-squared statistic with Yates correction of 1.0 was 0.056. The 
corresponding p-value (2 tails) was 0.814. The odds ratio equals 1.0 with 95% Confidence 
interval from 0.397 to 2.519 (Table 3.3). This indicates a non-significant impact of 











Table 3.3: Impact of tonsillectomy on oral HPV infection in cohort aged 14 years and 
over. Table showing number of participants positive for oral HPV infection before and after 
tonsillectomy in individuals aged 14years and over. Although there was a reduction in oral 
HPV positivity post-operatively, this was not statistically significant on McNemar’s testing 
due to occurrence of new infections in previously oral HPV negative participants.   




































3.10 Children’s cohort:  
Only 25 children < 14 years old, had paired oral rinse pre- and post-tonsillectomy available 
for inclusion in this analysis. Understandably, there were difficulties obtaining oral rinse or 
urine from children waiting for surgery or even after surgery. The age range of this cohort of 







Table 3.4: Demographic data for the tonsillectomy cohort of children. Table showing 
sample size, age range, median and mean age for children having tonsillectomy aged <14 
years, stratified by their oral HPV status.  
















3.4 – 13.3  
 
3.9 – 7.9 
 
3.4 – 13.3  
 
Median age    
(IQR) 
7.6 
(5.6 – 10.2) 
7.4 
(6.2 – 7.6) 
8.2 








3.11 Oral HPV positivity in children: 
5/25 (20%) children had oral HPV positivity in oral rinse pre-operatively (Table 3.4). The 
majority of these infections were due to low risk HPV as ‘non-typeable HPV’ was found in 4 
children and HPV 35 in one child. Low-risk HPV therefore accounted for 4/25 (16%) in 
children, while high-risk HPV was found in 1/25 (4%) pre-operatively. There were 3/13 males 
(23.1%) and 2/12 females (16.7%) positive for oral HPV among this cohort of children. The 
mean age of children overall was 8.1 years with the breakdown along oral HPV positive (6.6 
years) and oral HPV negative (8.5 years) groups. There was no difference in mean age 
between the two groups on student T-test with a p-value=0.205 (Table 3.4).  
3.12 Impact of tonsillectomy on oral HPV infection in children: 
Of the 5/25 (20%) children with oral HPV positivity before tonsillectomy, 2/25 (8.0%) 




Both children with oral HPV on repeat testing following tonsillectomy had low-risk HPV 
(both had non-typeable HPV). The only child with high-risk HPV pre-operatively (HPV 35) 
had cleared this on oral rinse testing post-operatively. There was however a single child with 
a new infection post-tonsillectomy despite being negative pre-operatively. In assessing the 
impact of tonsillectomy on oral HPV infection, McNemar’s test statistic was 0.25, with a 2-
tailed p-value = 0.617 and an odds ratio = 3. This indicates the observed impact of 
tonsillectomy in reducing oral HPV prevalence, was not statistically significant.  
Table 3.5: Impact of tonsillectomy on oral HPV infection in children. Table showing 
number of children less than 14 years old with oral HPV infection before and after 
tonsillectomy. There was a reduction in oral HPV positivity post-operatively but this finding 
was not statistically significant given the small numbers on McNemar’s test.  














































Impact of tonsillectomy on oral HPV infection in children 
<14 years old
Any Oral HPV High risk Oral HPV
 
Figure 3.1: Impact of tonsillectomy on oral HPV infection in children < 14 years old. 
Chart shows a comparison between oral HPV infection in children before and after 
tonsillectomy. Any oral HPV is depicted in blue while orange is high-risk oral HPV.  
 
3.13 Age distribution of oral HPV infection: 
The entire dataset obtained from this OROMOUTH cohort was further classified into age-
groups as follows (in years): [≤ 14], [14.0 – 19.9], [20.0 – 24.9], [25.0 – 29.9], [30.0 – 34.9], 
[35.0 – 39.9], [40.0 – 44.9], [45.0 – 49.9], [≥ 50]. The total number of participants within each 
age-group and the relative numbers of individuals with oral HPV positivity in each group is 
shown in Table 3.6 below. The age-group with the highest proportion of individuals in this 
cohort was the 14.0 – 19.9 years group with 34 patients, followed by the 20.0 – 24.9 years 
age-group with 30 individuals (Table 3.6). With 25 children aged <14 years, it clearly shows 
that 89/101 participants in this cohort were young and aged <25years. This is a consistent 




participants with oral HPV infection in this healthy cohort were the <14 years age group with 
5/25 (20%) HPV positive, the 20.0 – 24.9 years age-group with 6/30 patients (20%) positive 
for oral HPV and the the 40.0 – 44.9 years age-group with 1/6 patients (16.7%) positive for 
any oral HPV infection (Table 3.6 and Figure 3.2).  
Table 3.6: Age distribution for any oral HPV infection. Table showing the age distribution 
of the entire tonsillectomy cohort with the majority of participants being young and <25years.  
Age group (years) Total number of 
individuals 
Number Oral HPV 
positive 
% Oral HPV 
positive 
< 14 25 5 20.0 
≥14 – 19.9 34 3 8.82 
20 – 24.9 30 6 20.0 
25 – 29.9 9 0 0.0 
30 – 34.9 18 1 5.6 
35 – 39.9 1 0 0.0 
40 – 44.9 6 1 16.7 
45 – 49.9 0 0 0.0 









Figure 3.2: Age distribution of oral HPV infection. Figure showing the age distribution of 
the tonsillectomy population in this study. The total number of individuals in each age group 
is depicted in blue columns while the number of individuals with any oral HPV infection is 










3.14 Discussion:  
Persistent infection with high-risk HPV has been recognised as a precursor of invasive 
cervical cancer (Cuschieri et al., 2005; Vega-Pena et al., 2013; Remmink et al., 1995; 
Schettino et al., 2014). A similar association is yet to be characterised for persistent oral HPV 
infection and oropharyngeal cancer development. Oral HPV infection is dynamic and varies 
with the onset of sexual activity, changes in sexual behaviours and exposure to risk factors 
(Cook et al., 2014). Studies on the natural history of oral HPV infection show that immune-
competent individuals are able to clear the infection within 18 – 24 months (Chung et al., 
2014; Kreimer et al., 2013; Kero et al., 2012a; Edelstein et al., 2012; D'Souza et al., 2007a). 
Oral sex is an independent risk factor for acquisition of oral HPV infection when confounders 
are controlled for. In men, tobacco smoking is associated with persistent oral HPV infection 
(Kero et al., 2014), as is oral contraception in women. There are higher proportions of oral 
HPV infection in individuals with HIV infection (Beachler et al., 2012), a history of previous 
HPV in the cervix, and sex workers (Matsushita et al., 2011), with variations in the factors 
that will affect persistent infection. No previous studies have found an effect of tonsillectomy 
on the natural history of oral HPV infection. We sought to demonstrate for the first time, the 
potential effect of tonsillectomy on oral HPV infection in healthy subjects.  
Our study has shown a trend towards an abrogation of oral HPV infection following 
tonsillectomy in previously positive individuals. However, there was no statistically 
significant association found in adults or in children because several cases of new infections 
occurred post-tonsillectomy.  
The acquisition of oral HPV infection occurs mainly with the onset of sexual activity in 




transmission route is less convincing. Vertical transmission has been described in children 
(Vega-Pena et al., 2013) as well as correlation with maternal cervical HPV status (Chatterjee 
et al., 1998; Pinheiro Rdos et al., 2011; Koskimaa et al., 2012; Kravchenko, 2011). This study 
suggests there is a difference in the oral HPV genotype distribution between children and 
adults as expected, given the different drivers of infection in both groups. Children had more 
low-risk HPV strains compared with sexually active adults with more high-risk HPV. This is 
consistent with literature that shows oral HPV peaks in teenagers once they become sexually 
active (Flake et al., 2012).  
Oral HPV persistence: In the children’s cohort, only one child out of eleven pre-operatively 
positive patients (on any sample) remained positive on oral rinse after tonsillectomy. This was 
a seven year old girl with non-typable HPV (which is low-risk) and no significant risk factors. 
Amongst adults, two out of fifteen participants had persistence of oral HPV infection 
following tonsillectomy in any sample, with oral rinse positivity fractions reducing from 7 
pre-op to only 1 adult post-op. This was an 18-year old female, regular smoker, with multiple 
high-risk oral HPV infection (strains 11, 39, 66). She also provided a history of drinking 
alcohol twice a week, engaging in oral sex and has had 9 lifetime male sexual partners. 
Smoking does increase the risk of oral HPV persistence (Kero et al., 2014) but it is unclear 
what other risk factors could explain persistence in this case despite tonsillectomy.  
3.15 Study conclusions: 
This is the first UK study to provide crucial data on the potential impact of tonsillectomy on 
the natural course of oral HPV infection. Tonsillectomy appears to be associated with a 
reduction in oral HPV positivity. However, we do not have a control arm and so we cannot 
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Oropharyngeal cancer (OPC) are a sub-group of head and neck cancers that primarily include 
cancers of the tonsils, tongue base, soft palate, uvula and pharyngeal walls. Incidence of OPC 
is mainly in males aged >50 years with recognised risk factors of tobacco smoking and 
alcohol consumption. High risk strains of human papillomavirus (HPV) are now an 
established aetiology for a unique subset of oropharyngeal cancer (HPV OPC). HPV OPC is 
more common among younger males who do not smoke tobacco or consume excessive 
amounts of alcohol (Gillison et al., 2000). Oral sex and multiple sexual partners over a 
lifetime are risk factors for HPV OPC (D’Souza et al., 2007b). Determinants of survival 
include age (elderly patients have worse survival), gender (males worse), socio-economic 
status (worse in deprived populations), and significant co-morbidities (worse survival with 
increasing co-morbidity scores).   
4.2 Aims: To describe the baseline demographics and the epidemiologic determinants of 
overall survival in patients with oropharyngeal cancer recorded on the UK Hospital 
Episodes Statistics (HES) database. 
4.3     Methods: Retrospective analyses of the UK HES database for cases of 
oropharyngeal cancers. The database covers all NHS Trusts in England with admitted 
patient care information available only since 1989, attendance at Outpatient clinics since 
2003 and attendance in Accident and Emergency department since 2007. 
4.4       Statistical enquiry: We described demographic data on oropharyngeal cancers 
recorded on the UK HES database including the age distribution and described the 





The anatomic sub-sites for oropharyngeal cancer included tonsil, base of tongue, and other 
oropharyngeal sites (namely soft palate, uvula, posterior and lateral pharyngeal walls). These 
data were all coded using the ICD-10 classification including ICD 10 C09.0, C09.1, C09.8, 
C09.9 for tonsil cancers and C02.9, C10.9. The HES database was accessed via the licence 
granted to the Bioinformatics department of the Queen Elizabeth Hospital Birmingham. The 
data was anonymised and the student only had access to the files on the secure site. 
We investigated the gender distribution of oropharyngeal cancers recorded on the HES 
database as well as the regional proportions, and ethnicity, assessing for any significant 
differences with the X2 test. We documented behavioural risk factors such as tobacco 
smoking and alcohol consumption among patients with OPC on HES.  
We assessed for the impact of co-morbidity, deprivation, oropharyngeal cancer anatomic site 
and behavioural risk factors on overall survival from OPC in the HES database using Kaplan 
Meier and Cox regression analyses.  
We calculated yearly incidence of oropharyngeal cancers in the UK overall and by region. 
The numbers of oropharyngeal cancers documented on the HES database was utilised per 
region as the numerator while the population per year in every region was obtained from the 
UK Office of National Statistics (ONS). There were 21,135 males and 7,711 females with 
oropharyngeal cancers in the HES database over the study period.  
Human papillomavirus (HPV) status on the UK HES database was also reviewed. Only a 
small proportion of oropharyngeal cancers, specifically 161/28,846 (0.56%), were recorded to 
be HPV positive. It is therefore difficult to draw any conclusions from this variable in 
particular because HPV status only recently became part of the documentation records from 





Using the UK HES (Hospital Episodes Statistics) Database, all data recorded for 
oropharyngeal cancer in the United Kingdom between the years 2001 and 2016 were 
analysed. There were 28,846 patients recorded on the HES database with a diagnosis of 
oropharyngeal cancer that also had demographic data available for analysis. In this 
oropharyngeal cancer cohort, there were predominantly more males accounting for 21,135 
(73.27%) of cases, while females were 7,711 (26.73%). This indicates a male:female ratio of 
2.7: 1. (Figure 4.1) 
4.5.1 Age distribution: 
The mean age for all oropharyngeal cancer in this HES cohort was 60 years. The data was 
further stratified into age group categories as follows: [‘<40 years’, ‘40 – 49 years’, ‘50 – 59 
years’, ‘60 – 69 years’, ‘70 – 79 years’ and ‘≥ 80 years’]. The age group with the highest 
proportion of oropharyngeal cancer diagnoses in the UK from the HES database was the ‘50 – 
59 years’ cohort with 9,642 cases (33.43%). This age group was followed in descending order 
of cancer frequency by the ’60 – 69 years’ with 8,640 cases (29.95%); the ‘70 – 79 years’ 
with 4,285 cases (14.85%); the ‘40 – 49 years’ with 4,079 cases (14.14%); the ‘≥ 80 years’ 
with 1,520 cases (5.27%); and finally the ‘<40 years’ group with only 680 cases (2.36%) 
[Table 4.1]. Oropharyngeal cancer therefore remains a condition that predominantly affects 
people aged over 50 years old in the UK with a peak prevalence in people aged 50 – 59 years 






Table 4.1: Age distribution of Oropharyngeal cancer in the UK by gender. The total 
numbers of oropharyngeal cancers in each age group are shown and the proportions by 
gender.  






<40 680 417 (61.3%) 263 (38.7%) 
40 - 49 4079 3080 (75.5%) 999 (24.5%) 
50 - 59 9642 7319 (75.9%) 2323 (24.1%) 
60 - 69 8640 6445 (74.6%) 2195 (25.4%) 
70 - 79 4285 2979 (69.5%) 1306 (30.5%) 
≥80 1520 895 (58.9%) 625 (41.1%) 
Total 28,846 21,135 (73.3%) 7,711 (26.7%) 
 
4.5.2 Gender distribution: 
Males account for a higher proportion of Oropharyngeal cancer in ALL age groups recorded 
on HES. Males accounted for 417/680 cases (61.3%) in patients aged <40years; 3,080/4079 
cases (75.5%) in the 40 – 49 years age group; 7319/9642 cases (75.9%) in the 50 – 59 years 
age group; 6445/8640 cases (74.6%) in the 60 – 69 years age group; 2979/4285 cases (69.5%) 
in the 70 – 79 years age group; and 895/1520 cases (58.9%) in the ≥80 years age group. The 
age group with the highest proportion of OPC was therefore the 50 – 59 years group with 




The results for both gender, follow a normal distribution with the highest gender fractions for 
Oropharyngeal cancer seen in the 50 – 59 years age group for both males and females 
(34.63% and 30.13% respectively) and the lowest proportions in the extremes of age.  
In males, there were a total of 21,135 oropharyngeal cancer in HES UK. Of this total, there 
were 417 (1.97%) in males aged <40years; 3080 (14.57%) in the 40 – 49 years group; 7319 
(34.63%) in the 50 – 59 years group; 6445 (30.49%) in the 60 – 69 years group; 2979 
(14.10%) in the 70 – 79 years group; and 895 (4.23%) in the patients aged ≥80 years old 
(Table 4.2 and Figure 4.2). 
Similarly in females, there were a total of 7711 oropharyngeal cancer in HES UK. Of this 
total, there were 263 (3.41%) in females aged <40years; 999 (12.96%) in the 40 – 49 years 
group; 2323 (30.13%) in the 50 – 59 years group; 2195 (28.47%) in the 60 – 69 years group; 
1306 (16.94%) in the 70 – 79 years group; and 625 (8.11%) in the female patients aged ≥80 












Table 4.2: Age-specific distribution of Oropharyngeal cancer in the UK. Total number of 
oropharyngeal cancers in each age group by gender.  








<40 680 (2.4%) 417 (2.0%) 263 (3.4%) 
40 - 49 4079 (14.1%) 3080 (14.6%) 999 (13.0%) 
50 - 59 9642 (33.4%) 7319 (34.6%) 2323 (30.1%) 
60 - 69 8640 (30.0%) 6445 (30.5%) 2195 (28.5%) 
70 - 79 4285 (14.9%) 2979 (14.1%) 1306 (16.9%) 
≥80 1520 (5.3%) 895 (4.2%) 625 (8.1%) 
Total 28,846 21,135  7,711 
 
The extremes of the age group categories had the lowest proportions of Oropharyngeal cancer 
recorded on HES UK. Young patients (aged <40 years) had OPC fractions of 1.97% in males, 
3.41% in females while the elderly (≥80 years) had 4.23% in males and 8.11% in females. 
There was however, no statistically significant difference between the two gender proportions 
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Figure 4.1: Oropharyngeal cancer by gender and age distribution on HES UK. 
Histograms showing distribution of oropharyngeal cancer cases in the UK at the age of 







<40 40 - 49 50 - 59 60 - 69 70 - 79 ≥80
Total OPC % 2.4 14.1 33.4 30 14.9 5.3
Males OPC % 2 14.6 34.6 30.5 14.1 4.2























Oropharyngeal cancer by gender and age group 
(years)
 
Figure 4.2: Oropharyngeal cancer distribution in years by sex and age. Figure showing 
proportions of oropharyngeal cancers in each age group with total proportions in blue, male 
proportions in red and female proportions in green. The highest proportions were found in 

















4.5.3 Ethnicity and oropharyngeal cancer: 
81.8% of this oropharyngeal cohort had an ethnicity recorded as ‘White’ which is expected, 
given the underlying population is a UK mainly Caucasian population (Table 4.3). Males had 
higher frequency of oropharyngeal cancer diagnosis on HES UK for all the ethnic groups 
except Bangladeshi where it was even. These disparities between ethnicity by gender were not 
statistically significant on Chi-squared (X2) testing. A baseline analysis using available UK 
population data on each of these ethnic groups is required to estimate disease prevalence in 
















Table 4.3: Impact of ethnicity on oropharyngeal cancer proportions in UK HES. Table 
shows proportions of OPC with ethnicity data available on UK HES. The majority of cases 
were in the ‘White’ ethnic group consistent with the background population. There were small 
numbers in the other ethnic groups available for comparison.  






White 23,597 (81.80%) 17,332 (82.01%) 6265 (81.25%) 
Unknown 4349 (15.08%) 3196 (15.12%) 1153 (14.95%) 
Black or Black 
British 
240 (0.83%) 160 (0.76%) 80 (1.04%) 
Other Ethnic Group 179 (0.62%) 128 (0.61%) 51 (0.66%) 
Indian 170 (0.59%) 118 (0.56%) 52 (0.67%) 
Mixed 91 (0.32%) 60 (0.28%) 31 (0.40%) 
Pakistani 73 (0.25%) 51 (0.24%) 22 (0.29%) 
Bangladeshi 67 (0.23%) 33 (0.16%) 34 (0.44%) 
Other Asian 
Background 
60 (0.21%) 46 (0.22%) 14 (0.18%) 
Chinese 20 (0.07%) 11 (0.05%) 9 (0.12%) 





4.5.4 UK regional variations in oropharyngeal cancer epidemiology: 
An analysis of the regional variations in the incidence of oropharyngeal cancers in the UK 
based on the HES database was performed using the total number of oropharyngeal cancers in 
each UK region recorded on HES (Table 4.4) and population data obtained from the Office of 
National Statistics (ONS). The regional proportions of oropharyngeal cancers in the UK are 
shown in Figure 4.3, with the highest proportions recorded in the North West region.  
Table 4.4: Regional variations in Oropharyngeal cancer proportions on UK HES. OPC 
cases recorded on HES by UK region and by gender.  
UK Region Total OPC  Males  Females  









OPC - N 
Females OPC 
(%) 
North West 4778 16.56 3519 16.65 1259 16.33 
South East 4293 14.88 3082 14.58 1211 15.70 
London 3700 12.83 2689 12.72 1011 13.11 
Yorkshire 
and Humber 
3080 10.68 2254 10.66 826 10.71 
South West 3068 10.64 2270 10.74 798 10.35 
West 
Midlands 
2820 9.78 2038 9.64 782 10.14 
East of 
England 
2770 9.60 2081 9.85 689 8.94 
East 
Midlands 
2255 7.82 1653 7.82 602 7.81 
North East 1825 6.33 1375 6.51 450 5.84 
No Fixed 
Abode 
56 0.19 30 0.14 26 0.34 
Unknown 201 0.70 144 0.68 57 0.74 






Figure 4.3: OPC proportions in the UK HES by region. Figure shows proportions of OPC 
in each UK region with total % in blue, male proportions in red and female proportions in 
green.  
 
4.5.5 Overall incidence of OPC in the UK: 
The incidence of oropharyngeal cancer in the UK was calculated from the recorded yearly 
cases of oropharyngeal cancer retrospectively retrieved from the HES UK database between 
2001 – 2014 as well as the UK yearly population estimates (overall and by sex) obtained from 
the Office of National Statistics (2016). The results are presented as per 100,000 population 
for each year, by sex and by UK region.  
There has been an increasing incidence of oropharyngeal cancer in the UK over the study 
period. OPC incidence has risen steadily from 2.7 cases per 100,000 in 2001 to a peak of 5.8 
per 100,000 in 2014 (Figure 4.4). This represents a doubling of the incidence rate over the 





Figure 4.4: Oropharyngeal cancer increasing incidence trend in England. Year on year 
incidence of OPC in England shows there has been an increasing trend over the study period 
 
4.5.6 OPC incidence by gender: 
The incidence of oropharyngeal cancer in the UK was further stratified by gender. The data 
shows that although there has been an increase in OPC incidence in both males and females, 
the overriding driver in the observed increasing trend is shown in the male incidence. There 
has been a remarkable increase in OPC incidence among males in the UK with a doubling of 
the rate in a steady rise from 4.0 per 100,000 population in 2001 to 8.3 per 100,000 in 2014. 










































Figure 4.5: Incidence of oropharyngeal cancer in England by gender. OPC incidence has 
increased in both males and females over the study period but the greatest increase is 
observed in male incidence (per 100,000).  
 
4.5.7 OPC incidence by UK region: 
OPC incidence by UK region was also analysed in this cohort. The regional incidence rates in 
all UK regions studied showed an increasing incidence trend regardless of location (Figure 
4.6). However, when compared with other UK regions, the North East and North West 
regions had the highest incidence rates of OPC at any given time in the study period. By 
2014, the highest incidence was reported in the North East at 7.3 per 100,000 population. 




variation needs further investigation which is not possible with the data available from the 
























Figure 4.6: Oropharyngeal cancer incidence in England by region. There has been a 
steady increasing incidence in OPC across all UK regions with the highest incidence in the 








4.5.8 Anatomic sub-sites of oropharyngeal cancer: 
The anatomic sub-sites for oropharyngeal cancer include tonsil, base of tongue, and other 
oropharyngeal sites (namely soft palate, uvula, posterior and lateral pharyngeal walls). In the 
UK HES database overall, there were predominantly tonsil cancers with 11,924 cases 
(41.34%), followed by base of tongue cancers with 9922 cases (34.40%) and other 
oropharyngeal sites at 7,000 cases (24.27%) as shown in Table 4.5. This trend was maintained 
when the data was stratified by gender with tonsil cancer being the most frequent anatomic 
site, followed by base of tongue and lastly other oropharyngeal sites in both males and 
females (Table 4.5).  
4.5.9 Risk factors: 
An analysis of known risk factors for the development of oropharyngeal cancer included 
variables such as smoking history, alcohol consumption, HPV status, Co-morbidity scores and 
Deprivation scores. Almost 2/3rd of this dataset on oropharyngeal cancer did not have a 
history of ever smoking recorded on HES. There were 18,408/28,846 OPC cases (63.81%) 
who did not smoke tobacco and 10,438 cases (36.19%) who were smokers. Amongst males, 
7705/21,135 cases were smokers (36.46%) while amongst females, there were 2733/7,711 
(35.44%) smokers (Table 4.5). Similarly, a history of alcohol consumption was recorded on 
the UK HES in 5,840/28,846 OPC cases (20.25%) overall and in 4,613/21,135 males 







Table 4.5: Anatomic sites and risk factors for Oropharyngeal cancer. Table showing the 
total numbers and proportions by gender for cancer subsite, smoking status, alcohol 
consumption, co-morbidity scores, and deprivation scores for all OPC on the HES database.  
 Total 


















      
Tonsil 11,924 41.34 8930 42.25 2994 38.83 




7000 24.27 4849 22.94 2151 27.90 
Smoking        
Smoker 10,438 36.19 7705 36.46 2733 35.44 
Non Smoker 18,408 63.81 13,430 63.54 4978 64.56 
       
Alcohol       
Alcohol 5840 20.25 4613 21.83 1227 15.91 
No Alcohol 23,006 79.75 16,522 78.17 6484 84.09 
Comorbidity 
Score 
      
< 5 9457 32.78 6534 30.92 2923 37.91 
5 to 10 1249 4.33 955 4.52 294 3.81 
10 to 15 10,100 35.01 7628 36.09 2472 32.06 
15 to 20 3388 11.75 2503 11.84 885 11.48 
20 + 4652 16.13 3515 16.63 1137 14.75 
Deprivation 
Score 
      
1 6956 24.11 5202 24.61 1754 22.75 
2 6049 20.97 4402 20.83 1647 21.36 
3 5692 19.73 4114 19.47 1578 20.46 
4 5171 17.93 3766 17.82 1405 18.22 
5 4689 16.26 3452 16.33 1237 16.04 
Unknown 289 1.00 199 0.94 90 1.17 
       







4.5.10 Survival analyses:  
Survival analyses of the oropharyngeal cancer cohort from the UK HES database was 
undertaken using Cox regression and Kaplan Meier survival analyses techniques. 
Demographic and risk factor variables were included in the analyses and hazard ratios (with 
95% confidence intervals) provided as an estimate of the effect size. Statistical significance 
was set at a p-value less than 0.05. All OPC and by gender stratification were analysed using 
their age group, ethnicity, UK region of residence, cancer subgroup, deprivation score, 
Charlson co-morbidity index, smoking history, and alcohol consumption (Table 4.6).  
4.5.10.1 Gender impact on survival: 
There was no statistical difference by gender observed on survival in this oropharyngeal 
cancer cohort. With males as the reference group, the hazard ratio for females was 0.96 (95% 
C.I. 0.91 – 1.00) and a p-value of 0.079. (Table 4.6 and Figure 4.7).  
 
Figure 4.7: Kaplan Meier survival of oropharyngeal cancer by gender. Survival shown in 




Table 4.6: Cox Regression analyses of oropharyngeal cancer and survival determinants. 
Results of the analysis on prognostic factors for survival in OPC using UK HES data.  
Hazard Ratio P-Value
Males 1 (baseline group)
Females 0.96 (0.91,1.00) 0.079
Under 40 1 (baseline group) 1(baseline group) 1 (baseline group)
40 to 49 1.25 (1.04,1.51) 0.019 1.07 (0.85,1.33) 0.576 1.71 (1.21,2.42) 0.002
50 to 59 1.84 (1.54,2.20) <0.001 1.59 (1.28,1.97) <0.001 2.42 (1.74,3.37) <0.001
60 to 69 2.42 (2.02,2.90) <0.001 2.18 (1.75,2.70) <0.001 2.79 (2.01,3.89) <0.001
70 to 79 3.65 (3.04,4.39) <0.001 3.33 (2.67,4.14) <0.001 4.25 (3.04,5.94) <0.001
80 + 5.15 (4.24,6.25) <0.001 4.61 (3.65,5.83) <0.001 6.39 (4.52,9.04) <0.001
White 1 (baseline group) 1 (Baseline Group) 1 (baseline group)
Mixed 1.45 (0.80,2.66) 0.223 1.22 (0.63,2.37) 0.558 2.73 (0.63,11.88) 0.18
Indian 1.11 (0.54,2.27) 0.774 0.94 (0.40,2.21) 0.882 1.98 (0.42,9.30) 0.389
Pakistani 1.41 (0.78,2.54) 0.262 1.37 (0.71,2.63) 0.346 1.87 (0.43,8.04) 0.403
Bangladeshi 1.68 (0.67,4.20) 0.271 1.32 (0.42,4.16) 0.631 3.31 (0.55,19.84) 0.189
Other Asian 
Background
1.77 (0.97,3.25) 0.065 1.84 (0.95,3.57) 0.072 1.81 (0.40,8.26) 0.444
Black or Black 
British
0.89 (0.44,1.79) 0.735 1.00 (0.46,2.17) 0.992 0.83 (0.15,4.51) 0.826
Chinese 0.82 (0.38,1.78) 0.624 0.72 (0.30,1.74) 0.464 1.40 (0.26,7.66) 0.696
Other Ethnic 
Group
1.39 (0.81,2.40) 0.235 1.21 (0.67,2.20) 0.519 2.35 (0.59,9.39) 0.228
Unknown 1.34 (0.78,2.32) 0.29 1.18 (0.65,2.13) 0.593 2.25 (0.56,9.05) 0.252
North East 1 (baseline group) 1 (Baseline Group) 1 (baseline group)
North West 0.92 (0.84,1.01) 0.099 0.92 (0.82,1.02) 0.123 0.94 (0.78,1.13) 0.532
Yorkshire and 
Humber
0.83 (0.75,0.92) <0.001 0.83 (0.74,0.94) 0.003 0.82 (0.67,1.01) 0.06
East Midlands 0.75 (0.67,0.84) <0.001 0.76 (0.67,0.86) <0.001 0.72 (0.58,0.90) 0.004
West Midlands 0.88 (0.79,0.97) 0.013 0.90 (0.80,1.01) 0.073 0.83 (0.68,1.02) 0.073
East of England 0.80 (0.72,0.88) <0.001 0.81 (0.72,0.91) <0.001 0.76 (0.62,0.95) 0.013
London 0.92 (0.84,1.02) 0.113 0.92 (0.82,1.03) 0.136 0.94 (0.78,1.14) 0.546
South East 0.77 (0.70,0.85) <0.001 0.78 (0.69,0.87) <0.001 0.76 (0.63,0.93) 0.006
South West 0.80 (0.72,0.89) <0.001 0.82 (0.73,0.92) 0.001 0.75 (0.61,0.93) 0.008
No Fixed Abode 0.13 (0.04,0.42) 0.001 0.19 (0.05,0.76) 0.019 0.09 (0.01,0.61) 0.014
Unknown 0.13 (0.07,0.25) <0.001 0.16 (0.08,0.32) <0.001 0.08 (0.02,0.32) <0.001
1 1.64 (1.53,1.75) <0.001 1.75 (1.61,1.89) <0.001 1.36 (1.19,1.55) <0.001
2 1.32 (1.23,1.42) <0.001 1.36 (1.25,1.48) <0.001 1.23 (1.07,1.41) 0.003
3 1.16 (1.08,1.25) <0.001 1.21 (1.11,1.32) <0.001 1.04 (0.91,1.20) 0.57
4 1.05 (0.97,1.13) 0.238 1.08 (0.98,1.18) 0.112 0.98 (0.84,1.13) 0.75
5 1 (baseline group) 1 (Baseline Group) 1 (baseline group)
Tonsil 1.13 (1.02,1.25) 0.019 1.15 (1.02,1.30) 0.019 0.56 (0.50,0.62) <0.001
Base of Tongue 1.12 (1.07,1.17) <0.001 1.09 (1.04,1.15) 0.001 0.86 (0.78,0.95) 0.003
Other 1 (baseline group) 1 (Baseline Group) 1 (baseline group)
Smoker 1.57 (1.51,1.64) <0.001 1.62 (1.54,1.70) <0.001 1.45 (1.33,1.58) <0.001
Non Smoker 1 (baseline group) 1 (Baseline group) 1 (Baseline group)
Alcohol 1.64 (1.57,1.72) <0.001 1.64 (1.55,1.73) <0.001 1.67 (1.51,1.84) <0.001
No Alcohol 1 (baseline group) 1 (Baseline group) 1 (Baseline group)
HPV 0.39 (0.24,0.64) <0.001 0.43 (0.24,0.78) 0.005 0.34 (0.14,0.82) 0.016
No HPV 1 (baseline group) 1 (Baseline group) 1 (Baseline group)
< 5 1 (baseline group) 1 (Baseline group) 1 (Baseline group)
5 to 10 1.48 (1.33,1.65) <0.001 1.44 (1.28,1.63) <0.001 1.56 (1.25,1.94) <0.001
10 to 15 1.27 (1.20,1.34) <0.002 1.22 (1.14,1.30) <0.001 1.41 (1.26,1.56) <0.001
15 to 20 1.64 (1.53,1.76) <0.003 1.59 (1.47,1.73) <0.001 1.75 (1.52,2.00) <0.001






















4.5.10.2 Age impact on survival: 
The OPC cohort was divided into age groups as follows: <40 years, 40 – 49 years, 50 – 59 
years, 60 – 69 years, 70 – 79 years, ≥ 80 years. The age groups <40 years was used as the 
reference group. Survival analyses showed a statistically significant increase in the hazard for 
mortality with increasing age across all age groups. The hazard ratio increased steadily from 
1.25 (95% C.I. 1.04 – 1.51) in the 40 – 49 years age group to four times the hazard at 5.15 
(95% C.I. 4.24 – 6.25) in the ≥ 80 years age group (p-value <0.001) (Table 4.6 and Figure 
4.8). This impact of increasing age was replicated regardless of gender with similar trends 
observed in both males and females (p<0.001).  
 
Figure 4.8: Kaplan Meier survival of oropharyngeal cancer by age groups. Age is shown 





The hazard ratio for mortality did not show a statistically significant increase in males aged  
40 – 49 years at 1.07 (95% C.I. 0.85 – 1.33); p=0.576 but did show a consistent increase in 
males aged 50 – 59 years from 1.59 (95% C.I. 1.28 – 1.97) to a hazard ratio of 4.61 (95% C.I. 
3.65 – 5.83) in males aged ≥ 80 years; p<0.001. The effect size was even larger in females 
with OPC with worsening survival with increasing age. The hazard ratio for females aged          
40 – 49 years was 1.71 (95% C.I. 1.21 – 2.42) with a consistent increase in mortality hazard 
to a H.R of 6.39 (95% C.I. 4.52 – 9.04) in females aged ≥ 80 years; p<0.001 (Table 4.6 and 
Figure 4.8).  
4.5.10.3 Ethnicity impact on survival: 
The impact of ethnicity on survival in patients with oropharyngeal cancer was explored using 
the HES UK database. The ‘White’ ethnicity was used as the reference group. As expected, 
this was the predominant ethnicity with 23,597 cases (81.80%), mirroring the background UK 
caucasian population. There was no statistically significant impact of ethnicity detected on 
survival using Cox regression and Kaplan-Meier analyses. None of the p-values reached the 
0.05 threshold. This was a consistent finding for both males and females (Table 4.6 and 
Figure 4.9). The number of patients in the other ethnic groups were small and so there is a 










Figure 4.9: Kaplan-Meier survival of Oropharyngeal cancer by ethnicity. There was no 
significant impact of ethnicity demonstrated due to small numbers in each ethnic group.  
 
4.5.10.4 Region of residence and impact on survival: 
The impact of the region of residence of patients with OPC on their survival was investigated. 
The North East of England was designated the reference group. The North East had the lowest 
frequency of OPC over the study period with 1,825 cases (1,375 males and 450 females) 
representing 6.33% of the HES UK database (Table 4.6). The North East however had the 
highest incidence of OPC in the UK (Figure 4.6). The UK region previously shown to account 
for the highest proportion of oropharyngeal cancer in this HES UK database was however the 
North West with 4,778 cases (16.56%) (Table 4.4). The region of residence was ‘unknown’ in 




Meier survival analysis showed some disparity in survival across UK regions in comparison 
to the North East.  
The UK regions with better survival outcomes in comparison to the North East region with 
statistical significance demonstrated at p<0.001 for hazard ratios included Yorkshire and 
Humber [H.R: 0.83 (95% C.I: 0.75 – 0.92)], East Midlands [H.R: 0.75 (95% C.I: 0.67 – 
0.84)], East of England [H.R: 0.80 (95% C.I: 0.72 – 0.88)], South East [H.R: 0.77 (95% C.I: 
0.70 – 0.85)], and South West [H.R: 0.80 (95% C.I: 0.72 – 0.89)]. West Midlands [H.R: 0.88 
(95% C.I: 0.79 – 0.97)], also had a better survival outcome but with a p-value of 0.013. There 
was no statistical difference in survival in London [H.R: 0.92 (95% C.I: 0.84 – 1.02)] or in the 
North West [H.R: 0.92 (95% C.I: 0.84 – 1.01)].  
In males the best statistically significant survival outcomes (p<0.05) were recorded in the East 
Midlands, South East, East of England, South West, Yorkshire and Humber (Table 4.6). 
There was no difference in survival amongst males in North West (p=0.123), West Midlands 
(0.073), and London (p=0.136). 
Similarly in females, survival was better in the following UK regions (p<0.05) when 
compared to the North East: East Midlands, South West, South East, and East of England. 
There was no difference observed in survival in the North West (p=0.532), Yorkshire and 
Humber (p=0.06), West Midlands (p=0.073), and London (p=0.546) (Table 4.6).  
4.5.10.5 Survival outcomes and deprivation scores: 
This analysis crucially investigated the impact of deprivation on survival in patients with 
Oropharyngeal cancer. The degree of deprivation was categorised based on deprivation scores 




step-wise fashion with decreasing deprivation from score 1 to 5. Patients with oropharyngeal 
cancer identified on the HES database were uniquely stratified based on their deprivation 
scores on Kaplan-Meier and Cox-regression analyses. The survival outcome uniquely showed 
that survival worsens with increasing levels of deprivation (measured as deprivation scores). 
The least deprived patients with a score of 5 had the best survival outcome and were thus 
designated the reference group for univariate regression analyses.  
When compared to the least deprived group (score 5), patients with the most deprivation 
(score 1) had a hazard ratio of 1.64 (95% C.I: 1.53 – 1.75) (Table 4.6). This was strongly 
statistically significant with p<0.001 and indicates that patients with the highest deprivation 
scores were 64 times increased hazard for dying when compared to those patients with the 
least deprivation scores; with 95% confidence that the real increase in this hazard lies between 
a range of 53 times to 75 times risk (Table 4.6). Similarly, patients with a deprivation score of 
2 had an increased hazard of death when compared with the least deprived group [H.R: 1.32 
(95% C.I: 1.23 – 1.42)] with a p<0.001. This trend continues in patients with a deprivation 
score of 3 albeit with a lesser hazard of dying at 16% compared with the 32% hazard in the 
group with a deprived score of 2. A deprivation score of 3 was associated with a H.R: 1.16 
(95% C.I: 1.08 – 1.25) at a significant p<0.001 (Table 4.6 and Figure 4.10). There was no 
statistically significant difference between patients who had a deprivation score of 4 when 
compared with the reference group that had a deprivation score of 5. Deprivation score 4 was 
associated with a hazard ratio of 1.05 (95% C.I: 0.97 – 1.13) at p=0.238. Males had higher 
hazard ratios compared to females with the same deprivation scores indicating gender 






Figure 4.10: Kaplan Meier analysis of oropharyngeal cancer by deprivation scores. 
Deprivation was shown to have a significant impact on survival from OPC in the UK HES.  
 
4.5.10.6 Impact of co-morbidity on survival: 
The simultaneous presence of other conditions or diseases alongside the oropharyngeal cancer 
patients were documented as having on the UK HES was considered ‘co-morbidity’. Co-
morbidity was shown to have a significant effect on the survival of patients with 
oropharyngeal cancer, with increasing co-morbidity scores associated with worsening survival 
(Figure 4.11). The co-morbidities in this survival analyses have been previously discussed 
under the descriptive results section above and include presence of metastatic cancer, 
pulmonary disease, diabetes, acute myocardial infarction, cerebrovascular accidents, 
peripheral vascular disease, renal disease, and peptic ulcers. The ‘Charlson’s co-morbidity 




assigned to specific co-morbidities. Further categorisation into co-morbidity index groups 
depending on the aggregate scores per patient was as follows: [<5], [5 – 10], [11 – 15], [16 – 
20], and [>20]. Unsurprisingly, patients with low levels of co-morbidity on the Charlson’s 
index with a score <5 had the best survival in this oropharyngeal cancer cohort and were 
therefore designated the reference group for univariate regression analyses.  
The group with co-morbidity index score [5 – 10], when compared with the low co-morbidity 
index group [<5] had an increased hazard of dying with H.R: 1.48 (95% C.I: 1.33 – 1.65) 
which was significant at p<0.001. In patients with co-morbidity index score between [10 – 
15], there was also an increased hazard of dying of 27% observed when compared with the 
low co-morbidity reference group [H.R: 1.27% (95% C.I: 1.20 – 1.34)]; p<0.002. This trend 
increased exponentially in those patients with a co-morbidity index score >15. The group of 
patients with a co-morbidity index [15 – 20], had a 64% increased hazard of dying with H.R: 





Figure 4.11: Kaplan Meier analysis of oropharyngeal cancer by co-morbidity index. 
Co-morbidity had a significant impact on survival from OPC with mortality more likely with 
increasing number of co-morbidities present.  
 
The greatest effect on survival was observed in the patient group with a Charlson’s co-
morbidity index [>20] as they had a 123% increase in their hazard for dying when compared 
to patients with a low co-morbidity index [H.R: 2.23 (95% C.I: 2.10 – 2.37); p<0.004. 
4.5.10.7 Behavioural risk factors impacting on survival: 
Smoking is a recognised risk factor for head and neck cancers. In this UK HES cohort of 
oropharyngeal cancer, smoking maintained an expected significant effect on patient survival 
with smokers having a worse survival outcome when compared to non-smokers (Figure 4.12). 
Smokers had a 57% increased hazard of death in comparison to non-smokers (H.R: 1.57 (95% 





Figure 4.12: Kaplan Meier analysis of oropharyngeal cancer by smoking. Smoking had a 
significant impact on survival with worse survival observed in smokers.  
 
The effect of smoking on worsening overall survival was maintained across gender divides 
with males [H.R: 1.62 (95% C.I: 1.54 – 1.70); p<0.001] and females [H.R: 1.45 (95% C.I: 





Figure 4.13: Kaplan Meier analyses by smoking and gender. Smoking worsened survival 
in both males and females.  
 
Alcohol is also a risk factor known to work synergistically with smoking in the aetiology of 
head and neck cancers. Patients with oropharyngeal cancer and a record of alcohol intake on 
the UK HES database had a worse survival when compared with those patients who did not 
drink alcohol (Figure 4.14). Alcohol intake was associated with a 64% increased hazard of 
death in patients who drank compared to non-drinkers [H.R: 1.64 (95% C.I: 1.57 – 1.72); 
p<0.001] (Table 4.6).  
The alcohol intake recorded on the HES database was however not quantified so a sub-
analysis was not possible based on increasing alcohol intake or stratifying into mild, moderate 
or heavy drinkers. It was not also possible to establish the type of alcohol patients ingested in 




Alcohol intake was further analysed based on gender and a clear demarcation does exist 
between alcohol drinkers and non-drinkers in both males and females (Figure 4.14 and 4.15). 
 
Figure 4.14: Kaplan Meier analyses by alcohol consumption. Alcohol consumption was 
associated with worse survival in the OPC cases on HES. The alcohol consumption levels 










Figure 4.15: Kaplan Meier analyses by alcohol and gender. Alcohol consumption was 
associated with worse survival in OPC cases on HES. However the quantities of alcohol 
consumed was not recorded.  
In male patients who also had a history of alcohol ingestion, there was a 64% increased 
hazard of dying in comparison to male non-drinkers [H.R:1.64 (95% C.I: 1.55 – 1.73); 
p<0.001]. Similarly, females who had alcohol intake recorded, had a 67% increased hazard of 
dying when compared to females without alcohol intake recorded on HES [H.R: 1.67 (95% 









4.5.10.8 Oropharyngeal cancer subsites and survival: 
The HES UK database was duly interrogated for the impact of anatomic subsite of 
oropharyngeal cancer on overall survival. Oropharyngeal cancer subsites principally include 
the palatine tonsils, lingual tonsils (or base of tongue), and other sites such as soft palate, 
uvula, and pharyngeal walls. This analysis broadly looked at comparative survival at those 
cancers primarily in the tonsils, base of tongue in relation to other oropharyngeal cancer 
subsites (as the reference group for regression). Generally, the risk was shown to be higher in 
tonsil cancers and base of tongue cancers (Table 4.6 and Figure 4.16).  
In comparison to other OPC subsites, tonsil cancers had an increased hazard of death with 
H.R: 1.13 (95% C.I: 1.02 – 1.25); p=0.019. There was however a significant dichotomy in this 
trend when the analysis was stratified by gender. Males with tonsil cancer had a 15% 
increased hazard of dying when compared to males with OPC from other anatomic sites with 
a hazard ratio of 1.15 (95% C.I: 1.02 – 1.30) and this was significant at p=0.019. In sharp 
contrast, females with tonsil cancer had a reduced hazard of dying when compared with 
females with OPC from other anatomic sites at a hazard ratio of 0.56 (95% C.I: 0.50 – 0.62) 
and strongly significant at p<0.001 (Table 4.6).  
Similarly, patients with base of tongue cancers had a poorer prognosis in overall survival 
when compared with the reference group of patients with cancers from other anatomic 
subsites in the oropharynx. Overall, those patients with tongue base cancers when compared 
to the reference group of other subsites, had a hazard ratio of 1.12 (95% C.I: 1.07 – 1.17); 
p<0.001. By gender however, there was a reversal of this trend in an identical fashion to the 




increase in the hazard of dying when compared with males with cancers of other 
oropharyngeal subsites [H.R: 1.09 (95% C.I: 1.04 – 1.15); p=0.001. In contrast, females with 
base of tongue cancers had a 14% reduction in their risk of dying when compared with 
females with cancers of other subsites [H.R: 0.86 (95% C.I: 0.78 – 0.95); p=0.003]. 
Therefore, although there was an impact of anatomic subsites on the overall survival from 
oropharyngeal cancer, this effect was sharply modified by gender, with females with either 
tonsil or tongue base cancers having a better prognosis than females with cancers of other 
subsites and conversely males with tonsil or tongue base cancers doing worse.  
 
Figure 4.16: Kaplan Meier analyses by cancer subgroup. Tonsil cancer shown in blue, 
base of tongue cancer in red and the other oropharyngeal subsites in green. There was no 






The characterisation of oropharyngeal cancer using the UK HES database is important in 
broadening our understanding of the demographic factors associated with cancer states, the 
predisposing risk factors and the various determinants of survival. This UK-wide dataset 
uniquely covers a good proportion of oropharyngeal cancer (approximately 29,000 cancer 
cases) recorded over the last decade. Oropharyngeal cancer still remains a relatively rare 
cancer in the overall league tables of cancer diagnoses in the UK after lung cancer, breast 
cancer, prostate cancer, with a prevalence of 2.3 per 100,000 in 2010 (NCIN 2010). There is 
however documented evidence of the rising incidence of OPC in the developed world with a 
recent meta-analysis showing significant increase in America and across Europe in the last 30 
years (Mehanna et al., 2010). Similarly, in the UK, the incidence of OPC doubled between 
1996 and 2006 from 1.3 to 2.3 per 100,000 with this trend continuing in the last decade 
(NCIN 2010; Schache et al., 2016). Human papillomavirus 16 in particular has been identified 
as responsible for the vast majority of HPV-associated head and neck cancers (specifically 
oropharyngeal cancer). Whilst tobacco smoking and alcohol consumption still work in tandem 
as recognised risk factors for cancer development in the aerodigestive tract, HPV is now 
known to be causal for a subset of oropharyngeal cancer (IARC 2006).  
4.6.1 OPC and increasing age: 
The mean age at diagnosis of oropharyngeal cancer on the UK HES dataset was 60years with 
the entire dataset following a normal distribution. It is clearly a cancer that predominantly 
affects people aged over 40 years as these individuals accounted for 28,166 cancer cases 
(97.6%) of the entire cohort. The age group with the highest proportion of OPC was 




diagnosis of oropharyngeal cancer in this age group has been previously recognised. Gillison 
et al. (2016) described a bi-modal peak for oral HPV infection with the first peak observed 
when individuals become sexually active in their teenage years to early twenties, and the 
second peak around 50 – 60 years of age. It is instructive that this second peak of oral HPV 
infection coincides with the peak age of diagnosis for oropharyngeal cancer. A number of 
hypothesis have been put forward to explain the association between the two peaks of oral 
HPV infection and ultimately how this relates to cancer development. It is important to note 
that the latent period between oral HPV infection and OPC development is about 25 years so 
this crucially has meant a lack of longitudinal studies that can make concrete conclusions on 
the natural history of oral HPV infection. Two pathways of explanation are possible: the two 
oral HPV infection peaks as described by Gillison et al. (2016) are connected and represent 
latent infection that then overwhelms the host equilibrium in later life or the two peaks are 
independent and the second peak of infection represents ‘new infection’ in middle aged 
people at a time when their immune system is waning. The theory of ‘new infection’ with 
HPV in later life is predicated on changes in the sexual history of individuals with new 
partners, divorce, mid-life crises etc.  
The literature available on HPV causation of cervical cancer is however unified on the 
observation that it is persistence of high-risk HPV infection that leads to irreversible cellular 
changes and then progression through carcinoma in-situ stages and invasive cervical cancer. 
Transferring this plausible argument to oropharyngeal carcinogenesis would suggest that 
persistent infection with high-risk HPV genotypes (particularly HPV-16) would be the 
precursor to HPV-associated oropharyngeal cancer. There is of course, also an on-going 
discourse around the tumour microenvironment and the role of the host immune system in 




replication with significant changes to the underlying transitional epithelium of the tonsillar 
crypts and invasive disease. The immune system is either overwhelmed by viral replication or 
the human papillomavirus reactivates after a latency period. The theory of reactivation is one 
that is recognised in other virally-mediated cancers especially Epstein-Barr virus (EBV) and 
nasopharyngeal cancers.  
4.6.2 OPC and male predisposition: 
The UK HES dataset shows a significant male predisposition for oropharyngeal cancer.  
Males accounted for 73.3% of this UK cohort of oropharyngeal cancer, with a male: female 
ratio of 2.7: 1. This male preponderance is a feature of head and neck cancers generally and is 
partly because males tended to have exposure to tobacco smoking and excessive alcohol 
consumption – both of which act synergistically in cancer causation. The recent reality though 
is that HPV affectation in OPC tends to be in patients who are younger than HPV negative 
OPC and those affected often do not engage in smoking or alcohol ingestion. HPV is sexually 
transmitted with oral sex identified as an independent risk factor for HPV OPC alongside 
multiple lifetime sexual partners (D'Souza et al., 2009). Males are more likely to engage in 
‘high-risk’ sexual practices that involve oro-genital contact and / or have multiple lifetime 
sexual partners. This could explain the disparity in gender predisposition for HPV OPC. Some 
authorities have explored the possibility that hormonal factors could be protective in females 
but no substantial conclusions have been published.  
In the UK HES data, this male predisposition was maintained across all age groups analysed, 





4.6.3 OPC and ethnicity: 
The UK HES dataset was unsurprisingly predominantly white caucassian (81.8%). There was 
no data on ethnicity in 15.08% of the dataset leaving all other ethnicity groups accounting for 
only <1% of the OPC cohort. Evidently, there was insufficient data to rigorously interrogate 
any differences that may exist by ethnicity or to calculate incidence but of note was the fact 
that the male predisposition in OPC persisted in the various ethnic groups included. Males 
accounted for the following higher proportions in the ethnic groups studied: Black or Black 
British (160/240 – 66.7%), Indian (118/170 – 69.4%), other ethnic group (128/179 – 71.5%), 
Mixed (60/91 – 65.9%), Pakistani (51/73 – 69.9%), other Asian background (46/60 – 76.7%), 
and Chinese (11/20 – 55.0%). The only ethnic group with equivocal OPC male proportions 
was Bangladeshi (33/67 – 49.3%).  
Current world literature does indicate oropharyngeal cancer is prevalent across not just the 
developed world but also across the Asian continent. Crucially however, the HPV epidemic 
seems to have been more pronounced in the developed world. It is unclear how much HPV 
contributes as an aetiologic agent for OPC in Asia or Africa. The underlying risk factors in 
individuals from the Indian Sub-continent include the chewing of betel quid or areca nut 
alongside tobacco smoking. This has been put forward as a possible explanation for OPC 
prevalence in individuals who are resident in the UK but of Asian origins (NCIN 2010). 
These risk factors predispose to both oropharyngeal and oral cavity cancers. There is 
published evidence though on the risk of excessive alcohol consumption and cancer 
development in people from the Asian continent. There is a genetic susceptibility to glucose 
6-dehydrogenase deficiency which results in an accumulation of toxic metabolites of ingested 
ethanol. Small quantities of alcohol can therefore cause significant risk for cancer when there 




Americans are at an increased risk of developing oropharyngeal cancer when compared to the 
Caucasian population. This is in part due to higher socioeconomic deprivation in Black 
American communities and behaviours that put them at increased risk. It is important to think 
about access to health care and the prevalent practices in the diverse ethnic groups in the UK 
as some communities may in fact be at higher risk for cancer development. It was not possible 
to calculate the incidence of OPC by ethnicity as the population data by ethnicity and region 
was not available.  
4.6.4 OPC and regional variation: 
Regional OPC proportions:  
The UK HES dataset on OPC showed regional variation in the oropharyngeal cancer 
proportions documented in each UK region. OPC frequencies had a range of 6.35% - 16.56% 
over the timeframe recorded in the UK HES. The UK regions with the highest proportions of 
OPC (in descending order) were North West, South East and London. In contrast, the North 
East had the lowest proportion of OPC diagnoses. This finding is corroborated by the 
National Cancer Intelligence Network (NCIN 2010) report on head and neck cancers in 
England that indicated the highest prevalence of Oropharyngeal cancer was in the Cheshire 
Cancer Networks in North West England. Previous epidemiologic studies have confirmed an 
association between socioeconomic deprivation and high cancer prevalence rates. High levels 
of socioeconomic deprivation in parts of North West England may explain the high 
proportions of oropharyngeal cancer from the region. This unfortunately occurs 
simultaneously with exposure to tobacco smoking and alcohol consumption as poor 
communities are susceptible to these risk factors on the backdrop of malnutrition. The South 




regions are some of the most ethnically diverse regions of the United Kingdom with various 
communities having their own genetic profiles of cancer susceptibility as well as risk 
behaviours. For example, patients with origins in the Indian sub-continent have higher risks of 
oral cavity and oropharyngeal cancer due to betel quid chewing or ingestion of areca nut – 
risk factors for oropharyngeal carcinogenesis. 
Regional OPC Incidence:  
The incidence rates for oropharyngeal cancer in England, calculated from the HES database 
and population estimates from the Office of National Statistics clearly show an increasing 
incidence trend in England. The rising incidence of oropharyngeal cancer is also mainly 
driven by the higher rising incidence rates among males. This disparity in OPC incidence has 
been well-reported in the literature (Gillison et al., 2000; D,Souza et al. 2007). In general 
terms, head and neck cancers occur more frequently in men but it is currently unclear why 
oropharyngeal cancer in particular, with the HPV association in mind, has a predisposition for 
male affectation. Some authorities have suggested the observed differences could be due to 
high risk sexual practices that predispose males more to acquisition of oral high-risk HPV but 
hormonal and dietary factors need to be investigated further. The data from this study also 
shows that the OPC incidence in England has been increasing across all regions studied. The 
North East and North West of England however did consistently show the highest incidence 
rates year-on-year. The underlying reasons why this UK region is particularly at-risk for OPC 
is beyond the reach of the databases utilised in this study. The data however is corroborated 
by published studies from the National Cancer Intelligence Network (NCIN 2010) that show 
the highest rates of oropharyngeal cancer in the North of England and Cheshire cancer 
networks. A lower socio-economic balance with exposure to the risk factors of tobacco 




The age demographic is also important as shown in this data with London having 
comparatively lower incidence rates partly due to the higher proportions of young individuals 
in the nation’s capital.  
4.6.5 OPC and co-morbidity: 
The risk of developing oropharyngeal cancer increases with increasing co-morbidity scores 
with attendant worse outcomes. The Charlston’ Co-morbidity scoring system was useful in 
categorization this OPC cohort. Incredibly, 67.22% of this UK HES patient cohort had a co-
morbidity score ≥ 5 and included a range of medical conditions. 1 in 5 patients also had 
pulmonary disease and just over half the entire cohort had metastatic cancer – two factors 
which become significant in terms of overall survival and response to treatment long-term.  
4.6.6 OPC and behavioural risk factors: 
In this UK HES cohort of oropharyngeal cancer, the majority were diagnosed in the palatine 
tonsils (41.34%) while tongue base tumours accounted for 34.4%. Both the palatine tonsils 
and the lingual tonsils (tongue base) are lymphoid tissue that are part of the Waldeyer’s ring 
of lymphoid tissue in the oropharynx which perform a role in host immunity from birth but 
this role regresses after childhood.  
A history of ever smoking was recorded in the UK HES in 36.19% of this OPC cohort while a 
history of alcohol consumption was found in 20.25%. These figures are surprisingly lower 
than expected with several published series of head and neck cancers indicating smoking and 
alcohol as main risk factors for OPC development. The available data on HPV status on HES 
was equally inconclusive largely in part because HPV testing has only recently been 




Ang et al. (2010) published seminal work that stratified oropharyngeal cancer into 3 groups 
based on exposure to the risk factors of smoking and positivity to HPV. 260 cases of 
oropharyngeal cancer were studied, of which 187 were p16 positive. Based on their smoking 
history (greater or lesser than 10 pack years), TNM stage, and p16 test result, these patients 
with OPC were divided into low-risk, intermediate risk and high risk groups. Remarkably, 3 
year overall survival in the low-risk, intermediate risk and high-risk groups were 94%, 67%, 
and 42% respectively (Ang et al., 2010). 
4.6.7 OPC and determinants of overall survival: 
Kaplan Meier and Cox regression analyses of this UK HES dataset showed overall survival 
was worse with increasing age, worsening deprivation, smoking, alcohol consumption, and 
increasing co-morbidity scores. There was no demonstrable difference in overall survival by 
gender or ethnicity.  
4.6.8 Study strengths: 
This study using the UK HES database captures the burden of oropharyngeal cancer that 
require diagnosis and treatment in hospital. It has provided useful insights into the 
demographic variables that are associated with OPC including age at diagnosis, gender 
predisposition, and the impact of deprivation and multiple co-morbidities. Crucially, this 
study highlights significant determinants of overall survival in patients with oropharyngeal 
cancer. Survival worsens with increasing age of the patient, their socioeconomic status and 
worsening deprivation, a history of smoking and alcohol consumption and the presence of 





4.6.9 Study limitations: 
The main limitation of the UK HES database lies in the inherent challenges of obtaining 
adequate cancer records from each hospital with the required data including demographic 
variables, risk factors, and survival (disease-free and recurrence-free). For this investigation 
into oropharyngeal cancer nationwide, there was inadequate data available as regards risk 
factors such as smoking, alcohol consumption levels and HPV status. Smoking and alcohol 
consumption could not be stratified by the quantities of exposure that could have provided 
deeper insight into cancer association e.g. ex-smoker, on-going smoking, smoking greater or 
lower than 10 pack years, type of tobacco exposure, etc. Alcohol consumption could not also 
be subdivided into mild, moderate or heavy drinking or even into the type of alcohol ingested 
(spirits, beers, wines). A simplistic association with ever having had exposure to either 
smoking or alcohol consumption is flawed on these grounds and requires further analyses 
along the lines of quantification of exposure levels.  
The UK HES database did not convincingly provide the required data on HPV status in this 
cohort of oropharyngeal cancer. HPV as an aetiology of a subset of oropharyngeal cancer has 
only recently been recognised with HPV testing incorporated into routine diagnostic work-up 
of oropharyngeal cancer in many NHS Trusts. The responsible professional umbrella 
associations for Otolaryngology, Head and Neck Surgery as well as Maxillofacial Surgery in 
the UK e.g. ENT UK, BAHNO (British Association of Head and Neck Oncologists) and 
BAOMS (British Association of Oral and Maxillofacial Surgeons), have now adopted the 
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5.1 Background and hypothesis: 
We know from cervical cancer research that when the HPV E2 gene is disrupted in a mixed 
(intact and episomal) infection, the lower concentrations of E2 protein produced will 
preferentially bind to the high-affinity, promoter activating E2BS1 with over-expression of 
viral oncogenes E6 and E7 (Chaiwongkot et al., 2013). This partly explains tumorigenesis in 
oropharyngeal cancer however, in contrast to cervical cancers, HPV positive oropharyngeal 
cancer appear to be more episomally driven tumours with an intact E2 gene in a significantly 
larger proportion (Reuschebach et al., 2015; Barbieri et al., 2014). Therefore, it is plausible 
that other mechanisms are in play that mediate carcinogenesis aside from the viral physical 
status. Methylation is one such mechanism that merits investigation – in particular because 
increasing methylation has been shown to be associated with increasing grade of cervical 
cancer severity (Chaiwongkot et al., 2013). It remains largely unexplored in HPV associated 
oropharyngeal cancer with only a few studies currently available on the subject.  
Given the limited literature available on the impact of the HPV physical status and the 
methylation profiles at the E2 binding sites of the HPV 16 URR, this research focused on 
investigating the hypothesis: 
‘‘Carcinogenesis in those oropharyngeal cancer with an intact E2 gene is mediated by 
differential methylation at the E2 binding sites in the HPV 16 upstream regulatory region’’.  
As described in the Introduction (sections 1.15 and 1.17) in Chapter 1, E2 binding to the HPV 
16 upstream regulatory region (URR) occurs at four locations. E2BS1 is the high-affinity 
binding site at CpG positions 7453 and 7459 which stimulates the p97 promoter. In contrast, 
the low-affinity binding sites E2BS3 (CpG 37, 43) and E2BS4 (CpG 52, 58) are inhibitory to 




genome but has not been investigated in this thesis as it has not been shown to be significantly 
involved in regulation of transcription (Thierry 2009; Reuschenbach et al., 2015). CpG 
methylation has been shown however to directly inhibit binding of the human papillomavirus 
type 16 E2 protein to specific DNA sequences (Thain et al., 1996). The molecular differences 
in E2 binding sites seen in sequence variations could explain the differences in affinity with 
E2BS1 showing high-affinity and promoter stimulation while E2BS3 and E2BS4 are 
inhibitory.  
5.2 Study aims:  
To investigate the correlation of clinical outcomes (cancer overall survival, recurrence and 
behavioural risk factors) with HPV 16 viral physical status and aberrant methylation at E2 
binding sites in a cohort of HPV positive oropharyngeal cancers.  
5.3 Study objectives: 
1. To establish the integrity of the HPV 16 regulatory E2 gene (mixed or disrupted) in 
HPV positive oropharyngeal cancers using type-specific PCR with overlapping 
primers to the HPV 16 E2 open reading frame and URR in a number of samples.  
2. To determine the methylation profiles at E2 binding sites (E2BS1, E2BS3 and E2BS4) 
in the HPV 16 upstream regulatory region, using pyrosequencing of bisulfite-modified 
DNA from HPV positive oropharyngeal cancers.  
3. To confirm the proportion of the HPV oropharyngeal cancer samples that are 
transcriptionally active with expression of E2, E6 and E7 mRNA using reverse-




4. To correlate the HPV 16 E2 physical status (mixed or disrupted), the methylation 
profiles in each E2 binding site, and the RNA expression data with epidemiologic and 
clinical outcomes such as demographic variables, risk factors’ data, oropharyngeal 




















5.4.1 Patient samples:  
The original samples were obtained from FFPE (Formalin-Fixed Paraffin Embedded) biopsies 
taken from patients with oropharyngeal cancer entered into a multicentre UK study 
investigating the utility of the positron emission computerised tomography scan in monitoring 
cancer recurrence (PET-NECK) (Mehanna et al., 2016). HPV status was determined using 
adherence to rigorous protocols in a centralised laboratory at the Newcastle University 
Hospital by two independent pathologists using p16 immunohistochemistry (IHC) (CINtec 
Histology kit, Roche) and high risk HPV DNA in-situ hybridisation. Samples were positive 
on p16 IHC if there were >70% of the malignant cells with strong diffuse nuclear and 
cytoplasmic staining. Samples were classified as HPV positive if they were positive on both 
p16 immunohistochemistry and in-situ hybridisation. These initial HPV tests (p16 
immunohistochemistry and high risk in-situ hybridisation for HPV DNA) were not performed 
by myself as I was given FFPE samples for which the HPV status was already determined.  
40 FFPE blocks with known status as HPV positive oropharyngeal cancer were provided to 
me from Prof Mehanna’s laboratory for this genetic / epigenetic study. The workflow of 
laboratory techniques utilised in downstream applications is shown in Figure 5.1.  
5.4.2 Setting: 
The PET-NECK trial was a phase III, randomised controlled multicentre UK study 
incorporating 43 NHS hospitals from across the West Midlands, East Midlands, London, 




inferiority of PET-CT surveillance when compared with neck dissection in patients with 
advanced head and neck cancer (Mehanna et al., 2016).  
5.4.3 Ethical approval: 
Ethical approval for the PET-NECK study and further genomic studies using patient samples 
with valid consent was granted by the Oxfordshire Research Ethics Committee A (ISRCTN: 
13735240). 
 





5.4.4 Data analysis:  
All data were entered into an Excel spreadsheet which included HPV 16 E2 status, 
methylation proportion at each E2 binding site, RNA expression data (E2, E6 and E7) and 
clinical outcomes. The viral physical status, methylation profiles and RNA expression were 
correlated with both demographic and cancer clinical outcomes (recurrence and survival) 
using STATA SE. Statistical analyses included Chi-squared test (X2) for dichotomous 
variables such as E2 status with gender, smoking history, cancer recurrence. Student T-test 
was used to compare means of continuous variables such as age in the cohorts of E2 intact or 
disrupted. Time-to-event analyses using Kaplan-Meier curves were used for determining 
impact of E2 status and E2BS methylation on cancer recurrence or overall survival. 
Spearman’s correlation coefficient was used to assess the degree of correlation in the 
methylation frequencies observed in the CpG site pairs in each E2 binding site. Mann-
Whitney U test was used to check for any statistically significant differences between the 
mean methylation at each E2BS when comparing those cancer samples with disrupted E2 
gene with those that had an intact E2 gene. Statistical significance was set at a value of 
p<0.05.  






Figure 5.2: The flow chart of HPV16 genetics and epigenetics study in OPC 
5.5 Laboratory methods: 
5.5.1 FFPE sections using microtome: 
Each FFPE section was suspended on the microtome and any excess paraffin trimmed. A 
fresh blade was used between samples to minimise the risk of cross-contamination. 5 – 8 
scrolls per FFPE block were taken and each scroll measured 5–10 μm in thickness. The first 2 
scrolls were discarded to avoid contamination especially if the blocks had been exposed to air. 







5.5.2 DNA extraction from FFPE HPV OPC (Qiagen protocol adapted):  
DNA extraction was performed using the Qiagen protocol for FFPE. As preparation for DNA 
extraction, 1ml of xylene solution was added to each microtube containing oropharyngeal 
cancer scrolls. The lid was closed and the sample mixed by vortexing for 10seconds. Each 
sample was centrifuged at 20,000 x g (14,000 rpm) for 2 minutes at room temperature (15–
25°C). The solution was removed by pipetting and the pellet retained. 1ml of ethanol (96% - 
100%) was added to the pellet and mixed by vortexing. In this step, the ethanol was used to 
extract residual xylene from samples. Each sample was placed in the centrifuge and spun at 
20,000 x g (14,000 rpm) for 2 minutes at room temperature. The supernatant was removed by 
pipetting without removing any pellets. Residual ethanol was pipetted out using a fine tip. The 
samples were then incubated for 10minutes at room temperature or until all the residual 
ethanol had evaporated.  
180 μl of Buffer ATL was used to resuspend the pellet obtained. 20 μl proteinase K was 
added and the sample vortexed and incubated at 56°C for 1 h (or until the sample has been 
completely lysed). The samples were centrifuged briefly to remove any residual drops from 
the lid and allowed to cool to room temperature. To obtain RNA-free genomic DNA, 2μl 
RNase A (100 mg/ml) was added and incubated for 2 minutes at room temperature. 200 μl 
Buffer AL was next added to the samples, and mixed thoroughly by vortexing. Subsequently 
200 μl of ethanol (96–100%) was added, and vortexed to obtain a homogenous solution. A 
white precipitate may form on addition of Buffer AL and ethanol but it does not interfere with 
the extraction process.  
After briefly centrifuging to remove liquid droplets from the lid, the entire lysate was 




without wetting the rim. The samples were centrifuged at 6000 x g (8000 rpm) for 1 min. The 
QIAamp MinElute column was placed in a clean 2 ml collection tube while the flow-through 
was discarded. Repeat centrifugation can be performed at a higher speed if there is incomplete 
passage of the lysate through the membrane.  
In sequence, each QIAamp MinElute column was opened and 500 μl Buffer AW1 was added 
without wetting the rim. The samples were centrifuged at 6000 x g (8000 rpm) for 1 min. The 
column was placed in a clean 2 ml collection tube and the flow-through discarded. This 
process was then repeated using 500 μl Buffer AW2. Care must be taken to avoid contact 
between the QIAamp MinElute column and the flow-through (which contains ethanol). This 
can occur if the centrifuge rotors vibrate when decelerating or when the collection tube is 
being retrieved from the centrifuge.  
After adding Buffer AW2, the samples were centrifuged at full speed (20,000 x g; 14,000 
rpm) for 3 min to dry the membrane completely. This ensured residual ethanol did not 
interfere with downstream applications. The QIAamp MinElute column was then placed in a 
fresh 1.5ml microcentrifuge tube and the collection tube with the flow-through was discarded. 
20–100 μl Buffer ATE (at room temperature) was then carefully applied to the centre of the 
membrane to facilitate complete elution of bound DNA. The volume of eluate was determined 
by the downstream application but keeping in mind the final volume of eluate retrieved is 
approximately 5 μl less than that applied. The column lid was closed, incubated at room 
temperature for 1 minute and then centrifuged at full speed (20,000 x g; 14,000 rpm) for 1 
min. Incubating with Buffer ATE for 5 min at room temperature before centrifugation 





5.5.3 RNA extraction from FFPE HPV OPC: (The PureLink™ FFPE Total RNA Isolation 
protocol adapted): 
The paraffin from thin sections of a FFPE specimen was melted using heat in the presence of 
a specially designed Melting Buffer. The tissue was separated from the melted paraffin by 
centrifugation and digested with Proteinase K. The tissue lysate was further processed by 
selective binding of RNA to a silica-based membrane in the spin cartridge (PureLink™). 
Impurities were removed by thorough washing with Wash Buffer. The total RNA was eluted 
in RNase-Free Water. The expected total RNA yield exceeds 1μg from 3-8 FFPE sections of 
10 μm each. The RNA yield is dependent on tissue type and quality of the specimen. 
De-paraffinization and lysis:  
3 – 8 scrolls of 10 μm FFPE samples were placed in a sterile RNAase-free 1.5ml 
microcentrifuge tube. 300μl of the melting buffer was added to the tube and centrifuged at 
maximum speed for 10 – 20 seconds. The samples were then incubated at 72°C for 10 
minutes with intermittent gentle mixing and tapping every 2 – 3 minutes to ensure paraffin 
melting and that the scrolls remained under the melting buffer. 20 μl Proteinase K is then 
added and incubated at 60°C for 10-60 minutes with occasional mixing (Figure 5.3). On 
occasion, it was necessary to extend the incubation time by an additional 30-60 minutes and 
up to 3 hours, until lysis is complete. After this step, the samples were centrifuged at 20,000 x 
g (14,000 rpm) for 1 minute with a thin paraffin layer forming at the top, separate from the 
lysate below. The lysate was aspirated by pushing through this paraffin layer using a clean 





Purification procedure (binding step):  
400μl Binding Buffer (L3) and 800μl 100% ethanol was added to each sample (after de-
paraffinization and lysis) and mixed well. 700μl from this sample mix was then transferred to 
a spin cartridge in a collection tube. This was centrifuged at 800 x g for 1 minute, the flow-
through was discarded and the cartridge re-inserted into the collection tube. The remaining 
unspun sample (approximately 700μl) was then transferred to the spin cartridge in the 
collection tube, the centrifugation process repeated and the flow-through discarded (Figure 
5.3).  
Purification procedure (washing step): 
20 ml Wash Buffer (W5) was added to 80ml of 100% ethanol and stored. 500μl Wash Buffer 
(W5) (with ethanol) is added to the cartridge. The cartridge was centrifuged at maximum 
speed for 1 minute and the flow through discarded. This step was repeated twice for a total of 
3 washes. Each time the flow-through was discarded and the cartridge reinserted into the wash 
tube. Finally the cartridge was centrifuged at maximum speed for 1 minute to ensure all 
residual wash buffer with ethanol was removed. The wash tube was then discarded.  
Elution step: 
An aliquot of RNase-free water was pre-heated to 65°C. The spin cartridge was placed in a 
clean 1.7ml recovery tube and 50μl of the pre-heated RNase-Free water added to the centre of 
the cartridge. The cartridge was incubated for 1 minute and centrifuged at maximum speed for 
1 minute. The recovery tube ultimately contained the total RNA. A second elution with 50μl 
of RNase-free water (if desired) can be performed as it may increase total RNA yield by 20 – 




placed on ice prior to commencing downstream applications or stored at –80°C until needed 
(Figure 5.3).  
DNase I digestion (protocol adapted from 5 – 8μl RNA sample): 
DNase I digestion can be performed either with an aliquot of each of the purified RNA 
samples or with the entire amount of the purified RNA samples. In this study, a sterile tube 
was placed on ice and the following components added:  
 Purified RNA sample:   28uL 
 DNase I, Amplification Grade (1 U/ μl): 3.5uL 
 10X DNase I Buffer:    3.5uL 
 Total volume:     35uL 
The components were mixed by vortexing, spun briefly and incubated at room temperature 
for 5 – 15 minutes. Samples were centrifuged briefly and add 3.5uL of 25mM EDTA added to 
each tube on ice. Following further mixing by gently pipetting up and down, the samples were 
centrifuged and incubated at 65°C for 10 minutes. On completion of incubation, a final 
centrifugation was performed and each sample tube placed on ice prior to reverse 










5.5.4 DNA quantification using Qubit fluorimeter: 
DNA concentrations were assessed using the Qubit DNA broad range assay kit (Life 
Technologies). For those samples with DNA concentrations below detectable levels using the 
broad range kit, the Qubit DNA High Sensitivity Assay kit (Life Technologies) was used 
instead according to the manufacturer’s instructions.  
5.5.5 RNA quantification using Qubit fluorimeter: 
Similarly, RNA concentrations were assessed using the Qubit RNA broad range assay kit 
(Life Technologies). This broad range kit was able to quantify RNA concentrations between 
20 – 1000ng/µL. For those samples with RNA concentrations below detectable levels using 
the broad range kit, the Qubit RNA High Sensitivity Assay kit (Life Technologies) was used 
instead according to the manufacturer’s instructions.  
5.5.6 Polymerase chain reaction of HPV 16 E2, E6, E7 genes and URR: 
DNA was analysed for viral E2 gene integrity using PCR and the results were repeated 
independently in duplicates. The assay utilised overlapping primers to the E2 gene with the 









Table 5.1: PCR primers for HPV 16 E2, E6, E7, and L1 genes, the URR regions as well 
as host GAPDH 
Target Nucleotide sequence Melting 
temp (Tm) 
HPV 16  




HPV 16  




HPV 16  




HPV 16  




HPV 16  
E2 Set 5 
5’- GGCATTGGACAGGACATAAT -3’ 
5’-CAAAAGCACACAAAGCAAAG -3’ 
54oC 
   





































These 5 sets of overlapping primers span the entire length of the HPV 16 E2 gene and have 
previously been validated in a study on viral E2 gene integrity in cervical cancer specimens 
(Woodman et al., 2013). The melting temperature for these primers are shown in Table 5.1. 





Figure 5.4: Primers for analysing HPV 16 E2 gene integrity with overlapping 
nucleotides 
 
The HPV 16 E6, E7 and L1 genes were used as positive controls for viral DNA presence 
while GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) is the house-keeping gene used 
for data normalization. Any samples not expressing GAPDH were excluded from further 
analysis. The respective primer sequences and melting temperatures are shown in Table 5.1. 
DNA from two cell lines, Archie and SiHA was used as controls. Archie was obtained from 
HPV positive keratinocytes and contains intact E2 gene while SiHA contained disruption of 
the E2 gene detectable by the E2 primer sets 2 and 3. The PCR process is described below for 
E2, E6, E7 on all 40 samples using the respective primers shown in Table 5.1. URR PCR was 
only performed on 10 samples where it was not possible to establish the methylation profiles 
at the E2 binding sites following pyrosequencing.  
Each reaction contained 20 – 25ng of DNA in 5 µL from each patient sample. However, it 




than 5 ng/µl (Table 5.5). In these cases, 5µL of undiluted DNA was added to the reaction. 
Each reaction contained 10µL of PCR MasterMix (Promega), 5µL of DNA sample (or 
nuclease-free water for negative control), 3.5 µL of nuclease-free water and 1.5µL of each 
forward and reverse primer separately. The 96 well plate containing the primers and nuclease-
free water was prepared in a separate laboratory in a designated hood that had been sterilised 
prior by meticulous cleaning with alcohol and UV light for 20 minutes. This was to minimise 
the risk of contamination from DNA fragments. The plate was then transferred to the main 
laboratory bench where the DNA samples were added,  the plates were sealed and labelled 
appropriately. The PCR with the overlapping E2 primers, E6, E7, L1 primers were run as 
follows: 95°C for 10 minutes, followed by 50 cycles of  95°C for 20 seconds, 54°C for 
40seconds, and 72°C for 50 seconds. On completion of PCR, the PCR products were analysed 
using agarose gel electrophoresis for the presence of bands indicative of the presence of the 
amplified HPV segment.  
To investigate the integrity of the HPV 16 URR in those samples that failed amplification 
prior to pyrosequencing, PCR reactions were set up in duplicate using 10µL of PCR 
mastermix, 3.5µL of water, 1.5µL of primers and 5µL of DNA. PCR was performed running 
denaturation step at 95°C for 15 minutes, followed by 50 cycles at 95°C for 20 seconds, 54°C 
for 40 seconds, 72°C for 50 seconds. Final step of 72°C for 1 minute and 4°C holding 
temperature. The PCR reactions included a positive control (CaSki), a negative control 
(DNase – free sterile water), a house keeping gene (GAPDH) and a viral positive control 
(HPV 16 E6 gene). The reactions were separated for both the Long Control Region (LCR) 





5.5.7 1.5% agarose gel electrophoresis: 
Agarose (2.25g) was weighed and mixed with 150mL of 1X TBE (Tris-Borate-EDTA). The 
1X TBE was made by diluting 100mL of 10X TBE with 900mL of sterile water. The agarose 
and TBE mixture was then heated in a microwave for 1 minute and intermittently checked for 
complete dissolution of the agarose. The mixture was allowed to cool and then 5µL of 
ethidium bromide was carefully added to the 150mL of agarose gel. The required number of 
combs were inserted and the gel was allowed to set over a 30 – 40 minutes. The gel was 
subsequently placed in an electrophoresis tank and the DNA ladder and each PCR product 
was sequentially added using a micropipette. The DNA ladder (100 bp) was prepared by 
diluting 1µg of DNA ladder (concentration 1µg/µL) with 9µL of nuclease-free water. 2.5µL 
of orange / blue loading dye (5x) was then added to the ladder mix. 5µL of the 5x loading dye 
was added to each 20µL PCR product. The electrophoresis tank was filled with 1X TBE and 
the electrophoresis ran at 150 volts for 25 minutes (ensuring a cephalo-caudal direction of 
electricity i.e. black electrode at top and red at bottom). On completion of the electrophoresis 
run, the gel was gently retrieved from the tank and immediately transferred to the UV light 
box for assessment of the presence / absence of bands in each well. The presence of a band in 
each OPC sample indicates the presence of episomal HPV (although does not exclude the 
presence of integrated forms of the virus elsewhere in the HPV genome) while the absence of 
a band indicates disruption of the gene (A representative sample is shown in Figure 5.5). E2 
gene disruption was recorded if there was an absence of a band in any of the wells containing 
the 5 overlapping primers to the HPV 16 E2 gene. All PCR reactions to assess HPV 16 E2 






Figure 5.5: HPV 16 E2 gene integrity assessed by PCR using overlapping primers to E2 
Figure shows a representative PCR with overlapping primers to the E2 gene as well as 
positive controls E6, E7 and L1 genes. The absence of bands in any of the E2 primer sets 
indicates a disrupted E2 gene and this is shown by primer sets 1 and 4 in patient samples 44, 
321, 69 adjacent to a patient sample with an intact E2 gene (414). Control cell line Archie 
has intact E2 while SiHa has disrupted E2 in primer set 2.  
 
5.5.8 Bisulfite-modification of DNA samples: 
To evaluate the methylation profiles at the E2 binding sites in the HPV 16 URR, the extracted 
DNA from patients’ samples had to undergo bisulfite modification prior to pyrosequencing 
amplification. In a result of bisulfite modification, the methylated cytosines remain intact 
while the unmethylated cytosines are converted into uracil. Subsequently, the uracil is then 




In this study, bisulfite modification of DNA was performed using the EZ DNA Methylation-
GoldTM kit (Zymo research) and manufacturer’s protocol. The initial step was to prepare the 
Cytosine – Thymine (CT) conversion reagent by mixing 900 µL of nuclease-free water, 300 
µL of M-Dilution buffer, 50 µL of Dissolving buffer and one tube of CT conversion reagent. 
This mixture was vortexed for 10 minutes. 130 µL of the prepared CT conversion mixture 
was then added to 20 µL of the extracted DNA sample and mixed. This was placed in a 
Thermal cycler and incubated at 98°C for 10 minutes, 64°C for 2.5 hours and then  4°C hold. 
Each sample was added to 600 µL of M-Binding buffer in a Zymo-SpinTM IC column and 
mixed. Each sample was centrifuged at full speed (>10,000 x g) for 30 seconds and the flow-
through discarded. 100 µL of the M-Wash Buffer was added to the column and spun for 30 
seconds. Subsequently, 200 µL of M-Desulphonation buffer was added to the column and left 
for 15 – 20 minutes incubation on the benchside in room temperature. After incubation, 
samples were spun at full speed for 30 seconds. This step was then followed by addition of 
200 µL of M-Wash Buffer to the column and the solution was spun for 30 seconds. This 
particular wash step was repeated, the column changed to a new, dry one and the sample spun 
at full speed for 1 minute to dry. 10 µL of M-Elution Buffer was then added to the column 
matrix without making contact with the matrix in the column. The entire column was placed 
in a 1.5mL eppendorf tube and spun for 1 minute to elute the now bisulfite-modified DNA 
sample. Depending on the downstream applications, the bisulfite-modifided DNA can then be 
diluted and in this study, it was diluted to make up 20 µL of final sample needed for 






5.5.9 PCR amplification of bisulfite-modified DNA: 
Following bisulfite-modification of the DNA extracted from oropharyngeal cancer, PCR 
amplification and agarose gel electrophoresis were performed prior to any pyrosequencing. 
The primers used cover the location of the CpG sites in the E2 binding sites at the HPV 16 
URR and are shown in Table 5.2.  
The HPV 16 LCR primer covers E2BS1 (CpG positions 7452 and 7458) while the HPV 16 
promoter primer covers E2BS3 (CpG positions 37, 43) and E2BS4 (CpG positions 52, 58). 
The 96 well plates were prepared in the dedicated hood in a separate laboratory to avoid 
contamination with PCR fragments. Each well contained 25 µL of PCR Mastermix 
(Promega), 18 µL of nuclease-free water, and 2 µL of each reverse and forward primers. 5 µL 
of nuclease-free water was added into the wells for negative controls. The plate was taken to 
the main laboratory where 5 µL of the bisulfite-modified DNA from each patient cancer 
sample was added. 5 µL of each control cell line DNA (SiHa and CaSki) were also added to 
their separate wells, the plate sealed and placed in the thermal cycler. PCR amplification was 
performed at the following settings: 95°C for 10 minutes, followed by 60 cycles of 95°C for 
30 seconds, 50°C for 45 seconds, 72°C for 1 minute. After the 60 cycles were completed, the 
reaction ran at 72°C for 10 minutes and then 4°C holding temperature.  
5.5.10 Agarose gel electrophoresis of PCR products before pyrosequencing: 
On completion of PCR amplification, the 96 well plate was placed on a separate laboratory 
bench reserved for PCR products in preparation for 1.5% agarose gel electrophoresis. The 
agarose gel and ladder were prepared as previously described in section 5.13. 3µL of loading 




cases where PCR bands were either faint or absent following electrophoresis, those samples 
were not expected to amplify satisfactorily on subsequent pyrosequencing.  
5.5.11 Pyrosequencing of bisulfite-modified DNA samples: 
The pyrosequencing was performed using the Pyro Q-CpGTM system (Qiagen, Uppsala, 
Sweden) and PyroMark reagents (Qiagen). A single-stranded template of HPV DNA 
specifically the HPV 16 upstream regulatory region containing the E2 binding sites, is 
hybridized to sequencing primers for the LCR and promoter regions separately. The 
pyrosequencing primers were optimised in duplicates using VU147 as the reference sample 
and normalized to β-actin, with clear water controls prior to any analysis of patient samples. 
Unmethylated cytosine is converted to uracil on bisulfite modification. Uracil is then 
converted on PCR amplification to thymine which is recognised during pyrosequencing. 
5.5.11.1 Pyrosequencing methodology: 
Pyrosequencing is based on ‘DNA sequencing by synthesis’. It was developed by Mostafa 
Ronaghi and Pal Nyren in Sweden in 1996 at the Royal Institute of Technology. During DNA 
synthesis, only one nucleotide at a time can be added to the complementary single-stranded 
DNA. Pyrophosphate is emitted on nucleotide incorporation and this is detectable as a light 
signal on a pyrogram. Solutions of each nucleotide are added one after another and each is 
cleared from the reaction by enzymes before the next nucleotide is added.  
The enzymes necessary for the reaction include DNA polymerase, ATP sulfurylase, luciferase 
and apyrase. The substrates required are adenosine 5’phosphosulfate (APS) and luciferin.  
DNA polymerase attaches the complementary nucleotide to the HPV DNA template of the 




released pyrophosphate to ATP. Luciferase requires ATP to convert luciferin to oxyluciferin. 
This process generates light that is captured on the PyroMark camera with the resulting 
analysis shown on a pyrogram. Any remaining nucleotides and ATP not used up in the 
preceeding reaction becomes degraded by the enzyme apyrase in preparation for the next 
reaction. The ratio of unmethylated cytosine (now thymine) to methylated cytosine (now 
cytosine) at each CpG site is recorded as the mean methylation at that CpG site (Figure 5.6 
shows an example of the entire process with E2BS1 as an example). A cytosine that is not 
immediately followed by guanine on the HPV DNA sequence for amplification acts as the 
control for the efficiency of bisulfite modification.  
5.5.11.2 Pre-pyrosequencing steps: 
Prior to pyrosequencing a number of preparatory steps were undertaken. Firstly, the 
PyroMark reagents (Qiagen) including Binding buffer, Annealing buffer and Streptavidin 
were all retrieved from the refrigerator and left in room temperature for 15 – 20 minutes. The 
primers required were retrieved which include the LCR primer (CpGs 7452, 7458), promoter 
primer (CpGs 37, 43), the sequencing primer for the LCR and the sequencing primer for the 
promoter end (Table 5.2). Also required was nuclease-free water, a 96 well pyrosequencing 
plate and the actual PCR plate containing the PCR products of the bisulfite-modified DNA. 
The PCR plate contained 40µL of PCR products in each well. The heat block was set to 80°C 
and allowed to reach this temperature. The pyrosequencing cartridges were cleaned by rinsing 
with water to ensure each needle channel was open and unblocked. This step is crucial as the 
entire experiment could fail if reagents are not dispensed due to cartridge blockage. Tap water 
is pressed through each channel with a finger without touching the needle ends. The 
pyrosequencing troughs were rinsed out with tap water as required (especially the 




38µL of nuclease-free water and 2µL of LCR and promoter primers (in separate wells) as well 
as 39 µL of nuclease-free water and 1µL of sequencing primers to both the LCR and promoter 
regions.  
5.5.11.3 Preparation of plates: 
A mastermix was produced containing 37 µL of Binding buffer and 3µL of Streptavidin beads 
for each sample. This makes up the 40µL of the mastermix pipetted into each well on the 96 
well PCR plate already containing 40µL of PCR products from bisulfite-modified DNA. This 
plate was left to stand in room temperature on a bench for 10 – 15 minutes. After this 
incubation period, the plate contents were mixed using a multi-channel pipette or put on a 
plate shaker for 5 minutes at 1,300rpm. The pyrosequencing 96 well plate was then prepared 
by pipetting 38.5µL of annealing buffer into each well. 1.5µL of sequencing primers (LCR 
and promoter) were then added separately to each well containing the annealing buffer.  





Amplification primers (5’ → 3’) Sequencing 






FW: 5’- ATTGTGTTGTGGTTATTTATTGTA -3’ 
 RV: 5’-AAAAAACACATTTTATACCAAAAA -3’ 
Annealing temp – 57°C 












 FW: 5’-ATTTATGTATAAAATTAAGGGTGT -3’ 
RV: 5’- TCACTCCTATAAATCCTAAAACAT -3’ 
Annealing temp – 56°C 










This process starts with a series of sequential wash steps in various solutions using a 
hedgehog (a hand-held device with 96 metallic tubes sealed with a permeable seive and 
connected to a suction machine). There are individual troughs filled separately with 180mL of 
70% ethanol, 120mL of denaturation buffer (sodium hydroxide 8g), 180mL of Wash Buffer 
(1:10 dilution), 180mL of sterile water, and 180mL of sterile water in the parking station for 
the hedgehog.  
Once the plate and samples were ready, the vacuum was switched on and the hedgehog placed 
in the sterile water in the parking station. The samples were then carefully suctioned using the 
hedgehog ensuring that the residue of beads were attached to each end of the hedgehog. With 
the beads attached, the hedgehog was placed in the ethanol trough, allowed to suction for 5 
seconds, lifted out and this process repeated sequentially through the Denaturation Solution 
and Wash Buffer. The vacuum was then turned off after the beads have dried. This step is 
critical as omitting to turn the vacuum off will allow suctioning away of the pyrosequencing 
primers!. The whitish beads that formed on the ends of the hedgehog were placed into the 
pyrosequencing plate containing the annealing buffer and sequencing primers and gently 
dislodged into solution. The hedgehog was replaced into sterile water and the plate taken to 
the main laboratory and placed on the heat block. The plate was heated at 80°C on the heat 
block for 2 minutes to ensure complete denaturation of beads-bound DNA.  
The pyrosequencing reagents and nucleotides were then pipetted into each well on the 
pyrosequencing plate which was then transferred into the PyroMark Instrument. The volume 
information required for each run is indicated on the instrument for example in a typical run, 




cytosine 62 µL, guanine 67 µL, thymine 71 µL. The nucleotides were pipetted into the 
pyrosequencing cartridge and placed into the PyroMark Instrument. 
The 96 well pyrosequencing plate was labelled on the Instrument databoard appropriately for 
each sample indicating which sequences were to be analysed. Upon completion of the 
pyrosequencing reaction, the results were analysed by the Pyro Q-CpGTM software (Qiagen). 
It calculated the proportion of methylated to unmethylated cytosine (after bisulfite-
conversion) at each HPV 16 E2 binding site. Mean methylation at each E2BS was calculated 
from the individual readings for every separate sample. Pyrosequencing of OPC patient 
samples were performed in triplicates.  
Pyrosequencing was chosen to carry out this project as it was the methylation determination 
technique available in our institution and had been previously validated on a cohort of 
cervical and vulval cancer FFPE specimens with optimised assays and algorithms for bisulfite 






Figure 5.6: Pyrosequencing methodology. Bisulfite modification converts the cytosines in the E2 
binding sites of the HPV16 Upstream Regulatory Region into uracil which is then converted to 









5.5.12 cDNA synthesis: 
RNA samples were obtained from FFPE of 40 oropharyngeal cancers as described above 
(section 5.9). RNA concentrations were measured using a Qubit fluorimeter in ng/µL and 
dilutions were made with nuclease-free water if necessary. 1µg of RNA was used for c DNA 
synthesis. The positive control used was RNA from VU147 HNSCC cell line which is HPV 
positive.  
Reverse transcription was performed using the ‘High-capacity cDNA reverse transcription 
kit’ by Applied Biosystems. Each 20µL reaction consisted of 1µg of each RNA sample 
diluted with nuclease-free water to a volume of 10µL, 2µL of 10x RT buffer, 2µL of 10x 
Random primers, 0.8 µL of 25x dNTPs, 1µL of reverse transcriptase and 4.2µL of nuclease-
free water.  cDNA reaction was carried out in 0.2µL tubes using a thermocycler and the 
following settings: 25°C for 10 minutes, followed by 37°C for 120 minutes and 85°C for 5 
minutes and held at 4°C. 
5.5.13 E6 and E7 mRNA expression in OPC samples using real time quantitative PCR 
(qPCR): 
Each cDNA sample was prepared for qPCR as follows: 2 µL of cDNA (1:3 dilution) was 
added to 2 µL of E6 or E7 probe (1:20 dilution), 3 µL of E6 or E7 primer, 3 µL of nuclease-
free water, and 10 µL of Luminaris low ROX mastermix (Thermoscientific UK). The reaction 
was normalised to β-actin and this control was similarly prepared as follows: 1 µL of cDNA 
(1:3 dilution), 1 µL of β-actin primers, 8 µL of nuclease-free water and 10 µL of Luminaris 






Table 5.3: qPCR primers and probes for E6 and E7 RNA expression 
Primers and probes Sequences (51 – 31) 
HPV 16 E6 (nt 99 – 178)  Forward primer: CTGCAATGTTTCAGGACCCA 
Reverse primer: TCATGTATAGTTGTTTGCAGCTCTGT 
Probe: FAM-AGGAGCGACCCGGAAAGTTACCACAGTT-
BHQ 
HPV 16 E7 (nt 739 – 816)  Forward primer: AAGTGTGACTCTACGCTTCGGTT 




qPCR was performed on the samples using the ‘7500 Real time PCR system’ by Applied 
Biosystems. The ‘Quantitative comparative’ set up was chosen for a reaction volume of 20 
µL. Taqman reagents and a standard run were indicated on the set up screen. The targets 
recorded were β-actin, E6, E7 with the quencher for each indicated as NFQ-MGB, None, and 
None respectively. The following were recorded: negative control (nuclease-free water), 
reference sample (VU147: cDNA obtained from a HPV positive cell line), endogenous 
control (β-actin), passive reference dye (ROX), reaction volume (20 µL).  
The qPCR conditions were: 50°C for 2 minutes in step 1, 95°C for 10 minutes in step 2, 
followed by 50 cycles of 95°C for 15 seconds in step 1 and then 55°C for 1 minute in step 2. 
The assay was first fully optimised using a control with known expression of E6 and E7 
(VU147). This HPV positive control cell line also expressed β-actin. Any patient samples that 




the reactions was monitored by melting curves. The E6 and E7 qPCR on patient samples were 
performed in triplicates and the results recorded as normalised to β-actin.  
5.5.14 E2 mRNA expression in OPC samples using real time quantitative PCR: 
Expression of E2 m-RNA and E2 isoforms (‘E2 880^2709’ and ‘E2 880^2582’) was 
performed with a similar qPCR set up as the E6 and E7 assays described above. Primers for 
all isoforms of E2 investigated were prepared and their respective nucleotide sequences 
shown in Table 5.4. In each tube, 2µL of each E2 primer was separately added to 2µL of 
cDNA (1: 10 dilution), 6µL of nuclease-free water and 10µL of SYBR green Mastermix. 
Separately, 1µL of β-actin primers was mixed with 7µL of nuclease-free water.  
Table 5.4: qPCR primers for HPV 16 E2 gene isoforms 
 Primer Names Nucleotide 
positions 
Sequences 
E2 AM771 (sense) 
AM772 
(antisense) 
3302 – 3321  









866 – 880, 
           










866 – 880  
 





Real-time PCR was performed using the ‘7500 Real time PCR system’ by Applied 




in √7500 (96 wells). SYBR reagent and a standard run were indicated on the set up screen. 
The targets recorded were E2, ‘E2 880^2709’, ‘E2 880^2582’, and β-actin. All four targets 
had the reporter labelled as SYBR and the quencher as ‘None’. 
The qPCR settings were as follows: 95°C for 10 minutes, followed by 50 cycles of 95°C for 
10 seconds (denaturation) and 60°C for 60 seconds (annealing and extension). After these 
stages, the melting curve was set at 95°C for 15 seconds, 60°C for 60 seconds, 95°C for 30 
seconds and a final 60°C for 15 seconds. These experiments were optimised adequately for the 
assays using the positive control VU147 in duplicates. Any patient samples that did not 
express β-actin in two separate runs were subsequently excluded from the analysis. The E2 
qPCR on patient samples were performed in triplicates and shown as normalised to β-actin. 
Expression of any of the three E2 isoforms investigated was regarded as satisfactory for E2 
expression in that sample. Each isoform was however analysed separately and correlated with 





5.6 Results:  
5.6.1 DNA and RNA extraction from FFPE samples:  
40 Formalin-Fixed Paraffin Embedded (FFPE) blocks of HPV-positive OPCs randomly 
selected were available for this study from the multicentre UK PET-NECK trial. DNA and 
RNA were extracted from the FFPE blocks using the standard protocols described in the 
Methods section. Concentrations for each DNA and RNA extracted sample were determined 
using the Fluorimeter and shown in Table 5.5.  
 
DNA concentrations (ng/L) obtained from the Qubit fluorimeter for the 40 HPV positive 
oropharyngeal cancer samples ranged between (0.01 – 54.9) ng/L (Table 5.5). Similarly, the 
RNA concentrations for the 39 available samples ranged widely between (10.0 – 1,842.0) 
ng/L. There was no tissue left on the FFPE block for one cancer sample (OPC 70) to allow 











Table 5.5: DNA and RNA concentrations of 40 oropharyngeal cancer FFPE samples  




1 48 54.90 600.00 
2 414 44.00 525.00* 
3 400 38.00 450.00 
4 321 32.10 317.00 
5 141 28.10 902.00 
6 22 26.00 1842.00 
7 490 25.10 1200.00 
8 418 18.20 900.00 
9 57 17.40 1120.00 
10 449 15.60 236.00 
11 346 15.40 172.00 
12 525 15.20 1040.00 
13 69 14.20 347.00 
14 450 13.70 1000.00 
15 519 12.50 892.00 
16 462 10.60 580.00 
17 142 10.20 530.00* 
18 145 9.83 479.00 
19 451 9.18 748.00 
20 320 8.59 566.00 
21 42 8.56 698.00 
22 19 6.42 456.00 
23 537 6.22 526.00 
24 14 5.98 590.00* 
25 491 4.32 654.00 
26 408 3.83 10.00 
27 311 2.84 176.00 
28 44 2.53 170.00* 
29 55 2.27 170.00* 
30 201 2.14 165.00 
31 224 1.80 700.00 
32 372 1.08 314.00 
33 185 0.84 119.00 
34 39 0.78 269.00 
35 70 0.61 No sample 
36 423 0.01 1200.00 
37 488 0.01 388.00 
38 214 0.01 412.00 
39 350 0.01 172.00 
40 330 0.01 498.00 




5.6.2 HPV 16 E2 gene disruption on type-specific PCR: 
In the type-specific PCR using overlapping primers to the HPV 16 E2 open reading frame 
(ORF), the absence of a band on 1.5% agarose gel electrophoresis for one or more of the 
overlapping primers (E2 sets 1 – 5) was interpreted as ‘E2 gene disruption’.  All the samples 
had detectable bands at E6, E7 and L1 indicating the samples indeed contained HPV 16 viral 
DNA, and were of reasonable quality.  
40% (16/40) of the HPV positive oropharyngeal cancer samples had HPV 16 E2 gene 
disruption shown by PCR (Table 5.6). HPV 16 E2 gene disruption was found with the 
overlapping primers in differing proportions. The most frequent E2 disruption was within ‘E2 
set 1 primer’ as it identified 93.8% (15/16), in contrast to the least frequent location within 
primer (E2 Set 5) which was intact in all samples and did not pick up any of the 16 samples 
with E2 disruption (Table 5.6). It is worth mentioning that the nucleotide positions for the E2 
set 5 primer overlap part of the E5 gene (Figure 5.7) and this may explain why this primer set 
was the least frequent location for E2 gene disruption. A representative sample with E2 gene 
disruption is shown in Figure 5.7.  
OPC 346 showed absence of a band with E2 set 1 primer in two separate PCR reactions. This 
was classed as ‘E2 gene disrupted’ as one of the five overlapping E2 primers had absence of a 
band demonstrated on duplicate PCR. OPC 346 also showed intact positive controls with E6, 
E7 and L1 bands present. The cell line controls were also consistent with the HPV positive 
keratinocyte cell line (Archie) showing intact E2 gene and the presence of bands in all 
overlapping E2 primer sets. As expected the HPV positive cervical cancer cell line (SiHa) 
showed E2 gene disruption in the E2 primer set 2 and a faint band in E2 primer set 3. SiHa 




disruption. The negative control (nuclease-free water) was free of contamination and did not 
amplify any bands as expected.  
The remaining 60% (24/40) of the HPV OPC samples had intact HPV 16 E2 gene. An 
example is shown in Figure 5.7 in the PCR done 22/2/16, where OPC 224 and OPC 70 both 
demonstrated the presence of bands in all the E2 primer sets as well as E6, E7 and L1. Both 
these patient samples were therefore classified as having an ‘intact E2 gene’. The limitations 
of this assay have already been highlighted in the methods section. In particular, the presence 
of bands on electrophoresis over the span of the E2 gene did not exclude the presence of viral 
integrations elsewhere in the HPV 16 genome. In addition, the presence of an intact band does 
not rule out the presence of both episomal and integrated forms (mixed).  
Samples that did not amplify the housekeeping gene (GAPDH) on duplicate PCR, such as 
OPC 81 were excluded from further analysis (see Figure 5.7). In every case of discordance in 
establishing E2 gene integrity following duplicate PCR i.e. a band was present on agarose gel 
electrophoresis but absent on the second gel, a third confirmatory PCR was performed and the 










Table 5.6: HPV 16 E2 gene disruption pattern at each primer site in 16/40 samples 
tested (all other samples had intact E2 gene)  
Number OPC ID E2 set 1 E2 set 2 E2 set 3 E2 set 4 E2 set 5 
1 519 x x x x present 
2 462 x x x x present 
3 423 x x x x present 
4 350 x x x x present 
5 330 x x x x present 
6 490 x x present x present 
7 449 x x present x present 
8 488 x x present x present 
9 22 x x present x present 
10 14 x x present x present 
11 408 x present present x present 
12 346 x present present present present 
13 44 x present present x present 
14 321 x present present present present 
15 69 x present present present present 
16 214 present present present x present 










Figure 5.7: HPV 16 E2 gene disruption in patient sample 346 on duplicate PCRs.  A 
representative sample demonstrating E2 gene disruption by PCR and 1.5%  agarose gel 
electrophoresis in patient sample 346 (in red) by duplicate PCRs done on separate dates 





5.6.3 HPV 16 E2 gene status and clinical correlation: 
The status of the HPV 16 E2 gene in each oropharyngeal cancer sample (intact or disrupted), 
as established by PCRs, was correlated with demographic and clinical data to investigate any 
differences between the two groups. These clinical correlates include anatomic subsite, age, 
gender, tumour size, smoking, alcohol consumption, overall survival and cancer recurrence. 
  
Table 5.7: HPV 16 E2 gene integrity correlated with OPC anatomic site and gender 

















      
Total 
number 
40 16 40 24 60  
Tonsils 25 9 36 16 64  
Tongue 
base 
10 4 40 6 60  
Not known 5 3 60 2 40  
      Chi-square 
statistic = 




      
Males 35 13 37.1 22 62.9  
Females 5 3 60 2 40  
      Chi-square 






5.6.3.1  Anatomic subsite: 
The anatomic subsite was available in 35/40 (87.5%) of oropharyngeal cancer in this study. 
Of the 35 samples with known subsite, the tonsil subsite accounted for 25/35 (71.4%) and the 
tongue base for 10/35 (28.6%). By subsite, the HPV 16 E2 gene was disrupted in 9/25 (36%) 
in the tonsil samples and 4/10 (40%) in the tongue base cancer samples. There was therefore 
no statistically significant difference between the tonsil and tongue base anatomic sites when 
considering E2 gene disruption (p=0.825) (Table 5.7). The finding of higher proportions of 
episomal HPV i.e. intact E2 gene, in oropharyngeal cancer was consistent regardless of 
whether the tumour was tonsil cancer (64%) or tongue base cancer (60%).  
5.6.3.2  Gender: 
The majority of the oropharyngeal cancer samples were obtained from males with 35/40 
(87.5%) in this cohort. Only 5 samples (12.5%) were obtained from females. By HPV E2 
gene status, 13/35 males (37.1%) had disruption of the E2 gene compared with 3/5 (60%) 
disruption in females (Table 5.7). The observed gender difference with females having higher 
proportions of OPC with HPV E2 gene disruption is however not statistically significant 










Table 5.8: HPV 16 E2 gene integrity correlated with OPC tumour size  














Tumour size       
T1 (≤ 2cm) 9 3 33.3 6 66.7  
T2 (> 2cm - < 
4cm) 
18 8 44.4 10 55.6  
T3 (> 4cm) 6 2 33.3 4 66.7  
T4 (Invasion) 7 3 42.9 4 57.1  
      p = 0.930 
 
5.6.3.3  Tumour size: 
HPV E2 gene status was investigated by oropharyngeal cancer tumour size based on the 
following divisions: T1 (≤2cm), T2 (>2cm - <4cm), T3 (>4cm), T4 (invasion). The majority 
of the tumours in this cohort were T2 (18/40), followed by T1 (9/40), T4 (7/40) and T3 (6/40). 
HPV E2 gene was disrupted in T1 (33.3%), T2 (44.4%), T3 (33.3%) and in T4 (42.9%) 
(Table 5.8). There was no statistically significant difference between tumour size categories 
and HPV E2 gene disruption (p=0.930) (Table 5.8).  
5.6.3.4  Age: 
Mean age for this OPC cohort of 40 patients was 56.98 years. The OPC samples with HPV 16 
E2 gene disruption were from older patients with a mean age of 60.63 years when compared 
with the OPC samples with intact HPV 16 E2 gene that had a patient mean age of 54.54 years. 
This indicates that on average, patients who had tumours with intact HPV were approximately 
6 years younger than those patients found to have disrupted HPV. This was a significant 




Table 5.9: HPV 16 E2 gene integrity stratified by age and gender 






Age (years)     
Overall 56.98 60.63 54.54 T-test: 
t = 2.223; 
p = 0.032 
Males  57.62 54.5 T-test: 
t = 1.169; 
p = 0.251 
Females  73.63 55 T-test: 
t = 2.592; 
p = 0.081 
 
On further stratification by gender however, the data showed that although males with 
disrupted HPV 16 E2 gene were marginally older at a mean age of 57.62 years compared with 
the intact HPV 16 E2 group at 54.5 years, this effect was not statistically significant on 
student T-test (p=0.251). In contrast amongst females, there was a greater dichotomy shown 
on age stratification by E2 status albeit not statistically significant but trending towards 
significance. Females with OPC that had disrupted HPV 16 E2 gene had a mean age of 73.63 
years in contrast to females with OPC that had intact HPV 16 E2 gene who were younger at a 
mean age of 55 years (Table 5.9). Student T-test showed a trend towards significance 
(p=0.081).  
With increasing mean age, there appears to be a tendency towards increasing HPV 16 E2 gene 
disruption in OPC, with this age effect more marked amongst females. This observation 






5.6.3.5  Smoking: 
Smoking is an established risk factor in the development of oropharyngeal cancer. Smoking 
status was defined by the following categories: ‘current smoker’, ‘ex-smoker’ and ‘non-
smoker’. There were 3 patients for whom their smoking status was not known. There were 
26/37 (70.3%) of this OPC cohort who gave a history of ever having smoked (12/37 (34.4%) 
were current smokers, 14/37 (37.8%) were ex-smokers), compared to 11/37 (29.7%) non-
smokers (Table 5.10).  
In this cohort, smoking did not show a statistically significant impact on viral E2 status in 
OPC when stratified into current smoker, ex-smoker or non-smoker on X2 test (p=0.651).  
Table 5.10: HPV 16 E2 gene integrity and smoking status (N – 37)  
Smoking status Overall OPC HPV 16 E2 
disrupted 





12 5/12 (41.7%) 7/12 (58.3%)  
Ex-Smoker 14 4/14 (28.6%) 10/14 (71.4%)  
Non-Smoker 11 5/11 (45.5%) 6/11 (54.5%)  




Even when analysed as ‘Ever smoked’ versus ‘Non-smoker’, smoking did not show a 
statistically significant difference in terms of E2 gene integrity on X2 test (p=0.534) as shown 






Table 5.11: HPV 16 E2 gene integrity and ‘ever having smoked’ status (N – 37)  
Smoking status Overall OPC HPV 16 E2 
disrupted 
HPV 16 E2 
gene intact 
X2 test 
Ever smoked 26 9/26 (34.6%) 17/26 (65.4%)  
Non-Smoker 11 5/11 (45.5%) 6/11 (54.5%)  




5.6.3.6  HPV 16 E2 gene integrity and overall survival: 
The integrity of the HPV 16 E2 gene was next correlated with overall survival (in years). 39 
patients in this cohort had data available for survival analyses i.e. number at risk (16 with 
disrupted E2 gene and 23 with an intact E2 gene). Median follow up time for this cohort was 
35.5 months (approximately 3 years). Range of follow up was 0 – 67.6 months. The 25th 
November 2015 was the date the survival data was most up to date for this analysis, so time to 
event analyses were calculated to this fixed point. Kaplan-Meier survival analyses were 
performed for both the disrupted and intact HPV E2 groups. 1-year survival probabilities in 
the disrupted E2 group was 14/16 (87.5%) and in the intact E2 group was 21/23 (91.3%). 
Similarly, the 3-year survival probabilities in the disrupted E2 group was 5/16 (31.3%) 
compared with the intact group of 11/23 (47.8%). The 5-year Kaplan-Meier survival 
probability in the disrupted E2 group was 0/16 (0%) while in the intact group there was 1/23 
(4.3%). The Kaplan-Meier probabilities show a trend of worse survival at 1, 3 and 5 years 
following diagnosis for oropharyngeal cancer in the cohort with disrupted HPV E2 gene but 






Figure 5.8: Impact of the HPV 16 E2 gene integrity on overall survival from OPC 
 
5.6.3.7  HPV 16 E2 gene integrity and OPC recurrence: 
The number of patients included in the Kaplan-Meier time-to-cancer recurrence analysis 
stratified by HPV 16 E2 gene status was 39 (16 disrupted and 23 intact). The number of 
events i.e. cancer recurrence was 6 with 2 recurrences in the E2 disrupted group and 4 
recurrences in the E2 intact group. Time to recurrence (in months) in the 6 patients in 
ascending order was 1.1, 3.0, 4.5, 6.0, 10.5, 15.1. Oropharyngeal cancer recurrence in the 6 
patients therefore had a median time to recurrence of 5.3 months and a range 1.1 – 15.1 
months. There was no statistically significant difference observed between the E2 disrupted 




Cancer recurrence occurred in distant organs in 4 of the 6 patients with recurrent disease.               
1 patient had a recurrence in the ipsilateral neck while 1 patient had recurrence in the 
contralateral neck. Significantly, Oropharyngeal cancer recurrence was associated with an 
increased likelihood of mortality on Kaplan-Meier survival analyses (p<0.05). 5 out of the 6 
patients with oropharyngeal cancer recurrence (83.3%) died within the 1 year follow up 
period (Figure 5.9).   
 
Figure 5.9: Kaplan-Meier analysis of the impact of HPV 16 E2 gene integrity on 







5.6.4 Methylation profiles of the E2 binding sites in the HPV 16 URR: 
There were 39 oropharyngeal cancer DNA samples available for methylation studies in the 
HPV 16 URR. It was not possible to obtain any further DNA from one sample from the 
original 40 FFPE. A valid result for the E2BS methylation studies consisted of triplicate 
results that satisfied the thresholds set on the Pyro Q-CpGTM software (Qiagen).  Valid results 
did not include results with high background noise on pyrosequencing, unusual pattern 
sequences or results that lacked the internal controls for satisfactory bisulfite conversion (a 
cytosine that is not immediately followed by guanine on the HPV DNA sequence for 
amplification acts as the control for the efficiency of bisulfite modification). Valid results 
were depicted in colour blue on analysis with yellow and red coloured results indicative of 
intermediate and low confidence results, respectively. Only results that met the rigorous 
thresholds were included in methylation analyses as valid mean methylation at each E2BS.  
Of the 39 OPC samples tested, 29 samples had valid results for investigating methylation 
profiles at the long control region (LCR) and 29 samples had methylation results for the 
promoter region of the HPV 16 URR. There was one sample (414) with the result for LCR 
only and one sample (201) with the result for the promoter region only. Unfortunately 10 
samples did not amplify on pyrosequencing and these were investigated further to explain 
why this occurred. Of significance was that 9 out of the 10 samples that failed the 
amplification using pyrosequencing were in the HPV 16 E2 gene disrupted cohort. Primer-
specific PCR for the HPV 16 URR confirmed the presence of disruptions within the URR (see 
section 5.6.8: Investigating HPV URR disruptions in select OPC samples).  
The methylation thresholds were based on current literature in which similar studies were 




1. Low methylation:  <20% methylation 
2. Intermediate methylation: 20 – 80% methylation 
3. High methylation:  >80% methylation 
Two cell line controls were used for pyrosequencing experiments and included a cell line 
from primary foreskin keratinocytes containing HPV and ‘CaSki’ which is a cervical cancer 
cell line and contains approximately 600 copies of integrated HPV with two transcriptionally 
active HPV. The HPV positive cell line from primary foreskin keratinocytes had low mean 
methylation at all the E2BS (Figure 5.10) while ‘CaSki’ had intermediate mean methylation 
levels at E2BS1 and high mean methylation at E2BS4 on pyrosequencing (Figure 5.11). The 
optimised assay was therefore able to detect the spectrum from low to high methylation and 









Figure 5.10: Low methylation at all E2BS in an HPV positive primary keratinocyte 
control with an intact E2 gene. (A1) shows low methylation at the E2BS1 that modulates 
promoter activation with 5% and 6% mean methylation at CpG 7452 and CpG 7458, 
respectively. (B1) shows low mean methylation at both inhibitory E2BS3 and E2BS4. E2BS3 
has mean methylation of 2% and 3% at CpG 37 and CpG 43, respectively while E2BS4 also 
has low mean methylation of 2% and 3% at CpG 52 and CpG 56, respectively. The ‘C’ not 
followed by a ‘G’ after the E2BS4 is the internal control for the efficiency of bisulfite 






Figure 5.11: Methylation at E2BS in cervical cancer cell line ‘CaSki’. (A3) shows 
intermediate methylation at the E2BS1 that modulates promoter activation with 70% and 68% 
mean methylation at CpG 7452 and CpG 7458, respectively. (B3) shows high mean 
methylation at both inhibitory E2BS3 and E2BS4. E2BS3 has high mean methylation of 92% 
and 100% at CpG 37 and CpG 43, respectively while E2BS4 also has high mean methylation 
of 91% and 100% at CpG 52 and CpG 56, respectively. There was high correlation between 
mean methylation observed at both CpG sites within each E2 binding site which was 






Figure 5.12: A representative patient sample (OPC 42) with an intact E2 gene and low 
mean methylation at all E2BS. (A7) shows low methylation at the E2BS1 that modulates 
promoter activation with 4% and 4% mean methylation at CpG 7452 and CpG 7458, 
respectively. (B7) similarly shows low mean methylation at both inhibitory E2BS3 and 
E2BS4. E2BS3 has low mean methylation of 7% and 8% at CpG 37 and CpG 43, respectively 






Figure 5.13: A representative patient sample (OPC 22) with a disrupted E2 gene and low 
mean methylation at all E2BS. (A5) shows low methylation at the E2BS1 that modulates 
promoter activation with 7% and 7% mean methylation at CpG 7452 and CpG 7458, 
respectively. (B5) similarly shows low mean methylation at both inhibitory E2BS3 and 
E2BS4. E2BS3 has low mean methylation of 3% and 3% at CpG 37 and CpG 43, respectively 






Figure 5.14: A representative patient sample (OPC 69) with a disrupted E2 gene and 
intermediate mean methylation at all E2BS. (A10) shows intermediate methylation at the 
E2BS1 that modulates promoter activation with 41% and 38% mean methylation at CpG 
7452 and CpG 7458, respectively. (B10) similarly shows intermediate mean methylation at 
both inhibitory E2BS3 and E2BS4. E2BS3 has intermediate mean methylation of 46% and 
47% at CpG, 37 and CpG 43 respectively while E2BS4 also has intermediate mean 
methylation of 50% and 41% at CpG 52 and CpG 56, respectively.  
 
There were 29 samples from which mean methylation results were obtained in triplicates. Of 
the 29 samples, 7 had disruption of the HPV 16 E2 gene while 22 had intact HPV 16 E2 gene. 
There was no sample in the entire cohort (regardless of E2 status) that had high mean 




In the E2 gene disrupted group (N – 7), at the promoter activating E2BS1, 14.3% (1/7) had 
intermediate mean methylation while the majority 85.7% (6/7) had low mean methylation. In 
the promoter inhibiting E2 binding sites 3 and 4, 28.6% (2/7) had intermediate mean 
methylation while 71.4% (5/7) had low mean methylation (Table 5.12).  
 
Table 5.12: HPV 16 E2 gene status and methylation at E2BS in OPC (N – 29)  
 E2 
disrupted 











    
High 0/7 0.0 0/22 0.0 
Intermediate 1/7 14.3 1/22 4.6 
Low 6/7 85.7 21/22 95.5 




    
High 0/7 0.0 0/22 0.0 
Intermediate 2/7 28.6 5/22 22.7 
Low 5/7 71.4 17/22 77.3 
 
In the E2 gene intact group (N – 22), at the promoter activating E2BS1, 4.6% (1/22) had 
intermediate mean methylation while the vast majority 95.5% (21/22) had low mean 




intermediate mean methylation while 77.3% (17/22) had low mean methylation (see Table 
5.12).  
The mean of the methylation results obtained from each E2 binding site in the HPV 16 URR, 
in those patient samples that also had disruption of the regulatory E2 gene, is presented in 
Table 5.13.  
Table 5.13: Methylation levels at E2BSs in OPC with disrupted E2 gene 
This table shows OPC samples with E2 gene disruption. Individual methylation levels at each 
CpG site as well as the mean methylation levels of the CpG sites in each E2 binding site are 
shown. E2BS1 is mean methylation of CpG 7452, 7458. E2BS3 is mean methylation of CpG 
37, 43. E2BS4 is mean methylation of CpG 52, 56. The overall inhibitory mean methylation 
was obtained from the average of methylation levels at E2BS3 and E2BS4. The samples 
highlighted in green (14, 22, 346, 214, 321) all have mean methylation less than 20% across 
all E2 binding sites. The sample highlighted in yellow (44) has mean methylation (≥ 20% to < 
80%) in E2BS3 and E2BS4 but <20% mean methylation at E2BS1. The sample highlighted in 
red (69) has mean methylation levels (≥ 20% to < 80%) across all the E2 binding sites.  
 



















            
1 14 8.7 9.0 8.3 3.0 3.0 3.0 2.0 4.0 0.0 2.5 
2 22 5.7 6.0 5.3 7.6 7.2 8.0 6.9 7.8 6.0 7.3 
3 346 8.4 9.0 7.7 6.5 6.2 6.7 6.1 6.8 5.3 6.3 
4 214 12.5 11.5 13.5 7.8 7 8.5 7.5 8 7 7.7 
5 321 9.2 9.8 8.5 17.5 20.0 15.0 16.0 20.0 12.0 16.8 
6 44 9.8 10.5 9.0 56.3 51.0 61.5 56.5 61.5 51.5 56.4 
7 69 33.9 34.7 33.0 45.9 43.7 48.0 45.3 51.3 39.3 45.6 
            
Mean  12.6 12.9 12.2 20.7 19.7 21.5 20.0 22.8 17.3 20.4 
 
The pattern that emerged in the methylation results from the entire cohort (regardless of their 




sites (depicted in green), b) low mean methylation at E2BS1 (<20%) and intermediate 
methylation (20 – 80%) at E2BS3 and E2BS4 (depicted in yellow), and c) intermediate 
methylation at all the binding sites (depicted in red) (see Tables 5.13 and Table 5.14).  
Specifically in the HPV 16 E2 gene disrupted cohort, 5/7 samples demonstrated low 
methylation in all the E2BS (Table 5.13). This pattern was similar to that observed in the 
majority of the E2 intact group where there was also low methylation across E2BSs (Table 
5.14). One of the 7 samples had low methylation in E2BS1 and intermediate methylation in 
E2BS3 and E2BS4. There was also one sample with intermediate methylation in all E2BS 
sites. (Table 5.13). There was a high correlation observed in the mean methylation between 
the two CpG sites located in each E2 binding site regardless of E2 status. Overall, in the E2 
gene disrupted group, the average of mean methylation readings at the promoter stimulating 
E2BS1 was 12.6% while it was 20.7% and 20.0% at the promoter inhibiting E2BS3 and 
E2BS4, respectively. Although the data show a slightly higher mean methylation at the 
inhibitory E2BS3 and 4, when compared to E2BS1 within the E2 disrupted group, this 
difference was not statistically significant given the methylation means were practically in the 
same ‘low methylation’ category and the observed difference could simply be due to 
background noise in pyrosequencing.  
In the group with intact E2 gene (N – 23), there were 22 samples with methylation results in 
the promoter stimulating E2BS1 and 22 samples with methylation results in the inhibitory 
E2BS3 and 4 (Table 5.14). 18/22 samples had low mean methylation (<20%) across all the E2 
binding sites. 4/22 samples had intermediate mean methylation (20 – 80%) at the inhibitory 
E2BS3 and E2BS4 alongside low mean methylation in their associated E2BS1. One sample 
(400) had intermediate mean methylation across all the E2 binding sites (Table 5.14). There 




each CpG site located therein. In terms of the overall average of the mean methylation 
observed at the specific E2 binding sites (regardless of the 3 methylation patterns just 
described), there was low mean methylation across all sites in the HPV 16 E2 intact group 




















Table 5.14: Methylation levels at E2BSs in OPC with Intact E2 gene 
This table shows OPC samples with an intact E2 gene. Individual methylation levels at each 
CpG site as well as the mean methylation levels of the CpG sites in each E2 binding site are 
shown. E2BS1 is mean methylation of CpG 7452, 7458. E2BS3 is mean methylation of CpG 
37, 43. E2BS4 is mean methylation of CpG 52, 56. The overall inhibitory mean methylation 
was obtained from the average of methylation levels at E2BS3 and E2BS4. The samples 
highlighted in green all have mean methylation less than 20% across all E2 binding sites. The 
samples highlighted in yellow (201, 491, 141, 372)) have mean methylation (≥ 20% to < 80%) 
in E2BS3 and E2BS4 but <20% mean methylation at E2BS1. The sample highlighted in red 
(400) has mean methylation levels (≥ 20% to < 80%) across all the E2 binding sites.  



















1 320 2.5 2.7 2.3 3 3 3 2.8 3 2.5 2.9 
2 42 4.5 4.7 4.3 6.9 6 7.7 7.4 7.7 7 7.2 
3 145 5 5.3 4.7 3.1 4.3 1.8 3 4.3 1.7 3.1 
4 39 5.1 4.8 5.3 6 5 7 6 6 6 6 
5 185 5.4 6.7 4 3.3 4 2.5 2.8 2.5 3 3.1 
6 537 5.4 4.7 6 4.5 4.3 4.7 3.7 3.7 3.7 4.1 
7 414 5.5 6 5 N/A N/A N/A N/A N/A N/A N/A 
8 48 5.5 5.3 5.7 6.3 6.8 5.8 6.8 6.5 7 6.6 
9 19 5.9 6 5.8 4.8 5.3 4.3 4.2 4 4.3 4.5 
10 450 6 6.3 5.7 7 8 6 7.3 6.5 8 7.2 
11 142 6.3 5.3 7.3 4.7 5.7 3.7 4 3.7 4.3 4.4 
12 311 6.4 6.7 6 7.2 7.3 7 7.2 7 7.3 7.2 
13 224 7.4 7 7.7 3.5 2.5 4.5 2.5 3 2 3 
14 451 7.4 7.3 7.5 6 6.7 5.3 6 6 6 6 
15 525 8.4 8.7 8 4 4.3 3.7 4.4 4 4.7 4.2 
16 57 8.5 8.6 8.4 11.3 10.25 12.25 10.3 10.75 9.75 10.8 
17 55 10.4 10.7 10 6 5 7 4.5 9 0 5.3 
18 418 12.2 11 13.3 7.7 8 7.3 8 7.7 8.3 8 
19 201 N/A N/A N/A 22.9 21 24.7 23.7 25 22.3 23.3 
20 491 11.6 11.8 11.3 25.9 28.7 23 25.8 28.3 23.3 25.9 
21 141 11.9 12.7 11 40.3 38.5 42 38.7 39.3 38 39.5 
22 372 17.3 17.3 17.3 61.2 59.5 62.8 60.2 60 60.3 60.7 
23 400 20.8 21.3 20.3 48.5 47.7 49.3 48.7 49 48.3 48.6 
            





A comparative analysis of mean methylation recorded at each E2 binding site stratified by 
their E2 gene status was undertaken in line with the set objectives of this study with results 
detailed in Table 5.13 and Table 5.14. The mean methylation data for the entire OPC cohort 
was non-parametric with a left skew (see Figures 5.15 and 5.16), therefore a Mann-Whitney 
U-test was used to assess for any differences between the two independent groups. 
Significance level was set at p<0.05.  
At E2BS1, the overwhelming majority of the samples were hypomethylated with mean 
methylation <20% in 27/29 samples (93.1%) and intermediate methylation in only 2/29 
(6.9%) (Figure 5.15 and Tables 5.13, 5.14).  
 
 





Similarly, at the inhibitory E2BS3 and E2BS4, there were 21/29 samples (72.4%) with low 
mean methylation and 8/29 (27.6%) with intermediate methylation (Figure 5.16 and Tables 
5.13 and 5.14). 
 
Figure 5.16: Methylation distribution at E2BS3 and 4 for all samples (N – 29)  
 
The promoter stimulating E2BS1 had higher mean methylation in the disrupted E2 group 
(12.6%) when compared with the intact E2 group (8.2%). This difference was tending 
towards significance at p=0.061. There was however no conclusive difference as the two 
independent means were both <20% which puts them in the same ‘low methylation’ category. 
There was no statistically significant difference when the individual CpG sites at E2BS1 





Table 5.15: Mean methylation by E2 status at each E2BS in the HPV 16 URR of OPCs 
  
Methylation (%) 
in OPC with 
intact E2  
 
Methylation (%) 
in OPC with 
disrupted E2 
 
2 tailed P-value  
(Mann Whitney U-
test) 
E2 Binding Site 1 8.2 12.6 0.061 
CpG 7452 8.2 12.9 0.064 
CpG 7458 8.0 12.2 0.093 
E2 Binding Site 3 13.4 20.7 0.157 
CpG 37 13.3 19.7 0.223 
CpG 43 13.4 21.5 0.135 
E2 Binding Site 4 13.1 20.0 0.231 
CpG 52 13.5 22.8 0.093 
CpG 58 12.6 17.3 0.338 
Overall Inhibitory 
(E2BS3 and 4) 
13.3 20.4 0.189 
 
At the promoter inhibiting E2BSs, overall methylation when E2BS3 and E2BS4 mean 
methylation were combined, showed higher mean methylation in the E2 disrupted group 
(20.4%) when compared with the E2 intact group (13.3%). This was however not statistically 
significant on Mann-Whitney U test (p=0.189) (Table 5.15). When assessed separately, there 
was still no observed difference with E2BS3 having 20.7% and 13.4% in the ‘E2 disrupted’ 
and ‘E2 intact’ groups, respectively (p=0.157). Similarly, at the E2BS4, intermediate 




13.1% in the ‘E2 intact’ group but not statistically significant on Mann-Whitney U test 
(p=0.231). There was still no difference in mean methylation by E2 status when assessed at 
individual CpG sites (Table 5.15).  
5.6.5 Correlation of methylation levels within E2 binding sites: 
Spearman’s Correlation coefficient showed a strong positive association between the mean 
methylation at CpG sites 7452 and 7458 (R=0.919 and p<0.05) (Figure 5.17) 
 
Figure 5.17: Correlation of mean methylation at CpG sites 7452 and 7458 in E2BS1 
 
There was a strong correlation in the mean methylation obtained at CpG sites within the 





Figure 5.18: Correlation in mean methylation at the E2BS3 CpG sites 37, 43. 
 
Mean methylation at the CpG sites in E2BS4 (CpG 52 and 56) also showed strong positive 





Figure 5.19: Positive correlation of CpG sites 52, 58 at the E2BS4.  
 
5.6.6 Overall survival in OPC by E2BS1 methylation and E2 status: 
The impact of E2BS1 methylation on overall survival was assessed using Kaplan-Meier 
analysis. There were 29 samples that had both methylation data and survival data. Of the 29 
samples, 27 samples had low methylation (6 E2 gene disrupted and 21 E2 gene intact). There 
were 2 patient samples that had intermediate methylation (one each of disrupted and intact E2 
gene). There were 4 events (deaths) in this cohort and in all 4 patient samples, there was low 
methylation. The 2 patients with intermediate methylation were still alive. There was no 
demonstrable difference in overall survival between those patients with low mean methylation 





Figure 5.20: E2BS1 methylation categories and survival. No signficant impact of E2BS1 
methylation observed on survival.  
 
5.6.7 E2BS3 and 4 intermediate methylation with disrupted E2 and survival: 
Of the 29 patients, low methylation was present at the E2BS3 and E2BS4 in 22 patients (5 
disrupted, 17 intact). There were 7 patients with intermediate methylation (2 disrupted, 5 had 
the viral E2 gene intact). There was no statistically significant difference in overall survival 
between the E2 intact and E2 disrupted groups on log rank test (p=0.731). 
There was no difference in overall survival by E2 status in the inhibitory E2 binding sites 3 





Figure 5.21:  Overall survival in OPC patients with E2BS3 and 4 low methylation and 
disrupted E2. No significant impact on survival shown in OPC cases with low methylation at 













5.6.8 Investigating HPV URR disruptions in select OPC samples: 
10 Oropharyngeal cancer DNA samples failed to amplify prior to pyrosequencing. These 
samples were therefore excluded from the analysis on methylation profiles in the HPV 16 
URR. Further exploratory tests were performed to examine why amplification was 
unsuccessful in these samples.  
 
Figure 5.22: Investigation of HPV URR disruptions by PCR 
HPV 16 URR integrity was assessed in 10 OPC samples by PCR reactions set up using 10µL 
of PCR mastermix, 3.5µL of water, 1.5µL of primers and 5µL of DNA. PCR was performed 
running denaturation step at 95°C for 15minutes, followed by 50 cycles at 95°C for 
20seconds, 54°C for 40seconds, 72°C for 50seconds. Final step of 72°C for 1 minute and 4°C 
holding temperature. The PCR reactions included a positive control (Caski), a negative 
control (DNAse – free sterile water), a house keeping gene (GAPDH) and a viral positive 
control (HPV 16 E6 gene). The reactions were separated for both the Long Control Region 




The initial observation was that 9/10 samples also had HPV 16 E2 gene disruption. From 
current literature, it is now known that HPV integrates in various regions of the HPV genome 
and it was possible that HPV integrations had occurred in tandem (alongside the E2 gene 
disruption observed) at the viral upstream regulatory region. This was investigated using 
primers specific to the HPV 16 URR using PCR performed in duplicates on DNA samples. 
The first PCR result is displayed in Figure 5.22 above.  
Remarkably, there were disruptions (absence of PCR bands) observed in the HPV 16 URR in 
the following OPCs: 
LCR region:  OPC 519, 423, 330 
Promoter region: OPC 519, 423, 330, 462, 490, 350 
The OPC samples that did have bands present on PCR may have failed bisulfite conversion or 
simply contain too low DNA concentrations to amplify on pyrosequencing. OPC 350 was 
found to also be disrupted at E6 while OPC 408 did not give amplification product for 





Figure 5.23: Duplicate PCR investigating HPV URR disruptions 
HPV 16 URR integrity was re-assessed in 9 OPC samples by duplicate PCR reactions set up 
using 10µL of PCR mastermix, 3.5µL of water, 1.5µL of primers and 5µL of DNA. PCR was 
performed running denaturation step at 95°C for 15minutes, followed by 50 cycles at 95°C for 
20seconds, 54°C for 40seconds, 72°C for 50seconds. Final step of 72°C for 1 minute and 4°C 
holding temperature. The PCR reactions included a positive control (Caski), a negative 
control (DNAse – free sterile water), a house keeping gene (GAPDH) and a viral positive 
control (HPV 16 E6 gene). The reactions were separated for both the Long Control Region 
(LCR) and the Promoter region of the viral HPV 16 URR. 
 
The disruptions were confirmed in duplicate PCR (Figure 5.23).   
In both the LCR and promoter regions, the following OPC had absent bands on PCR: OPC 
519, 423, 330. There was faint amplification in OPC 462, 490, 350 in the promoter region of 
the HPV 16 URR (Figure 5.23). It can be deduced that the low levels of DNA concentrations 




duplicate PCR including OPC 449, 201, 488. The house-keeping gene (GAPDH) was also 
absent in OPC 408 and 350 and as such, both samples were excluded from further analysis. 
By the time of this experiment, the DNA stores were depleted and no further experiment was 
possible.  
Overall, Pyrosequencing results of the E2 binding sites in the HPV 16 URR showed the 
following:  
1. Overall hypomethylation in the HPV 16 URR 
2. Hypomethylation at the promoter stimulating E2 binding site 1  
3. Moderate methylation at the inhibitory E2 binding sites 3 and 4 
4. There are no statistical differences at E2 binding sites for methylation between intact 
and integrated HPV 
5. There was no statistically significant correlation between mean methylation at E2 












5.6.9 HPV 16 E2, E6, E7 RNA expression profiles in Oropharyngeal cancer using reverse 
transcription real-time quantitative PCR (qPCR):  
40 OPC samples were further investigated for RNA expression of HPV 16 E2, E6 and E7 
genes. These results were normalised to β-actin with VU147 (an HPV positive cell line) as the 
endogenous control. The average fold changes were obtained using the standard 2^-ΔΔCт 
calculations and then log transformed.  
3 OPC samples did not express the control (β-actin) and were hence excluded from the 
analysis. The excluded samples included a sample with disrupted E2 gene (OPC 346) while 
the other two samples had intact HPV 16 E2 gene (OPC 525, 201). In addition, there were no 
available samples for further analyses in 2 patients (OPC 70 and 414).  
Three Isoforms of the HPV 16 E2 RNA were investigated for any clinical correlation with 
duplicate real-time PCR. These isoforms were ‘E2’, ‘E2 880ᴧ2709’, and ‘E2  880ᴧ2582’. 
These E2 isoforms have been previously investiged by Soeda et al. (2016) who showed that 
translation of the E2 protein was mainly by the 880^2709 RNA species with only very low 
levels of 880^2582 mRNA species. 
All samples expressed at least one isoform of E2 RNA except a single sample with disrupted 
E2 gene – OPC 423 (Table 5.16). The E2 expression fold change relative to reference VU147 
sample was calculated for each triplicate and the average E2 fold changes with their 







Table 5.16: E2 RNA expression in oropharyngeal cancer by qPCR Average fold change 
for E2 RNA expression assessed by qPCR in triplicate reactions. Samples highlighted in pink 
have E2 gene disruption while samples highlighted in white have an intact E2 gene. 
Reference sample VU147 is highlighted in green. 
Tumour 
ID ΔΔCт 










VU147 0 1 0 1 0 1 1 0 
185 -2.4 5.3 -0.7 1.6 5.7 0.0 2.3 2.7 
330 -2.1 4.2 -1.9 3.6 -2.0 3.9 3.9 0.3 
519 -0.4 1.3 4.5 0.0 -4.1 17.2 6.2 9.5 
57 0.3 0.8 -5.1 34.1 -0.2 1.2 12.0 19.1 
449 4.3 0.0 5.6 0.0 -5.3 39.6 13.2 22.9 
462 0.2 0.9 7.0 0.0 -6.2 71.5 24.1 41.0 
490 8.3 0.0 0.1 0.9 -7.1 136.1 45.7 78.3 
55 -8.1 283.9 0.1 0.9 -4.0 16.2 100.3 159.1 
142 -5.7 53.8 -7.9 237.0 -6.8 112.9 134.6 93.5 
224 -8.7 408.6 -6.6 97.7 -2.9 7.3 171.2 210.5 
321 -7.5 177.1 -7.7 214.0 -8.3 322.4 237.8 75.5 
408 -9.7 816.5 -5.6 49.6 1.9 0.3 288.8 457.7 
44 -6.7 101.0 -9.2 601.7 -7.9 246.5 316.4 257.6 
145 -10.6 1502.2 -6.2 74.5 -2.1 4.2 527.0 845.3 
14 -11.6 3057.8 -4.5 22.3 -8.0 260.9 1113.7 1687.9 
451 -5.9 58.6 -5.0 32.8 -11.8 3631.4 1240.9 2070.2 
42 -9.8 870.6 -11.3 2545.7 -8.6 379.3 1265.2 1135.8 
48 -4.6 23.7 -4.2 18.9 -12.2 4810.1 1617.6 2764.8 
69 -12.7 6580.4 -10.0 1021.7 -1.6 3.1 2535.1 3540.2 
19 -5.1 33.1 -5.0 32.3 -13.1 8530.9 2865.4 4906.4 
488 -0.1 1.0 -1.3 2.5 -14.0 16599.6 5534.4 9582.8 
214 -5.4 41.1 -14.2 18732.5 -9.8 877.9 6550.5 10558.2 
22 -13.6 12108.4 -15.0 32168.0 -8.0 255.1 14843.8 16131.3 
39 -15.5 45091.5 -14.6 24100.7 -8.1 274.3 23155.5 22423.6 
450 -6.6 94.1 -16.5 93824.3 0.2 0.9 31306.4 54142.1 
418 -7.7 211.4 -16.6 96595.4 0.6 0.7 32269.2 55708.3 
311 -16.4 85467.0 -12.4 5376.2 -14.5 22939.3 37927.5 42096.5 
423 6.1 0.0 -16.9 122981.8 7.4 0.0 40993.9 71003.5 
372 -11.2 2300.2 -17.3 158252.6 -1.8 3.4 53518.7 90709.5 
537 -7.3 162.6 -18.0 269411.8 -1.7 3.3 89859.3 155497.1 
400 -8.2 294.0 -18.2 292755.8 -2.1 4.3 97684.7 168936.6 
491 -7.5 179.2 -18.6 398886.2 -0.5 1.5 133022.3 230244.9 
350 -6.5 87.6 -7.0 131.7 -20.4 1430917.7 477045.6 826077.4 
141 -11.4 2785.4 -22.2 4759072.7 -6.0 65.0 1587307.7 2746829.4 





There was an inverse relationship observed between E2 gene integrity and E2 RNA 
expression. There was lower E2 RNA expression in those oropharyngeal cancer with a 
disrupted E2 gene compared to those with an intact E2 gene (mixed infection) (Table 5.17, 
Figure 5.24). This is consistent with published literature (Reuschenbach et al., 2015). E2 RNA 
expression is not compatible with E2 gene disruption so it is likely these samples had both 
intact and disrupted forms (mixed) that allowed the limited expression of some E2 RNA. The 

















Table 5.17: E2 RNA average fold change in comparison to VU147 Average fold change 
for E2 RNA expression assessed by qPCR in triplicate reactions. Samples highlighted in pink 
have E2 gene disruption while samples highlighted in white have an intact E2 gene. 
Reference sample VU147 is highlighted in green.  
Tumour ID Average E2 fold change 
Standard 
deviation 
E2 Log10(fold change) E2 E2 status 
VU147 1 0 0 Intact 
185 2.3 2.7 0.4 Intact 
330 3.9 0.3 0.6 Disrupted 
519 6.2 9.5 0.8 Disrupted 
57 12.0 19.1 1.1 Intact 
449 13.2 22.9 1.1 Disrupted 
462 24.1 41.0 1.4 Disrupted 
490 45.7 78.3 1.7 Disrupted 
55 100.3 159.1 2.0 Intact 
142 134.6 93.5 2.1 Intact 
224 171.2 210.5 2.2 Intact 
321 237.8 75.5 2.4 Disrupted 
408 288.8 457.7 2.5 Disrupted 
44 316.4 257.6 2.5 Disrupted 
145 527.0 845.3 2.7 Intact 
14 1113.7 1687.9 3.0 Disrupted 
451 1240.9 2070.2 3.1 Intact 
42 1265.2 1135.8 3.1 Intact 
48 1617.6 2764.8 3.2 Intact 
69 2535.1 3540.2 3.4 Disrupted 
19 2865.4 4906.4 3.5 Intact 
488 5534.4 9582.8 3.7 Disrupted 
214 6550.5 10558.2 3.8 Disrupted 
22 14843.8 16131.3 4.2 Disrupted 
39 23155.5 22423.6 4.4 Intact 
450 31306.4 54142.1 4.5 Intact 
418 32269.2 55708.3 4.5 Intact 
311 37927.5 42096.5 4.6 Intact 
423 40993.9 71003.5 4.6 Disrupted 
372 53518.7 90709.5 4.7 Intact 
537 89859.3 155497.1 5.0 Intact 
400 97684.7 168936.6 5.0 Intact 
491 133022.3 230244.9 5.1 Intact 
350 477045.6 826077.4 5.7 Disrupted 
141 1587307.7 2746829.4 6.2 Intact 







Figure 5.24: HPV 16 E2 RNA expression in OPCs Average fold change for E2 RNA 
expression was assessed by real-time PCR in triplicate reactions and calculated in relation to 
the VU147 reference sample. OPC samples with E2 disruption are shown in red while OPC 
samples with an intact E2 gene are shown in blue. Samples with additional disruptions in the 
URR (330, 519, 462, 490, 423 and 350) are highlighted with an asterix * 
A good proportion of the oropharyngeal cancer with high expression levels of E2 RNA also 
had an intact E2 gene as shown on the right side of Figure 4.25. Of the samples with 
additional URR disruption, four of them have low E2 expression (330, 519, 462 and 490) and 
two of them have the highest E2 expression amongst samples with disrupted E2 gene (423, 
350). These samples had both E2 disruption and URR disruption and are highlighted with an 






5.6.10  E6 expression and E2 gene disruption: 
There were high levels of E6 expression in the oropharyngeal cancer cohort with E2 gene 
disruption when compared with those cancer samples with an intact E2 gene (Table 5.18). 
This is consistent with current literature on HPV carcinogenesis. The samples with E2 gene 
disruption are depicted in red, while the samples with an intact E2 gene are not coloured in 
Table 5.18. The positive control is VU147 shown in green. The standard deviations for each 
average fold change in E6 expression alongside the log transformation are shown. There were 
















Table 5.18: E6 RNA expression in oropharyngeal cancer by qPCR. Average fold 
change for E6 RNA expression assessed by qPCR in triplicate reactions. Samples highlighted 
in pink have E2 gene disruption while samples highlighted in white have an intact E2 gene.  
Tumour 
ID ΔΔCт 











330 3.2 0.1 4.4 0.0 0.1 0.0 -1.1 
VU147 0 1 0 1 1 0 0 
224 -4.1 17.3 -0.8 1.8 9.5 11.0 1.0 
145 -4.4 20.8 -3.0 8.2 14.5 8.9 1.2 
57 -5.9 61.0 0.6 0.6 30.8 42.7 1.5 
450 -6.1 67.8 -4.6 24.9 46.4 30.3 1.7 
400 -6.8 109.9 -5.1 34.8 72.3 53.1 1.9 
451 -7.1 141.6 -3.4 10.7 76.2 92.6 1.9 
537 -6.9 119.5 -6.0 66.0 92.7 37.8 2.0 
142 -7.5 179.2 -3.4 10.7 94.9 119.1 2.0 
48 -6.8 107.8 -6.9 120.6 114.2 9.1 2.1 
418 -7.5 187.2 -6.0 63.4 125.3 87.5 2.1 
321 -7.9 246.3 -7.9 245.1 245.7 0.8 2.4 
42 -9.0 505.6 -6.6 99.8 302.7 287.0 2.5 
19 -9.4 668.9 -5.4 42.9 355.9 442.6 2.6 
185 -9.0 513.3 -7.7 204.7 359.0 218.2 2.6 
141 -5.5 44.2 -9.5 738.6 391.4 491.0 2.6 
55 -9.7 816.7 -6.2 73.0 444.9 525.9 2.6 
491 -9.7 817.6 -8.7 418.0 617.8 282.6 2.8 
449 -9.8 883.6 -8.9 478.0 680.8 286.8 2.8 
39 -10.6 1597.4 -2.9 7.3 802.3 1124.4 2.9 
320 -10.9 1913.8 -10.3 1258.3 1586.0 463.5 3.2 
44 -11.6 3186.6 -10.0 1052.1 2119.4 1509.3 3.3 
14 -12.6 6146.6 -9.2 604.5 3375.6 3918.9 3.5 
488 -12.6 6155.8 -11.8 3566.3 4861.0 1831.0 3.7 
22 -13.2 9239.1 -10.7 1672.9 5456.0 5350.1 3.7 
350 -10.2 1152.2 -13.8 14317.5 7734.9 9309.2 3.9 
490 2.8 0.1 -14.2 18799.3 9399.7 13293.0 4.0 
311 -13.6 12741.8 -13.7 13444.5 13093.1 496.9 4.1 
214 -12.7 6569.9 -14.7 26197.5 16383.7 13878.8 4.2 
462 -21.1 2324712.1 5.1 0.0 1162356.0 1643819.6 6.1 
372 -16.5 89687.6 -23.1 8842933.9 4466310.8 6189479.8 6.6 
519 -25.5 46178322.6 5.7 0.0 23089161.3 32653005.0 7.4 
69 -12.5 5931.1 n/a n/a n/a n/a n/a 
408 -8.2 299.9 n/a n/a n/a n/a n/a 





The  high expression of E6 RNA in those samples with disrupted E2 gene is presented in 
Figure 5.25. This is a significant finding that confirms the oropharyngeal cancer in this cohort 
are transcriptionally active with dysregulation of the E6 oncogene. The samples with 
additional URR disruption are depicted by asterix and show either the highest E6 expression 
(four samples: 350, 490, 462 and 519) or lack of E6 expression (two samples: 330 and 423). 
 
 
Figure 5.25: HPV 16 E6 RNA expression in OPC by q PCR Average fold change for E6 
RNA expression was assessed by real-time PCR in triplicate reactions and calculated in 
relation to the VU147 reference sample. OPC samples with E2 disruption are shown in red 
while OPC samples with an intact E2 gene are shown in blue. Samples with additional 







5.6.11  E7 expression and E2 gene disruption: 
Similar to E6 expression, there was a high expression of E7 RNA in those oropharyngeal 
cancer samples that also had a disrupted E2 gene (see Table 5.19 and Figure 5.26). The 
average of the log10(fold change) in the disrupted group was 4.7 compared to 2.4 obtained in 



















Table 5.19: E7 RNA expression in Oropharyngeal cancer by qPCR. Average fold 
change for E7 RNA expression assessed by qPCR in triplicate reactions. Samples highlighted 














VU147 0 1 0 1 1 0 0 
450 -0.9 1.9 2.6 0.2 1.0 1.2 0.0 
145 -3.7 12.7 -3.1 8.3 10.5 3.1 1.0 
224 -3.7 12.9 -4.1 16.8 14.8 2.8 1.2 
400 -6.7 104.8 -4.5 22.3 63.5 58.4 1.8 
451 -5.4 43.2 -6.9 122.2 82.7 55.8 1.9 
142 -7.8 228.9 -6.0 62.9 145.9 117.4 2.2 
537 -8.1 274.0 -4.5 22.7 148.4 177.7 2.2 
48 -7.4 165.4 -7.1 134.0 149.7 22.2 2.2 
418 -8.3 316.9 -6.1 67.4 192.1 176.5 2.3 
185 -8.0 248.1 -7.5 175.3 211.7 51.5 2.3 
55 -9.2 569.9 -7.7 213.7 391.8 251.9 2.6 
449 -8.0 264.1 -9.6 761.5 512.8 351.7 2.7 
19 -9.2 578.9 -9.6 803.0 690.9 158.5 2.8 
321 -9.5 737.0 -9.7 849.9 793.5 79.8 2.9 
491 -10.4 1382.2 -8.0 264.4 823.3 790.4 2.9 
42 -11.4 2736.6 -6.6 99.7 1418.2 1864.6 3.2 
44 -10.9 1919.0 -10.7 1686.8 1802.9 164.2 3.3 
14 -11.7 3257.8 -8.9 471.6 1864.7 1970.1 3.3 
39 -12.1 4425.9 -8.8 452.2 2439.0 2809.8 3.4 
141 -12.1 4436.6 -8.9 487.5 2462.1 2792.5 3.4 
320 -12.3 4994.0 -9.9 973.7 2983.8 2842.8 3.5 
311 -11.6 3183.1 -12.1 4424.8 3804.0 878.0 3.6 
22 -13.3 9871.0 -9.0 519.6 5195.3 6612.5 3.7 
488 -12.7 6499.8 -12.9 7840.4 7170.1 947.9 3.9 
350 -14.1 17976.5 -12.5 5786.3 11881.4 8619.8 4.1 
214 -11.9 3792.3 -15.2 36653.3 20222.8 23236.2 4.3 
372 -15.5 46361.1 -17.5 179578.9 112970.0 94199.2 5.1 
490 -24.2 19677081.1 1.1 0.5 9838540.8 13913797.2 7.0 
462 -27.7 215232424.0 -14.4 21352.8 107626888.4 152177207.9 8.0 
330 -2.2 4.5 -30.1 1149663212.9 574831608.7 812934650.7 8.8 
57 -4.2 19.0 n/a n/a n/a n/a n/a 
69 -11.8 3584.0 n/a n/a n/a n/a n/a 
408 -8.3 305.5 n/a n/a n/a n/a n/a 
423 1.8 0.3 n/a n/a n/a n/a n/a 






Figure 5.26: HPV 16 E7 RNA expression in OPC by q PCR Average fold change for E7 
RNA expression was assessed by real-time PCR in triplicate reactions and calculated in 
relation to the VU147 reference sample. OPC samples with E2 disruption are shown in red 
while OPC samples with an intact E2 gene are shown in blue. Samples with additional 
disruptions in the URR (330, 519, 462, 490, 423 and 350) are highlighted with an asterix * 
 
The E2 disrupted cancer samples are depicted in red showing a higher proportion of samples 
in the E7 high expression profile in comparison to the intermediate to low expression levels 
demonstrated in those cancer samples with E2 gene intact depicted in blue (Figure 5.26). 
Similar to E6 expression, the samples with the highest E7 expression were those with 
additional URR disruption (350, 490, 462 and 330), the two other from this group did not 






Table 5.20: Summary of E2, E6, E7 expression data in OPC in relation to HPV 16 E2 
gene integrity and URR methylation levels. Comparison of average fold change for E2, E6 
and E7 RNA expression assessed by qPCR in triplicate reactions, stratified by URR 
disruptions. Samples highlighted in red have E2 gene disruption while samples highlighted in 
black have an intact E2 gene.  
Tumour 
ID E2 status 










VU147 Intact 1 1 1 n/a n/a 
350 Disrupted 477045.6 7734.9 11881.4 URR disruption n/a 
330 Disrupted 3.9 0.1 574831608.7 URR disruption n/a 
462 Disrupted 24.1 1162356.0 107626888.4 URR disruption n/a 
408 Disrupted 288.8 n/a n/a n/a n/a 
488 Disrupted 5534.4 4861.0 7170.1 n/a n/a 
490 Disrupted 45.7 9399.7 9838540.8 URR disruption n/a 
423 Disrupted 40993.9 n/a n/a URR disruption n/a 
519 Disrupted 6.2 23089161.3 n/a URR disruption n/a 
449 Disrupted 13.2 680.8 512.8 n/a n/a 
372 Intact 53518.7 4466310.8 112970.0 Intermediate 60.7 
44 Disrupted 316.4 2119.4 1802.9 Intermediate 56.4 
400 Intact 97684.7 72.3 63.5 Intermediate 48.6 
69 Disrupted 2535.1 n/a n/a Intermediate 45.6 
141 Intact 1587307.7 391.4 2462.1 Intermediate 39.5 
491 Intact 133022.3 617.8 823.3 Intermediate 25.9 
321 Disrupted 237.8 245.7 793.5 Low 16.8 
57 Intact 12.0 30.8 n/a Low 10.8 
418 Intact 32269.2 125.3 192.1 Low 8 
214 Disrupted 6550.5 16383.7 20222.8 Low 7.7 
22 Disrupted 14843.8 5456.0 5195.3 Low 7.3 
42 Intact 1265.2 302.7 1418.2 Low 7.2 
311 Intact 37927.5 13093.1 3804.0 Low 7.2 
450 Intact 31306.4 46.4 1.0 Low 7.2 
48 Intact 1617.6 114.2 149.7 Low 6.6 
39 Intact 23155.5 802.3 2439.0 Low 6 
451 Intact 1240.9 76.2 82.7 Low 6 
55 Intact 100.3 444.9 391.8 Low 5.3 
19 Intact 2865.4 355.9 690.9 Low 4.5 
142 Intact 134.6 94.9 145.9 Low 4.4 
537 Intact 89859.3 92.7 148.4 Low 4.1 
185 Intact 2.3 359.0 211.7 Low 3.1 
145 Intact 527.0 14.5 10.5 Low 3.1 
224 Intact 171.2 9.5 14.8 Low 3 
320 Intact 55934732.1 1586.0 2983.8 Low 2.9 




5.6.12  E2, E6 and E7 gene expression and E2 gene integrity: 
Expression levels of E2 RNA were further correlated with E6 and E7 RNA expression in this 
cohort. There was low E2 RNA expression in those oropharyngeal cancer samples with a 
disrupted E2 gene which was associated with high expression levels of E6 and E7 RNA 



















Table 5.21: Correlation of E2, E6, E7 expression in OPC by E2 gene status  
Comparison of average log10(fold change) of E2, E6 and E7 RNA expression by E2 gene 
status. Samples highlighted in red have E2 gene disruption while samples highlighted in black 
have an intact E2 gene. 
Tumour 
ID E2 status Log10(fold change) E2 Log10(fold change) E6 Log10(fold change) E7 
VU147 Intact 0 0 0 
14 Disrupted 3.0 3.5 3.3 
22 Disrupted 4.2 3.7 3.7 
44 Disrupted 2.5 3.3 3.3 
214 Disrupted 3.8 4.2 4.3 
321 Disrupted 2.4 2.4 2.9 
330 Disrupted 0.6 -1.1 8.8 
350 Disrupted 5.7 3.9 4.1 
449 Disrupted 1.1 2.8 2.7 
462 Disrupted 1.4 6.1 8.0 
488 Disrupted 3.7 3.7 3.9 
490 Disrupted 1.7 4.0 7.0 
519 Disrupted 0.8 7.4 n/a 
19 Intact 3.5 2.6 2.8 
39 Intact 4.4 2.9 3.4 
42 Intact 3.1 2.5 3.2 
48 Intact 3.2 2.1 2.2 
55 Intact 2.0 2.6 2.6 
141 Intact 6.2 2.6 3.4 
142 Intact 2.1 2.0 2.2 
145 Intact 2.7 1.2 1.0 
185 Intact 0.4 2.6 2.3 
224 Intact 2.2 1.0 1.2 
311 Intact 4.6 4.1 3.6 
320 Intact 7.7 3.2 3.5 
372 Intact 4.7 6.6 5.1 
400 Intact 5.0 1.9 1.8 
418 Intact 4.5 2.1 2.3 
450 Intact 4.5 1.7 0.0 
451 Intact 3.1 1.9 1.9 
491 Intact 5.1 2.8 2.9 
537 Intact 5.0 2.0 2.2 
57 Intact 1.1 1.5 n/a 
69 Disrupted 3.4 n/a n/a 
408 Disrupted 2.5 n/a n/a 




5.6.13  Correlation of E6 and E7 expression:  
There was a strong positive correlation between E6 and E7 expression levels when the log10 
(average fold change) values were correlated as shown in Figure 5.27. This was mainly driven 
by E6 and E7 expression levels showed a moderate positive correlation when the E2 gene was 
intact but no correlation when the E2 gene was disrupted (Figure 5.28). 
 
 









A       B 
 
Figure 5.28 (A and B): E6 and E7 RNA expression by E2 gene status.  No correlation in 
E6 and E7 expression shown in E2-disrupted OPC (A) although a downward trend and 
moderate positive correlation between E6 and E7 expression in E2-intact OPC (B) was 
observed with (R2=0.6975). 
 
5.6.14  Correlation of E2 expression with E6 and E7 expression: 
There was no significant correlation shown between E2 expression and either E6 or E7 
expression using the transformed fold change data (Table 5.21). The correlation between E2 
RNA expression was further divided by E2 gene status i.e. disrupted or intact. In the E2- 
disrupted group, E2 expression did not correlate with E6 (R2=0.0057) or E7 (R2=0.0361) 
RNA expression (Figure 5.29 A and B).  
Similarly, in the E2-intact group, E2 expression had no correlation with E6 expression 






Figure 5.29: Correlation of E2 expression with E6 and E7 expression, stratified by viral 
E2 gene status. No correlation of E2 expression with E6 in E2-disrupted samples (A), with 
E7 in E2-disrupted samples (B), with E6 in E2-intact samples (C), and with E7 in E2-intact 
samples (D).  
 
5.6.15  Methylation levels and E2, E6 and E7 RNA expression: 
Methylation data was sub-divided into low methylation (<20%), intermediate methylation (≥ 
20 – 80%) and high methylation (>80%) as described in the methodology. There was no 
sample in the high methylation group in this cohort. The analysis on methylation and E2 gene 
disruption has been presented in section 5.27. Methylation levels at the E2BS3 and E2BS4 
inhibitory sites were correlated with E2, E6 and E7 RNA expression in 26 OPC samples with 
methylation data. Intermediate mean methylation was observed in six OPC samples and low 
mean methylation in twenty OPC samples (Table 5.22). The average of mean methylation at 
E2BS3 and 4 was 6.2% in the low methylation group and 46.1% in the intermediate 




Table 5.22: Methylation at E2BS3 and E2BS4, E2 integrity and survival 
Tumour 







VU147 Intact n/a n/a n/a 
350 Disrupted URR disruption n/a 1111 
330 Disrupted URR disruption n/a 1069 
462 Disrupted URR disruption n/a 1068 
408 Disrupted n/a n/a 1032 
488 Disrupted n/a n/a 723 
490 Disrupted URR disruption n/a 714 
423 Disrupted URR disruption n/a 688 
519 Disrupted URR disruption n/a 657 
449 Disrupted n/a n/a 261 
372 Intact Intermediate 60.7 718 
44 Disrupted Intermediate 56.4 1781 
400 Intact Intermediate 48.6 984 
69 Disrupted Intermediate 45.6 1132 
141 Intact Intermediate 39.5 1349 
491 Intact Intermediate 25.9 1008 
321 Disrupted Low 16.8 799 
57 Intact Low 10.8 1069 
418 Intact Low 8 952 
214 Disrupted Low 7.7 876 
22 Disrupted Low 7.3 1767 
42 Intact Low 7.2 1127 
311 Intact Low 7.2 1082 
450 Intact Low 7.2 913 
48 Intact Low 6.6 1758 
39 Intact Low 6 1998 
451 Intact Low 6 340 
55 Intact Low 5.3 317 
19 Intact Low 4.5 1760 
142 Intact Low 4.4 1679 
537 Intact Low 4.1 734 
185 Intact Low 3.1 1579 
145 Intact Low 3.1 1338 
224 Intact Low 3 1011 
320 Intact Low 2.9 1067 





The log10 (average fold change) for each early gene (E2, E6 and E7) were calculated as 
shown in the respective Table 5.18, Table 5.19 and Table 5.20. The means of these individual 
values were calculated for the URR status (URR disruption, promoter intermediate 
methylation and promoter hypomethylation) and compared to the E2-intact and E2-disrupted 
groups (Table 5.23).  
Table 5.23: E2, E6 and E7 expression levels in relation to methylation, E2 status and 
URR disruption 
Mechanism E6 E7 E2 
Intact 
(22) 
2.3 2.3 4.0 
E2 disruption 
(15) 
3.5 3.3 2.5 
E2 disruption 
+ URR disruption 
(6) 
3.9 5.5 1.6 




2.7 3.1 4.9 
E2BS3 and 4 
Hypomethylation 
(20) 
2.4 2.5 3.2 
The data represent the mean of the log10(average fold expression) of each of E2, E6, E7.  
 
Oropharyngeal cancer samples with intermediate methylation at the inhibitory E2BS3 and 4 
had higher E2 RNA expression (4.9) than those cancer samples with low methylation (3.2). 
These intermediate methylation samples also had higher mean of log10(fold change) levels in 




methylation at 2.4 and 2.5, respectively (see Table 5.23). This observation was however not 
clinically significant.  
In OPC with intact E2 gene, there were higher levels of E2 RNA expression (4.0) when 
compared to those cancer samples with a disrupted E2 gene (2.5). The expression levels of E6 
(3.5) and E7 (3.3) in the cancer samples with disrupted E2 gene were higher than the levels of 
E6 (2.3) and E7 (2.3) in the samples with an intact E2 gene. Interestingly, although the cancer 
samples that had both E2 gene disruption and URR disruption (N – 6) had lower E2 
expression levels (1.6) when compared to the E2 intact group, there had significantly higher 
expression levels of both E6 (3.9) and E7 (5.5). This may be a significant carcinogenesis 
pathway as this group with multiple disruptions had levels of E6 and E7 expression higher 
than if all they had was E2 disruption (Table 5.23).  
5.6.16  Impact of HPV 16 URR disruption on E2, E6 and E7 gene expression: 
The URR disruptions have only been observed in samples with E2 disruption and may 
indicate large rearrangements of viral genome upon integration. This could lead to a loss of 
control mechanisms between the promoter, E2, E6 and E7 expression. Indeed, the high 
positive correlation between E6 and E7 expression observed in general in our cohort is not 
present in this subgroup. These samples are characterized by either very high expression of 
both E6 and E7 (OPC 350, 490, 462) or a complete loss of one (E7 in 519 and E6 in 330) or 
both of their expressions (423). This might or might not be accompanied by low E2 







Table 5.24: E2, E6 and E7 expression in samples with URR disruption 
 E6 E7 E2 
350 3.9 4.1 5.7 
490 4 7 1.7 
462 6 8 1.4 
519 7.3 0 0.8 
423 0 0 4.6 
















5.6.17  Summary: 
The overview of all results obtained in achieving the stated objectives of this HPV 16 genetics 
and epigenetics research are demonstrated in the flowchart in Figure 5.30.  
Figure 5.30: Comparison between E2, E6 and E7 expression with E2 gene status, URR status 
and promoter methylation. This comparative data is descriptive and preliminary due to the small 
sizes of the subgroups. Although E2 expression is generally lower in the E2 disrupted group as 
compared to the intact group (2.5 vs. 4) it appears to be mostly due to the values in the E2 + URR 
disrupted samples (1.6). These anti-correlate with high expression levels of E6 and E7 (3.9 and 5.5). 
The other disrupted samples, regardless of methylation, have similar E2 expression (3.4 and 3) to the 
intact group with hypomethylated promoter (3.2). The highest E2 expression (5.1) is observed in the 
E2-intact group with intermediate promoter methylation. E6 and E7 expression levels are generally 
higher in the E2-disrupted group as compared to the E2-intact group. (*The result for the E2-
disrupted with intermediate promoter methylation – only two samples with values 3.3 and 0.0 for both 
E6 and E7). Within the E2-intact group, intermediate promoter methylation group is characterized by 








Human papillomavirus-mediated carcinogenesis as it relates to a subset of Oropharyngeal 
cancer, remains poorly understood. Viral acquisition (especially of HPV 16 genotype), 
integration into host tissues, replication and ultimately genomic dysregulation of host defence 
mechanisms, are the focus of current scientific scrutiny worldwide. The molecular processes 
that underpin the development of cervical cancer from persistent infection with high-risk HPV 
are the current template from which our understanding of HPV-related interactions are built at 
this point in time. The tendency to extrapolate both laboratory and clinical facts that have 
been established since zur Hausen (2009) conclusively demonstrated high-risk HPV as an 
aetiology for cervical cancer is understandable. However, there are some key differences 
emerging between HPV in cervical cancer and HPV in oropharyngeal cancer. There exists 
limited data at present addressing pertinent questions relating to the HPV-mediated 
mechanisms of oropharyngeal carcinogenesis including both genomic and epigenetic events.  
There is currently an agreement that in order to control the host’s cell cycle mechanisms the 
expression of viral oncogenes E6 and E7 has to be maintained at high levels. How this is 
achieved is still under debate, especially in oropharyngeal carcinogenesis. This study 
contributes in some degree to the on-going discourse on HPV 16 – mediated oropharyngeal 
cancer by investigating the role of disruption of the viral regulatory E2 gene and the 
importance of aberrant methylation in the homeostasis of viral E6 and E7 proto-oncogenes. In 
highlighting what we already know from cervical cancer literature, the viral regulatory E2 
gene is invariably disrupted in approximately 70% of cervical cancers (Chaturvedi et al., 
2013). The reverse appears to be the case in HPV-oropharyngeal cancer as the limited 
literature indicates viral intergration occurs in 30 – 40% of tumours with the majority of 




host DNA is accompanied by the presence of multiple disruptions in the HPV 16 genome 
itself including E1, E2, E4, E5, and L1 (Wilson et al., 2013; Gao et al., 2013). The data 
obtained in the presented study, although preliminary due to the small group size, led to 
interesting observations discusses below.   
Physical status of the HPV 16 regulatory E2 gene in oropharyngeal cancer: 
This study evaluated the integrity of the HPV 16 regulatory E2 gene (intact or disrupted) in 
HPV positive-oropharyngeal cancer using type-specific PCR with overlapping primers to the 
HPV 16 E2 open reading frame. 16/40 (40%) of the HPV positive-oropharyngeal cancer 
samples had HPV 16 E2 gene disruption on PCR. This finding is consistent with the 16 – 43% 
HPV integration in oropharyngeal cancer published in PCR-based studies that included more 
than 10 cancer samples (Vojtechova et al., 2015; Reuschenbach et al., 2015; Olthof et al., 
2014; Barbieri et al., 2014; Park et al., 2011). This further adds weight to the observation that 
HPV-oropharyngeal cancer is mainly an episomally-driven tumour in contrast to cervical 
cancer with significantly higher viral integration events. The HPV 16 E2 gene is therefore 
intact but dysfunctional in maintaining viral homeostasis of E6 and E7 oncogenes. The 
hypothesis in this study was that methylation is responsible for the URR dysfunction and as 
such differential methylation profiles should be observable at the palindromic E2 binding sites 
in the HPV upstream regulatory region (URR), based on the status of the viral E2 gene.  
The main limitation of the technique used to assess viral physical status in this study i.e. 
overlapping primers aimed at the HPV 16 E2 ORF is that viral regulation is poly-cistronic and 
although disruptions occur predominantly in the viral E2 gene, integration is seen in multiple 
sites in the genome as well (Wilson et al. 2013; Gao et al., 2013). Although the absence of a 




a band cannot conclusively exclude the presence of viral integrations in other genomic sites or 
mixed infections.  
The scientific inquiry into the mechanisms that lead to over-expression of E6 and E7 viral 
genes and ultimately cancer in the two independent groups (E2 intact and E2 disrupted) of 
oropharyngeal cancers is valid and requires ascertainment. The presence of HPV in OPC is a 
good prognostic marker as these tumours (in comparison to their HPV negative counterparts), 
tend to respond better to chemo radiotherapy or surgical treatments. These viral genomic 
differences could therefore be additional biomarkers that provide further prognostic 
parameters in addition to the current prognostic marker that is the presence of HPV in 
oropharyngeal cancer.  
Differential methylation at the E2 binding sites of the HPV 16 upstream regulatory region: 
In this study, methylation profiles were further determined at each transcriptionally-relevant 
E2 binding site (E2BS1, E2BS3 and E2BS4) in the HPV 16 URR, using pyrosequencing of 
bisulfite-modified DNA from HPV positive OPCs. The first key finding from the 
pyrosequencing experiments in the HPV 16 URR was the overall hypomethylation state of the 
HPV 16 URR. The methylation levels in all of the E2 binding sites were generally less than or 
around 20% regardless of the viral E2 status (intact or disrupted). This in itself is a potentially 
useful biomarker in HPV oropharyngeal cancer as it has been previously reported by Park et 
al. (2011) and Balderas-Loaeza et al. (2007). Both studies indicate the HPV 16 genome is 
hypomethylated in cases of advanced HPV positive head and neck cancer with further 
preferential hypomethylated noted in the long control region (LCR) of the viral genome.  
There is however a contrasting information as to methylation at specific E2BSs. A recent 




modified DNA did however show higher methylation frequency in the E2BS1 when 
compared to E2BS3 and 4. This is in contrast to the findings in both our study and the study 
by Reuschenbach et al. (2015) where higher methylation in the E2BS3 and 4 was observed 
when compared with the E2BS1.  
The marginal differential methylation observed in our study between the promoter-stimulating 
E2BS1 and the inhibitory E2BS3 and E2BS4, is of uncertain clinical significance, mainly due 
to the small group sizes. However, methylation profiles published in recent studies in head 
and neck literature points to the existence of a certain dichotomy in the E2 binding sites with 
correlation to cancer survival. Reuschenbach et al. (2015) were able to stratify a cohort of 57 
HPV positive oropharyngeal cancer into three subgroups based on their differential 
methylation at the E2BS3 and E2BS4. High methylation frequencies at these inhibitory E2 
binding sites (E2BS3 and E2BS4) were shown to be associated with a worse overall survival 
(Reuschenbach et al., 2015). 
It is of importance that 10 HPV positive oropharyngeal cancer in this cohort (25%) failed 
PCR amplification prior to pyrosequencing largely because of the concomitant presence of 
disruptions in the HPV 16 URR itself that houses the E2 binding sites. These samples were 
excluded from the methylation results with an impact on the overall study sample size. 
However, at the same time they emphasized the role of URR disruption in OPC 







Impact of viral E2 gene status on expression of E2, E6 and E7 mRNA using qPCR: 
This study sought to confirm the proportion of the HPV oropharyngeal cancer samples that 
were transcriptionally active with expression of E2, E6 and E7 mRNA using reverse-
transcription real-time PCR. It is well-recognised that the mere presence of HPV DNA in 
cancer samples is not confirmation of cancer causation. In addition to HPV DNA positivity by 
PCR and p16 immunohistochemistry, high expression levels of E6 and E7 is required to 
demonstrate tumours are transcriptionally active. All the HPV OPC samples used in this study 
expressed E2 mRNA or its isoforms (‘E2 880ᴧ2709’ and ‘E2 880ᴧ2582’) although at highly 
variable levels. In fact, integration/E2 disruption accompanied with no E2 expression is very 
rare (Reuschenbach et al., 2015) pointing towards the co-presence of both intact/episomal and 
disrupted viral genomes. Similarly the levels of E6 and E7 expression were variable but the 
expression was not detected in three and five samples for E6 and E7, respectively.  
The viral gene expression was then compared to the methylation levels at the E2BS3 and 
E2BS4 sites. Unfortunately due to the small group sizes the statistical analysis was not 
possible and no firm conclusions could be made. 
E2 RNA expression: 
E2 expression was higher when the E2 gene was intact when compared to its expression 
levels when the E2 gene was disrupted. This is a recognised pattern of E2 expression 
dependent on E2 gene integrity (Reuschenbach et al., 2015) and our data reaffirms this 
mechanism in HPV carcinogenesis. In addition, E2 expression was the lowest when both E2 
and the HPV 16 URR were disrupted in the same sample. This is a unique finding that merits 




In terms of E2 expression and methylation, this study showed that intermediate methylation 
was linked to higher E2 expression levels when compared with samples that had low 
methylation and lower E2 expression. It is therefore possible that methylation affects E2 
expression or vice versa.  
E6 and E7 RNA expression: 
E6 RNA expression was lower when E2 gene was intact. This is in keeping with the 
understood mechanisms of HPV auto-regulation described by Reuschenbach et al. (2015). 
Interestingly, E6 expression was highest when both the viral E2 gene and the URR were 
disrupted. E6 expression was similar in both low and intermediate methylation at the 
inhibitory E2BS3 and E2BS4 but highest in URR disruption.  
Similarly, E7 RNA expression was lower when the E2 gene was intact compared to when the 
E2 gene was disrupted. E7 expression was also highest when both the regulatory E2 gene and 
the URR were disrupted in the same cancer sample.  
In terms of methylation, E7 expression was higher in the presence of intermediate methylation 
when compared with samples that had low methylation. E7 expression was however highest 
when URR disruption was also present. This suggests that URR disruption tends to accentuate 
the dysregulation of E6 and E7 with their further over-expression. However, there was no 
statistically demonstrable significance of this observation given the small sample size so these 
conclusions still require further investigation.  
In addition, E6 and E7 RNA expression levels showed a good positive correlation especially 
in the E2-intact cancers. E6 and E7 expression levels were generally higher in the E2-
disrupted group as compared to the E2-intact group. Within the E2-intact group, intermediate 




mentioned before the highest E2 expression. It is possible the decrease of promoter inhibition 
leads to increased levels of all E6, E7 and E2 genes, therefore the auto-regulatory element of 
viral transcription could still be maintained in these samples. Therefore, in OPC high E6/E7 
levels result primarily from the disruption of E2 gene, especially when accompanied by URR 
disruption. While, when the E2 gene remains intact, increased methylation at HPV 16 
promoter inhibitory E2 binding sites could lead to increased E6 and E7 expression despite 
high E2 expression levels.  
HPV 16 URR disruptions: 
This study highlights the possibility that URR disruption could be another mechanism of HPV 
carcinogenesis. Viral integration has been shown to occur elsewhere in the HPV genome 
aside just the E2 gene based on whole genome sequencing (Wilson et al., 2013). Specifically, 
the URR disruptions were found in the presence of E2 disruption but intact E6, E7 and L1 
genomic domains. In our cohort, the URR disruptions have only been observed in samples 
with E2 disruption and may indicate large rearrangements of viral genome upon integration. 
This could lead to a loss of control mechanisms between the promoter, E2, E6 and E7 
expression. Indeed, the high positive correlation between E6 and E7 expression observed in 
general in our cohort is not present in this subgroup. Specifically, two samples had a very high 
expression of one of the oncogenes with the other one remaining silent.  
This data underline the importance of the URR in OPC carcinogenesis and the fact that it can 







Viral E2 status and E2 binding sites’ methylation profiles correlation with clinical 
factors and overall survival in oropharyngeal cancer: 
HPV 16 E2 physical status (intact or disrupted), the methylation profiles in each E2 binding 
site, and the RNA expression data were correlated with epidemiologic and clinical outcomes 
such as demographic variables, risk factors’ data, Oropharyngeal cancer recurrence and 
overall survival from HPV positive Oropharyngeal cancer. The key findings include:  
a. There was no statistically significant difference between the tonsil and tongue base 
anatomic sites when considering E2 gene disruption. 
b. The observed gender difference with females having higher proportions of OPC with HPV 
E2 gene disruption is however not statistically significant given the small numbers of females 
in the analysis. This merits further investigation.  
c. On average, patients who had tumours with intact HPV were approximately 6 years 
younger than those patients found to have disrupted HPV. Increasing age is therefore an 
independent univariate predictor for HPV 16 E2 gene disruption in OPC. 
With increasing mean age, there appears to be a tendency towards increasing HPV 16 E2 gene 
disruption in OPC, with this age effect more marked amongst females.  
d. There was no statistically significant different between tumour size categories and HPV E2 
gene disruption  
e. In this cohort, smoking had a strong assocation with OPC (70% smokers) consistent with 
current literature but smoking did not show a statistically significant impact on viral E2 status 




f. The Kaplan-Meier probabilities show a trend of worse survival at 1, 3 and 5 years following 
diagnosis for oropharyngeal cancer in the cohort with disrupted HPV E2 gene but this trend 
was not statistically significant. Significantly, Oropharyngeal cancer recurrence was 
associated with an increased likelihood of mortality on Kaplan-Meier survival analyses.  
Due to the highly decreased group sizes, it was not possible to correlate epidemiological and 
clinical data with the URR methylation and viral gene expression status. 
In summary, this study observes the following potential mechanisms of HPV carcinogenesis 
in OPC:  
1. E2 disruption 
2. URR methylation – data inconclusive in this cohort however other studies support this 
view 
3. URR disruption – more likely to be connected with E2 disruption and multiple sites of 



















PhD CHAPTER 6: 













This thesis on the epidemiology and epigenetics of oral HPV infection and oropharyngeal 
cancer has been executed utilising a systematic review and meta-analysis, a prospective 
cohort study, a retrospective case series as well as a molecular study focused on HPV 16 
genome and epigenome. These interwoven strands of research have provided some new 
insights into our understanding of the natural history of oral HPV infection and highlighted 
observations on potential mechanisms of HPV carcinogenesis in the oropharynx. The findings 
have corroborated the current limited literature on oral HPV natural history and provided a 
window into future directions for epigenetic research into HPV-associated oropharyngeal 
cancer.  
6.1 Systematic review and meta-analysis: 
The systematic review and meta-analysis has provided a comprehensive analysis of the 
literature on the epidemiology of oral human papillomavirus infection in healthy adults. It 
corroborates the most recent systematic review on oral HPV infection in healthy populations 
published by Kreimer et al. (2010) in demonstrating a low prevalence of oral HPV infection, 
but with a seven fold population size.  
Kreimer et al. (2010) published a pooled prevalence of 4.5% (95% C.I: 3.9% – 5.1%) for any 
oral HPV, 3.5% (95% C.I: 3.0% - 4.1%) for oral high-risk HPV, and 1.3% (95% C.I: 1.0% - 
1.7%) for oral HPV 16 (Kreimer et al., 2010). In comparison, this thesis reiterates pooled 
prevalence in healthy individuals worldwide for any oral HPV of 4.9% (95% CI: 3.7% - 
6.3%); oral high-risk HPV of 1.8% (95% CI: 1.2% - 2.6%); oral HPV 16 of 0.7% (95% CI: 
0.4% - 1.0%). This thesis adds to the literature because it excludes population groups that are 




clinics, which had not been excluded in Kreimer’s study. The study population size pooled 
from worldwide papers in this thesis is approximately 7 times more than the one included in 
Kreimer’s review (28,516 participants compared to 4,070). The combination of a higher 
powered study with exclusion of ‘high-risk’ populations, provides a more robust evaluation of 
oral HPV prevalence in healthy adults provided by this thesis. This is demonstrated by the 
lower pooled prevalence for oral high-risk HPV in this thesis.  
The meta-analysis in this thesis also did not identify any differences in the pooled prevalence 
of oral HPV by gender. Males and females had similar prevalence rates amongst healthy 
adults which corroborates the reported prevalence rates by sex in the Kreimer et al. (2010) 
systematic review. The implications of this in clinical practice and the development of 
oropharyngeal cancer requires further investigation because men are more likely to present 
with HPV oropharyngeal cancer despite similar prevalence rates of oral infection when 
compared with females. The factors responsible for the susceptibility of males to HPV 
oropharyngeal cancer is unclear and as such future research is required into exposure to risk 
factors, hormonal differences, dietary factors, or genetic predispositions.  
Additionally, this thesis identified and reported separately from healthy individuals, oral HPV 
infection rates specifically in populations at-risk of higher oral HPV prevalence including 
individuals with immunodeficiency states such as infection with HIV, sex workers, and 
women with cervical HPV infection. These findings are corroborated by current literature 
(Matsushita et al., 2011; Beachler et al., 2012).  
Our meta-analysis observed geographic variation in oral HPV prevalence. The interpretation 
of this finding should be done cautiously given the heterogeneity inherent in the pooled 




studies had some PCR-based testing algorithms but the techniques are not standardised and as 
such lack uniformity. Some of the HPV testing techniques are more sensitive than others and 
this may exaggerate the variations observed in world regions. Notwithstanding this limitation, 
there are socio-cultural complexities in each world region that may either predispose or 
preclude high oral HPV prevalence. In Asia for example, there were only two studies included 
with high oral HPV rates shown in Pakistani men. Gichki et al., (2012) reported the highest 
prevalence for oral HPV of 24.5% (95% C.I: 18.9 – 31.0%) in 200 Pakistani men. There are 
also limited studies from Africa and as such the reported continental rates may be sub-
optimal.  
Studies have shown that oral HPV infection is sexually transmitted. This means prevalence 
could be in part dependent on the sexual practices inherent in each world region. Recent 
publications show the rising incidence of HPV-associated oropharyngeal cancer to be in the 
Western world. However, HPV may not necessarily be a driver for oropharyngeal cancer in 
regions such as Africa or Asia due to potentially different sexual practices and attitudes. More 
qualitative and quantitative research is needed to establish true geographic differences in both 
oral HPV prevalence in healthy adults, regional sexual practices and ultimately HPV 
oropharyngeal cancer development.  
This meta-analysis also demonstrates variation in the reported oral HPV prevalence rates 
depending on the sample taken for analysis. HPV detection was highest in studies using  
scrapings / brushings / swabs at 5.9%; followed by studies using oral rinse / gargle / saliva at 
3.5%; and the lowest in tonsils at 1.0%. This is useful information that can guide the 
development of population screening strategies for oral HPV. It was surprising to observe low 




localisation in the reticulated epithelium of tonsil crypts. Our finding of 0% in FFPE and 
1.0% oral HPV prevalence in normal tonsils in a UK population is corroborated by Palmer et 
al. (2014) in the single largest study on FFPE specimens and non-malignant tonsils in the UK. 
Palmer et al. (2014) found 0% in 3,377 FFPE and 0% in 511 tonsils. Demonstrating how oral 
HPV infection progresses from acquisition at sexual exposure to eventual HPV-oropharyngeal 
cancer thus remains a subject of future research in a longitudinal study which could last years.  
6.2 Prospective cohort study: 
An important research question assessed in Chapter 3 of this thesis is the potential impact (if 
any) of tonsillectomy on the natural history of oral HPV infection. This cohort sub-study is 
part of a larger multicentre prospective UK study evaluating the prevalence of oral HPV 
infection in a tonsillectomy population. This is the first UK study to provide crucial data on 
the hypothesis that surgical removal of tonsils results in a reduction in oral HPV prevalence or 
acquisition.  
Tonsillectomy did show a trend towards abrogation of oral HPV infection with HPV 
positivity in the pre- and post-tonsillectomy oral rinse samples being 11% and 2% 
respectively. However, this observation was not statistically significant due to the acquisition 
of new oral HPV infections in 9% of participants post-tonsillectomy who were previously 
negative before surgery. Therefore, tonsillectomy in itself did not appear to prevent oral HPV 
infection but could potentially be useful in reducing oral HPV burden. A limitation of this 
cohort study was the lack of control of confounding factors on oral HPV acquisition such as 
sexual activity, change in sexual relationships or behaviours between the pre- and post-
tonsillectomy samples. This could have been accounted for by sexual history questionnaires 




collections. The second limitation was the lack of a control group to adequately assess if 
tonsillectomy was indeed an intervention that reduced oral HPV infection or if this effect was 
due to chance and the natural cycle in immune-competent individuals. The Finnish family 
study has reported that oral HPV infection is cleared within 18 – 24 months in healthy 
individuals. A control group that were age and sex-matched who did not undergo 
tonsillectomy would have been useful in interpreting the data if they had oral rinse samples 
taken at two separate time points similar to the tonsillectomy group.  
The findings from this cohort study need validation in a future prospective study that is 
sufficiently powered to establish an association between tonsillectomy and reduced oral HPV 
infection.  
6.3 Retrospective UK population study: 
This strand of the thesis triangulated data on oropharyngeal cancer registered on the UK 
Hospital Episodes Statistics (HES) database and UK population-level data obtained from the 
Office of National Statistics (ONS) to describe the epidemiology, incidence and determinants 
of survival in patients diagnosed with oropharyngeal cancer. Kaplan-Meier survival and Cox-
regression analyses were performed with determinants of survival from oropharyngeal cancer 
shown to include age, gender, socioeconomic status, deprivation levels, and presence of co-
morbidities and smoking. These survival determinants are consistent with published literature 
(Granata et al., 2012). HPV positivity is known to be a significant prognostic classifier in 
oropharyngeal cancer (Ang et al., 2010) and the clinical significance in squamous carcinomas 
of the head and neck in the UK is also documented (Heath et al., 2012) but this could not be 




database. In future, HPV status will become more readily available as cancer networks across 
the UK now include this information in their data submissions.  
 
6.4 Genomics and epigenetics study: 
There is a need for additional diagnostic and prognostic biomarkers for OPC alongside HPV 
positivity. Disruption of the HPV regulatory E2 gene and methylation of the E2 binding sites 
in cervical cancer have been identified as potential prognostic mechanisms driven by HPV in 
cervical cancers. In contrast, there is currently limited data available on the genomic changes 
and epigenetic modifications that occur as a prelude to HPV-mediated oropharyngeal cancer. 
This section of the thesis investigated the frequency of occurrence of viral E2 gene disruption 
and the role of aberrant methylation in HPV mediated OPC, as well as and the impact of these 
on clinical outcomes. Firstly, this thesis demonstrates 40% viral E2 gene disruption in a 
cohort of HPV positive oropharyngeal cancer. This is similar to reported rates of viral E2 
gene disruption in the limited literature available on oropharyngeal cancer but in contrast to 
the higher rates reported in cervical cancers. The limitation in this study was inherent in the 
technique utilised for determining E2 gene disruption and by extension HPV integration. The 
methodology is limited to physical disruption within the E2 gene sequence which does not 
exclude the presence of viral integrations occurring elsewhere in the HPV genome that could 
also affect viral transcriptional regulation or the presence of mixed infections. In an attempt to 
address the limitation, the study was extended by the analysis of the E6, E7, L1 and URR 




This study also showed that E2 gene disruption (as evidenced by an absence of a band on 
agarose gel electrophoresis) was associated with oropharyngeal cancer recurrence in this 
cohort. This finding requires further validation in a larger study.  
The key finding of the epigenetic analysis was the general hypomethylation at the HPV 16 
URR. Further analysis of the methylation profiles at the E2 binding sites in the HPV 16 URR, 
revealed no statistically significant differences between E2-intact and E2-disrupted HPV 
OPC. There were some observations made in this study that merit further scrutiny. Firstly, in 
the E2-disrupted oropharyngeal cancer, there were lower E2 mRNA expression levels 
associated with higher E6 and E7 expression levels.  Secondly, disruptions in the HPV URR 
were observed especially among the E2-disrupted oropharyngeal cancer cohort. This 
observation could potentially be an additional mechanism of carcinogenesis but it requires 
further evaluation.  
HPV 16 DNA methylation has been shown to be a prognostic biomarker in cervical cancer. In 
Oropharyngeal cancer, hypermethylation of the inhibitory E2 binding sites in the HPV URR 
has been demonstrated by Reuschenbach et al. (2015) to confer worse survival. This requires 
further investigation in oropharyngeal cohorts and could lead to the development of novel 
clinical strategies and applications.  
6.5 Future perspectives on oral HPV: 
Epidemiologic and laboratory evidence have now conclusively shown that high-risk HPV 
genotypes are causative for cervical cancer, a fraction of cancers of the vagina, vulva, anus, 
penis and more recently a subset of oropharyngeal cancer. Persistent infection with high-risk 
HPV genotypes in the transitional epithelium of the cervix is demonstrably the precursor to 




persistent infection with high-risk HPV prior to ano-genital cancer development occurs 
similarly in cancers of the oropharynx. Such an assertion at this stage represents a huge leap 
in the dark in terms of HPV oropharyngeal cancer, for a number of reasons that require 
scientific scrutiny. Firstly, tonsil tissue and tongue base tissue are lymphoid tissue and are 
pre-eminently different from the cervical tissue from whence cervical cancer arises – namely 
the squamo-columnar junction. Secondly, there exists pre-malignant states in cervical cancer 
(cervical intraepithelial neoplasia I, II, III) which allow disease progression to be monitored 
and an early diagnosis made from biopsies. This is not the case in the oropharynx as there is 
no recognised ‘premalignant state’ for oropharyngeal cancer. Thirdly, the temporal trend that 
underlines progression from HPV infection in the cervix (or its detection) to cervical cancer 
development ranges from 10 years to 30 years (depending on the individual patient factors, 
exposure to other risk factors and the HPV genotype) with ≤50% of cervical intraepithelial 
neoplasia III (CIN3) transforming to invasive cervical cancer (McCredie et al., 2008). The 
time from the acquisition of HPV infection in the oral cavity / oropharynx, latency or 
persistent infection and ultimately cancer development is currently unknown as are all the 
suggested stages of progression or reinfection. In immune-competent individuals, the limited 
data indicates that HPV infection in the oral cavity is a dynamic process in which the 
person(s) affected are able to clear the infection within a period of 12 – 24 months. There is 
also a bi-modal peak described for oral HPV infection by (Gillison et al., 2012) with the first 
peak in individuals aged 20 – 29 years and the second peak in adults 50 – 54years. There are 
currently two schools of thought on the relatedness of these two peaks of oral HPV infection: 
either they are independent peaks and the second peak represents a re-infection or they are 
related peaks with the second peak simply being a reactivation of latent oral HPV infection 




carcinogenesis that will require prospective longitudinal studies to definitely answer - albeit 
predictably time and money-consuming.  
In addition to persistent HPV infection in the aetiology of cervical cancer, there are other 
recognised risk factors that include multiparity, multiple sexual partners, use of hormonal 
contraceptives, smoking, immunosuppression and co-infection with other viruses such as 
chlamydia trachomatis and herpes simplex (Munoz et al., 2006). In Oropharyngeal cancer, the 
risk factors primarily include the synergistic effect of tobacco smoking and excessive alcohol 
consumption alongside genetic predisposition and HPV involvement. Research into risk 
factors for OPC that can further stratify into prognostic groups is required including 
epidemiologic, epigenetic, hormonal and dietary factors. Viral factors including viral load, 
viral integration, and the HPV genotype involved are all areas with limited data currently as 
regards oropharyngeal cancer development. Host factors such as susceptibility to genomic 
instability, exposure to risk factors and immune states can also contribute to the severity and 
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